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Obesity, currently an epidemic, is a difficult disease to combat because it is marked by 
both a change in body weight and an underlying dysregulation in metabolism, making 
consistent weight loss challenging. We sought to elucidate this metabolic dysregulation 
resulting from diet-induced obesity (DIO) that persists through subsequent weight loss. 
We hypothesized that weight gain imparts a change in “metabolic set point” persisting 
through subsequent weight loss and that this modification may involve a persistent 
change in hepatic AMP-activated protein kinase (AMPK), a key energy-sensing enzyme 
in the body. To test these hypotheses, we tracked metabolic perturbations through this 
period, measuring changes in hepatic AMPK. To further understand the role of AMPK 
we used AICAR, an AMPK activator, following DIO. Our findings established a more 
dynamic metabolic model of DIO and subsequent weight loss. We observed hepatic 
AMPK elevation following weight loss, but AICAR administration without similar 
dieting was unsuccessful in improving metabolic dysregulation. Our findings provide an 
approach to modeling DIO and subsequent dieting that can be built upon in future studies 
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Chapter 1 - Introduction 
 
Prevalence and Consequences of Obesity in America 
Obesity has become an increasing problem in the United States (U.S.), affecting 
35.7% of adults and 17% of children (Blackburn, 2012). The percentage of Americans 
who are classified as “morbidly obese” (BMI > 40) has risen six fold, up from 0.9% in 
1962 to 6% in 2010 (Fryar, Carroll & Ogden, 2012). Projections estimate that by 2030, 
51% of Americans will be obese and 11% will be morbidly obese (Blackburn, 2012). 
The economic consequences of obesity in the U.S. can be seen in reduced 
productivity in the workforce and elevated healthcare costs. Finkelstein et al. (2009) 
estimate that obesity-related productivity loss costs employers roughly $36.4 billion per 
year. Obese individuals take 5.9 to 9.4 more absent days per year than their healthy 
weight counterparts and when they are present at work, their efficiency is reduced due to 
obesity-related health problems (Fryar et al., 2012). In 2008, roughly 9% of healthcare 
expenses in the U.S., or $147 billion, were obesity-related costs (Blackburn, 2012).  
Aside from the economic implications, obesity in humans has many health-related 
consequences. Research has shown that once a level of obesity is reached, there are 
increased risks of developing such conditions as coronary heart disease, Type II diabetes, 
certain types of cancer, hypertension, stroke, liver disease and osteoarthritis (Pi-Sunyer, 
2002). In addition, obesity has been documented to increase discrimination and social 
stigma, possibly impacting psychological health (Schafer & Ferraro, 2011).  
Etiology of Overweight and Obesity  
In a broad sense, the terms “overweight” and “obesity” describe a state of body 
weight that is greater than what is considered healthy and therefore individuals in these 
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categories have an increased chance of diseases and health complications (Centers for 
Disease Control, 2010). Body mass index (BMI), calculated by dividing weight by the 
square of the height (kg/m
2
), is most commonly used to define obesity because of its ease 
of measurement and low cost for assessment. The range for a healthy weight is 
considered to be 18.5 – 24.9 BMI units. At the same time, the range for overweight 
individuals is 25.0 – 29.9 BMI units while the range for obese individuals is 30.0 BMI 
units or above (Centers for Disease Control, 2010). In 2009-2010, the average BMI for 
U.S. adults was 28.7 for both men and women (Flegal, 2012). Although BMI reliably 
predicts body fatness, it does not directly measure body fat (Centers for Disease Control, 
2010). Thus, obesity can more accurately be described as ≥25% body fat in men and 
≥35% body fat in women (Grundy, 2004).  
Weight gain occurs when calories consumed exceed calories expended. Thus, 
when calories consumed exceed the daily energy requirements to support maintenance 
and activity, the additional energy is stored in the body in the form of fat. When this 
excess intake of calories occurs over a prolonged period, individuals may reach a state of 
obesity (Weinsier, et al., 1998). 
Body composition is modulated by a combination of two key factors: metabolism, 
as determined by genetic make-up, and diet and exercise regimens. Studies have shown 
the existence of such genetic factors that allow certain individuals to inherit 
“susceptibility genes” for obesity (Weinsier, et al., 1998). Such “susceptibility genes” 
account for variation in taste preferences, muscle composition, and overall energy 
requirements and expenditures (Weinsier, et al., 1998). While certain individuals may 
carry such genes that make them more likely to gain weight, they will not achieve an 
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overweight or obese state when maintaining a healthy lifestyle that includes consumption 
of lower fat diets and maintenance of a regular exercise routine (Bouchard, 1991). Thus, 
since genetic factors alone cannot explain the onset of weight gain and obesity, the 
increasing trend of obesity in the U.S. and worldwide can be attributed to environmental 
factors, specifically, reduced physical activity and increased energy intake. 
Eating habits that include over-consumption (hyperphagia) and consuming diets 
high in fat and simple sugars are also contributing factors. In particular, consuming high-
fat diets containing greater saturated and trans fats and refined sugars are considered 
leading contributors to the development of obesity because of the high caloric density of 
fats and the short-term satiating effects of refined sugars (Astrup et al., 2000). 
Consumption of high-fat diets also increases plasma levels of low-density lipoprotein 
(LDL) and plasma insulin, both of which contribute to the health risks associated with 
obesity (Astrup et al., 2000). The high availability, low cost, and popularity of such high 
calorie dense foods has contributed to an increase in caloric intake and obesity (Astrup et 
al., 2000). Caloric intake, combined with a lack of regular exercise (i.e. reduced energy 
expenditures), results in conversion of these excess calories into fat for storage in 
adipocytes. Thus, an increasingly sedentary lifestyle is also believed to be a major 
contributor to the obesity epidemic (Astrup et al., 2000). The prevalence of calorie dense 
foods combined with a sedentary lifestyle contribute to the prevalence of obesity in our 
society today. 
However, some metabolic differences may increase susceptibility to obesity for 
certain individuals. Obesity can be viewed as a metabolic syndrome. In addition to excess 
body fat, obesity can lead to metabolic symptoms such as high blood pressure as well as 
Chapter 1 – Introduction 4 
elevated blood glucose (≥100 mg/dl) and triglycerides (≥150 mg/dl) (Grundy, 2004). 
Body weight in non-obese individuals is regulated by multiple interdependent and 
connected metabolic pathways which sense and regulate energy expenditure and food 
intake. In obese individuals, this feedback system becomes dysregulated as the body fails 
to sense an excess energy state and continues a high level of food intake, which is 
exacerbated by a lower level of energy expenditure. This underlying metabolic 
dysregulation leads to the persistence of obesity (Friedman & Halaas, 1998). Genetic 
polymorphisms and quantitative trait loci, both of which are hereditary, have been 
identified as factors that lead to dysregulation of lipid metabolism and predisposition to 
excessive weight gain as fat (Du & Feskens, 2010; Sviridov & Nestel, 2007). An extreme 
example of obesity resulting from a genetic defect in energy regulation is morbid obesity 
in rodents with mutations in the genes encoding leptin, a hormone regulating appetite and 
metabolism (Clément et al, 1998). A dysfunctioning energy regulation system encourages 
the persistence of obesity.   
Solutions or Quick Fixes? 
The growing obesity epidemic in the U.S. is an ongoing problem with no clear 
solution in sight. The generally accepted course of action is a combination of steady 
dieting (i.e. reduced calorie intake), importantly, a reduced intake of high-fat, high-sugar 
foods, and exercise. Over the past several decades, many commercial supplements and 
fad diets have been popularized because they have been touted as providing a quick and 
maintainable weight loss (Miller et al., 2009). However, “quick-fix" dieting is clearly not 
a promising solution to the obesity epidemic in the U.S. and in other developed countries, 
with obesity statistics continuing to remain high; in fact, they continue to increase. One 
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problem with such dieting approaches is the issue of weight cycling, which refers to the 
continual process of dieting and regaining weight (Thomas et al., 2010). When restricting 
food consumption during a period of dieting, the body gradually adjusts to the lower 
intake of calories. However, when an individual stops dieting and returns to previous 
eating habits, the body remains in this “adapting” state where it becomes more efficient at 
storing the excess food calories as fat (Summermatter et al., 2007). This metabolic 
adaptation leads to weight gain and often the individual achieves a body weight that 
exceeds his or her previous increased weight. This suggests that strictly losing weight to 
fight obesity is not a maintainable solution. 
It would seem that after losing weight, as long as the individual maintains healthy 
eating habits, this weight cycling can be prevented. However, the body constantly makes 
metabolic adjustments throughout the different stages of weight gain and loss that alters 
normal physiology and eating habits. Understanding the derangements that alter the 
normal energy-sensing mechanisms and consequent redirection of metabolism could be a 
key toward developing long-term solutions to slow down and reduce the rate of obesity 
development. 
Research Questions, Hypothesis and Objectives 
Does diet-induced obesity leave a “nutritional imprint” that tends to maintain a 
“set point” of increased metabolic efficiency after subsequent weight loss, resulting in a 
failure to adequately sense energy status in the body? If so, to what extent is the energy 
sensing enzyme AMP-activated protein kinase involved in this nutritional imprinting as 
seen through effects on food efficiency and metabolic dysregulation? 
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We hypothesize that a cycle of diet induced obesity in mice will impart a long-
term shift in metabolic efficiency and that this imprinting will display disparate changes 
in AMPK activation in the liver. It is anticipated that once mice undergo one cycle of 
obesity and weight loss that AMPK activation will be lower in the liver due to a “thrifty 
metabolism” geared towards conserving energy. If AMPK proves to play a significant 
role in this metabolic dysregulation, we further expect the physiological response and 
food efficiency of obese mice to be altered upon administration of the compound 
aminoimidazole carboxamide ribonucleotide (AICAR) that activates AMPK. 
In order to test this hypothesis, we will achieve the following objectives: 
1) Determine that diet-induced weight gain and subsequent weight loss leads to a 
persistent nutritional imprint characterized by changes in metabolic efficiency and 
energy-sensing that maintains a set point defending the obese state. 
2) Determine the role of AMPK in this obesogenic nutritional imprinting 
phenomenon by manipulating AMPK activation. 
Experimental Approach 
To elucidate such metabolic changes following diet induced obesity and weight 
loss, we used mice as the experimental animal model. There are several advantages of 
using mice as a model for human metabolism. First, mice have many genetic, 
physiological, and metabolic similarities to humans that have made them one of the 
preferred models for studying human metabolic processes. Second, as in humans and 
other complex mammals, mice naturally develop obesity-induced Type II diabetes, 
hypertension and hyperglycemia (Bergen & Mersmann, 2005). Lastly, mice are relatively 
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low-maintenance and low-cost mammalian models that develop quickly, which greatly 
expedites research progress. 
While our research builds upon years of prior studies on AMPK and obesity, there 
has been insufficient research conducted that has investigated the role of AMPK in 
weight cycling and consequent effects on food intake.  
Thus, while it is known that AMPK is involved in energy homeostasis, it is not 
known whether changes in AMPK activation occur once an obese state is reached. At the 
same time, it is unknown whether these chronic changes in AMPK underlie long-term 
control of food intake that characterizes obese individuals who undergo bouts of weight 
loss and weight gain.  
The following explains how this thesis is organized. Chapter 2 is the literature 
review section which explains the features of metabolic syndrome, various pathways 
affected by diet induced obesity, the role of an energy regulator called AMP-activated 
protein kinase, a method for identifying important metabolites within the body and the 
concept of metabolic imprinting. The subsequent methodology chapter outlines the 
rationale and procedure for Experiment 1 followed by the rationale and procedure for 
Experiment 2. Chapter 4 contains the results and discussion for Experiment 1 while 
Chapter 5 explains the results and discussion for Experiment 2. The final chapter is the 
conclusion, which summarizes Experiments 1 and 2, ties them together, and elucidates 
the limitations of this study.  
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Chapter 2 - Literature Review 
Features of Metabolic Syndrome 
Overview. 
 Obesity is thought to be caused primarily by a chronic state of nutrient or “energy 
excess,” i.e. a high energy diet and little physical activity. The result of this is obesity-
related metabolic syndrome, characterized by such markers as hyperlipidemia, 
hyperinsulinaemia, peripheral insulin resistance leading to a reduced ability to clear blood 
glucose, hypertriglycerideaemia, decreased high density lipoprotein (HDL) cholesterol, 
and hypertension. This metabolic dysregulation results from high concentrations of lipids 
in the blood, liver, and muscle. In the obesity state, the levels of stored fat in the form of 
triacylglycerols (TAG) and non-esterified fatty acids (NEFA) increase. High levels of 
NEFA result during obesity due to an inability of muscle and adipose tissue to take up 
NEFA and esterify them to TAG (Aguilera et al., 2008).  
Hyperlipidimia and development of insulin resistance. 
Under normal conditions, adipose tissue is capable of storing excess energy as fat, 
but eventually these fat cells become filled, leading to a high level of circulating non-
esterified fatty acids (NEFA)—a condition known as hyperlipidemia (Muoio & Newgard, 
2006). Hyperlipidemia causes problems for several organs including the pancreas, 
skeletal muscle, and adipose tissue itself. The high circulating levels of NEFA have been 
found to disrupt pancreatic secretion of insulin and impair the action of insulin on skeletal 
muscle (Kahn & Flier, 2000). This dysregulation is a potential cause of insulin resistance 
which carries with it other problems that exacerbate the already elevated levels of NEFA 
in plasma. Hyperlipidemia also affects the adipose tissue’s natural secretion of hormones, 
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referred to as adipokines (Muoio & Newgard, 2006). This hormonal abnormality has 
been observed to worsen the situation by giving false energy signals to the brain. These 
signals tend to increase, rather than reduce, energy intake. Hyperlipidemia is also thought 
to cause “ER stress” in the endoplasmic reticulum (de Ferranti & Mozaffarian, 2008). 
Endoplasmic reticular stress is affected by excess NEFA and has the consequence of 
increasing cellular insulin resistance. Insulin resistance prevents the cell from extracting 
glucose from the blood, so when a cell is unable to store energy as fat, levels of NEFA in 
the plasma rise. Therefore, a cycle of increasing NEFA and insulin resistance may occur.  
Insulin Resistance. 
During obesity, high levels of NEFA cause tissues, primarily the muscle, to 
become insulin resistant despite high levels of circulating insulin. One consequence of 
this reduction in insulin sensitivity is the reduced ability of peripheral tissues such as 
muscle to uptake and metabolize glucose. NEFA reduce glucose oxidation in muscles 
through inhibition of pyruvate dehydrogenase via production of acetyl-CoA, the latter 
being an allosteric inhibitor of pyruvate dehydrogenase. Another reason for the high 
levels of glucose in the blood is that the increased levels of NEFA stimulate hepatic 
gluconeogenesis (Aguilera et al, 2008). 
NEFA can also interfere in the insulin signaling cascade in skeletal muscle 
resulting in decreased insulin-stimulated glucose uptake and glycogen synthesis. Insulin 
resistance may be a result of inflammatory cytokines such as tumor necrosis factor α 
which activates the nuclear transcription factor kappa B and related inflammatory 
pathways (Wilding, 2007). In type 2 diabetes, the expression of insulin-regulated glucose 
transporter 4 (GLUT-4) is reduced in skeletal muscle and significantly reduced in adipose 
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tissue. Insulin resistance in skeletal muscles is particularly important because muscle 
uptakes roughly 80% of circulating glucose. However, adipose-specific GLUT-4 
knockout mice have impaired insulin sensitivity in the liver and muscle. Food restriction 
also causes insulin resistance and decreased adipose GLUT-4 expression (Muoio & 
Newgard, 2006). 
Studies have shown that being more than 35 to 40% over an ideal body weight 
leads to insulin resistance. Normally, insulin suppresses hepatic glucose production and 
increases glucose uptake by muscle and fat cells. However, after obese individuals lose 
weight, peripheral tissues remain less responsive to insulin, causing a decrease in glucose 
uptake and storage (Kahn & Flier, 2000). The sensitivity of tissues to insulin, specifically 
muscle, decreases by 30 to 40% (DeFronzo & Ferrannini, 1991). The resulting insulin 
resistance leads to hyperinsulinemia followed by hypertension, hypertriglyceridemia, 
hypercholestrerolemia, HDL cholesterol, and eventually atherosclerosis (DeFronzo & 
Ferrannini, 1991). 
Lipotoxicity. 
Another reason for decreased glucose clearance is the lipid accumulation in 
skeletal muscles. Long periods of obesity lead to lipid accumulation in non-adipose 
tissues resulting in reduced glucose uptake, mitochondrial dysfunction, and lipotoxicity. 
Excess fatty acids lead to lipotoxicity and metabolic syndrome. Lipotoxicity results in 
impaired hormone sensitivity that eventually leads to the persistence of obesity. One 
hypothesis for the development of obesity related metabolic syndrome is the inability of 
white adipose tissues to continue to store fatty acids and the resulting lipotoxicity that 
occurs in non-adipose tissues. After a period of time, white adipose tissue can no longer 
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continue to expand, thus resulting in elevated NEFA. When this limit is reached, excess 
lipids form toxic reactive lipid species, such as diacylglycerols and ceramides. The 
presence of these toxic reactive lipid species in non-adipose tissues, such as pancreatic β 
cells, liver, kidneys, heart and skeletal muscles results in toxic responses and increased 
apoptosis (i.e. programmed cell death). In pancreatic β cells, glucolipotoxicity contributes 
to β-cell failure in type 2 diabetes. In the hypothalamus, lipotoxicity, increased 
inflammation as measured by a mediator of metabolic inflammation (IKKβ/NF-κB), and 
increased endoplasmic reticulum stress affect the regulation of energy homeostasis and 
lead to obesity (Martínez de Morentin et al., 2010). At high doses, salicylates (aspirin) 
suppress the activation of the NF-κB transcription factor mediated pathway, thus 
reversing insulin resistance and hyperlipidemia in obese rodents (Muoio & Newgard, 
2006).  
All of these metabolic and physiological issues are the result of chronic, often 
diet-induced, energy excess in the body. The metabolic dysregulation associated with 
obesity prevents the body from accurately sensing its energy status at the cellular and 
whole body basis. Obese animals often perceive themselves as being in a low energy or 
starvation state. The metabolism of an obese individual is geared towards energy 
conservation leading to the persistence of obesity (de Ferranti & Mozaffarian, 2008). 
Pathway Analysis  
 The key pathways involved in energy generation and energy utilization, such as 
the Krebs cycle, glycolysis, gluconeogenesis and fatty acid oxidation, are all affected by 
obesity-induced metabolic syndrome.  
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Citric Acid Cycle. 
As one of the main energy generators, the citric acid cycle, or Krebs cycle, plays a 
vital role in cellular metabolism. The citric acid cycle is the major pathway through 
which carbohydrates such as glucose are metabolized. Glucose is broken down through 
glycolysis into pyruvate, which feeds into the citric acid cycle. In addition to formation 
through the breakdown of pyruvate, acetyl-CoA is formed via the oxidation of fatty acids. 
The citric acid cycle forms ATP from the products of glucose and fatty acid metabolism. 
The relative rates of glucose and fatty acid metabolism are important factors that affect 
the development of the metabolic dysregulation due to obesity, which will be discussed 
later in the fatty acid metabolism section. 
This cycle is a major component of aerobic cellular respiration that oxidizes 
acetate to CO2 through a multi-step and highly regulated process. As a byproduct of these 
reactions, 3 NADH, an FADH2 and GTP are produced during a complete turn of the 
cycle, which, through oxidative phosphorylation and the electron transport chain, 
ultimately yields 12 ATP, the energy currency for cell metabolism (Berg, Tymoczko, & 
Stryder, 2011). 
The first and most crucial step in the citric acid cycle is the aldol condensation of 
acetyl-CoA with oxaloacetate to form citrate, which is catalyzed by citrate synthase.  This 
reaction, as well as those catalyzed by isocitrate dehydrogenase and α-ketoglutarate 
dehydrogenase, is highly thermodynamically favorable and irreversible, driving the cycle 
forward.  The high favorability of citrate synthesis is especially important, because the 
previous step, the conversion of malate to oxaloacetate, actually favors malate, thus 
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citrate synthesis drives the reaction forward to formation of oxaloacetate via mass action 
principles (Berg et al., 2011). 
  The citric acid cycle has many degrees and forms of regulation. The first 
regulated step is the formation of acetyl-CoA from pyruvate.  This reaction is catalyzed 
by pyruvate dehydrogenase, a multi-enzyme complex, and is irreversible. The reaction is 
largely regulated by product inhibition such that, as NADH and acetyl-CoA concentration 
increases within the mitochondria, various enzyme components of the pyruvate 
dehydrogenase complex are allosterically inhibited (Berg et al., 2011). 
 Within the cycle itself, there are a few key regulators including acetyl-CoA, 
succinyl-CoA, the NAD
+
/NADH ratio and the ADP/ATP ratio. The availability of acetyl-
CoA along with sufficient generation of oxaloacetate determines the rate of the citrate 
synthase reaction. Succinyl-CoA inhibits α-ketoglutarate dehydrogenase and competes 
with acetyl-CoA for citrate synthase. As the NAD
+
/NADH ratio decreases, indicative of 
sufficient energy production, NADH inhibits isocitrate dehydrogenase and α-
ketoglutarate dehydrogenase, both of which produce NADH.  Furthermore, isocitrate 
dehydrogenase is either allosterically activated by ADP or inhibited by ATP (Berg et al., 
2011). 
 An additional level of regulation occurs as a result of the availability of the 
substrate for each reaction. Because the citric acid cycle is at the center for several 
biosynthetic pathways, these substrate pools can be depleted for the production of lipids 
and amino acids. Some examples of depletion include conversion of acetyl-CoA to fatty 
acids, transamination of α-ketoglutarate to glutamate and oxaloacetate to aspartate, 
production of glucose through gluconeogenesis from oxaloacetate, and porphyrin 
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synthesis from succinyl-CoA. Most of these reactions are reversible and used to refill the 
substrate pool, known as anaplerotic reactions (Berg et al., 2011). 
 Due to its importance throughout the body in maintaining an energy balance, it 
seems logical that aspects of the citric acid cycle would be affected by obesity, which 
signals a disturbance in energy homeostasis. According to Satapati et al., (2012), Krebs 
cycle flux is elevated when an animal exhibits insulin resistance, which occurs as a result 
of obesity.  
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Figure 2-1. Citric Acid Cycle (Campbell & Farrell, 2011) 
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Gluconeogenesis.  
When the amount of stored glycogen and blood glucose in the body falls to low 
levels, such as during an overnight fast, gluconeogenesis from muscle and dietary derived 
amino acids and TAG-glycerol from mobilized adipose tissues is enhanced. Both the 
brain and the nervous tissues are especially dependent upon glucose for normal function. 
The liver plays a critical role in the synthesis of glucose during fasting as it converts 
lactate, amino acids and TAG-glycerol to glucose. About 25% of the liver’s production of 
glucose derives from gluconeogenesis during a period of fasting with the remainder 
derived from breakdown of stored glycogen. In prolonged fasting, gluconeogenesis by 
the kidneys becomes the major contributor to generation of glucose from amino acids. 
The carbon skeletons of all amino acids, except lysine, leucine and glycine, can be 
metabolized to make glucose with the predominant contributors to gluconeogenesis being 
alanine, glutamate, glutamine, valine and isoleucine (Hall, 2011).  
Amino acids take various enzymatic pathways for conversion to glucose. In the 
case of alanine, it is simply deaminated to form pyruvate, which is an immediate 
precursor for glucose. Other amino acids require interconversions prior to entry into the 
Krebs cycle, eventually leading to 3- and 4- carbon skeletons that feed into the 
gluconeogenic pathway. The main stimulus of gluconeogenesis is the reduction of both 
sugar and carbohydrates, which causes a decrease in the phosphogluconate and glycolytic 
pathways to form carbohydrates (Hall, 2011). The reduction in blood glucose is sensed 
by the anterior pituitary, which then secretes increased amounts of the hormone 
corticotropin. The adrenal cortex, in response, produces and secretes large quantities of 
glucocorticoids, in particular, cortisol. Cortisol stimulates the mobilization of amino acids 
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from skeletal muscles to enhance the supply to the liver and kidneys of amino acids for 
gluconeogenesis (Khani, 2001). A high proportion of these amino acids are deaminated in 
the liver (Hall, 2011). Figure 2-2 shows the pathways that amino acids enter the citric 




Figure 2-2. The routes of metabolism that amino acids follow to contribute to gluconeogenesis 
(Cynober, 1995). 
 
Gluconeogenesis and glycolysis pathway.  
 The net effect of gluconeogenesis is to counter glycolysis (the breakdown of 
glucose). However, for thermodynamic reasons, gluconeogenesis is not simply the 
reverse of glycolysis, certain steps must be bypassed. Glycolysis contains three 
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irreversible steps catalyzed by hexokinase, phosphofructokinase and pyruvate kinase 
(Hames, 1997). Figure 2-3 shows the general chemical equation for glycolysis and 
gluconeogenesis.  
Glycolysis 
glucose + 2 NAD
+
 + 2 ADP + 2 Pi  2 pyruvate + 2 NADH + 2 ATP 
Gluconeogenesis 
2 pyruvate + 2 NADH + 4 ATP + 2 GTP glucose +2 NAD
+
 + 4 ADP + 2 GDP + 6 Pi 
Figure 2-3. General chemical equation for glycolysis and gluconeogenesis  
 
In bypassing pyruvate kinase, the pyruvate must be converted to oxaloacetate, 
which is reduced to malate for cytosolic export and then re-oxidized again to 
oxaloacetate. Phosphoenolpyruvate carboxykinase (PEPCK) phosphorylates and 
decarboxlyates oxaloacetate to generate phosphoenolpyruvate. From this point, glycolysis 
is simply reversed chemically up until the point where fructose-1,6-bisphosphate is 
formed. Fructose-1,6-bisphosphate is dephosphorylated via fructose-1,6-bisphosphatase, 
which bypasses phosphofructokinase and generates fructose 6-phosphate, an important 
rate limiting enzyme of the glycolytic pathway. The reversal of glycolysis through the 
action of phosphoglucose isomerase converts the fructose 6-phosphate into glucose 6-
phosphate. Finally, to bypass hexokinase, glucose-6-phosphatase converts glucose-6-
phosphate into glucose (Hames, 1997).  
 Precursors for gluconeogenesis arise from any carbon skeleton whose metabolic 
pathway leads to either pyruvate or 3-phosphoglycerate (e.g. glycerol and serine). These 
precursors include lactate, glycerol, propionate (mostly in ruminants) and all amino acids 
except leucine, lysine, and glycine. Under anaerobic conditions, the muscle metabolizes 
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glucose to lactate and pyruvate to alanine via alanine amino transferase, whereas glucose 
is always metabolized (aerobic and anaerobic conditions) by the intestines to alanine and 
lactate. The recycling of lactate derived glucose for gluconeogenesis is referred to as the 
Cori cycle, while the use of glucose derived alanine for gluconeogenesis is referred to as 
the alanine cycle. Glycerol serves as the backbone of TAG and, upon breakdown of TAG 
in adipocytes, glycerol is released from adipose tissues, taken up by the liver and 
converted to glucose via formation of 3-phosphoglycerate. Propionate derived from 
metabolism of odd chain fatty acids, valine, methionine, isoleucine, threonine, and 
cholesterol, yields propionyl-CoA, which is converted to oxaloacetate, a glucogenic 
intermediate through a series of reactions in the Krebs cycle. Amino acids (mostly 
glutamine) formed from muscle catabolism of proteins, during starving or fasting, supply 
additional precursors for gluconeogenesis (Cynober, 1995).     
Regulation of Gluconeogenesis.  
The regulation of gluconeogenesis is reciprocal to that of glycolysis. Thus, in 
general, the negative controls of glycolysis are the positive effectors of gluconeogenesis. 
Local control includes allosteric regulation by adenine nucleotides. Hence, 
phosphofructokinase in glycolysis is inhibited by ATP and stimulated by AMP, while 
fructose-1, 6-bisphosphatase in gluconeogenesis is inhibited by AMP. When intracellular 
ATP levels are high, glucose is not further broken down to generate ATP, instead it is 
stored as glycogen in the liver and muscle. Subsequently, when intracellular ATP is low, 
stored glycogen is broken down to supply glucose and the pathway of gluconeogenesis is 
reduced dramatically to conserve energy. Global control in liver cells is via the cyclic 
AMP cascade that is triggered by the hormone glucagon when blood glucose levels are 
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low. The glucagon induced cAMP cascade stimulates gluconeogenesis, inhibits 
glycolysis, stimulates glycogen breakdown, and inhibits glycogen synthesis with the net 
effect of increasing glucose release into the blood from the liver. Protein Kinase A 
(cAMP-Dependent Protein Kinase) phosphorylates various enzymes and regulatory 
proteins to initiate gluconeogenesis. Proteins that are phosphorylated by Protein Kinase A 
include pyruvate kinase and CREB; the former is a glycolytic enzyme inhibited when 
phosphorylated and the latter is involved in the activation of the transcription of the gene 
for PEPCK that increases gluconeogenesis. Protein Kinase A also phosphorylates a bi-
function enzyme that generates and destroys fructose-2, 6-bisphosphate. Fructose-2,6-
bisphosphate stimulates glycolysis and inhibits gluconeogenesis, and it is reduced in liver 
cells due to the cAMP signaling cascade. Downstream effects cause glycolysis to slow 
and gluconeogenesis to increase (Hames, 1997).  
Obesity, Metabolic Syndrome & Glucose Metabolism. 
 Several studies have shown an association between fat distribution and increased 
cortisol secretion (Khani, 2001). It has been observed that in the short term, the increase 
in cortisol secretion enhances gluconeogenesis, however, long-term effects have yet to be 
investigated (Khani, 2001). Previous studies also show that leucine, isoleucine, and 
phenylalanine release from skeletal muscle and blood concentration are greater when 
cortical concentrations are elevated, hence, increasing the supply of substrates for 
gluconeogenesis (Khani, 2009). Metabolic syndrome also results in elevated blood 
NEFA, which accelerates gluconeogenesis since a continuous source of energy (ATP) 
and substrate is being provided from metabolism of NEFA (Wajchenberg, 2000). Liver 
AMP-activated protein kinase (AMPK) controls glucose homeostasis by inhibiting gene 
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expression of gluconeogenic enzymes and thus hepatic glucose production. AMPK 
suppresses FOXO1 and CRTC2, which increase gluconeogenesis. Hence, 
gluconeogenesis is reduced by AMPK activation. Studies found that endogenous hepatic 
glucose production and plasma glucose levels are reduced when AMPK is artificially 
activated by administration of the AMPK activator 5-aminoimidazole-4-carboxamide 
ribotide (AICAR) (Zhang, 2009).  
Non-Esterified Fatty Acid Metabolism. 
 NEFA are long-chained hydrocarbons with a terminal carboxylic acid group that 
serve as the primary source of energy in the body during the resting state (Berg et al., 
2011). NEFA are stored as TAG, which are compromised of three moles of fatty acids 
and one mole of glycerol. These lipid molecules are primarily stored in adipose tissue 
following absorption as chylomicrons from the gastrointestinal tracts into the lymphatic 
system. They are processed by the liver and transport HDL and very-low density 
lipoprotein (VLDL) molecules to target tissues. When energy from stored triglycerides in 
adipose tissues is required, hormone-controlled lipases catalyze the hydrolysis of adipose 
TAG, thus releasing NEFA and glycerol. NEFA circulate in blood associated with 
plasma-albumin, while glycerol is taken up by the liver for gluconeogenesis and 
reesterification of NEFA to TAG for liver export as HDL and VLDL (Berg et al., 2011). 
 NEFA are characterized by the length of their hydrocarbon chain, and more 
importantly, by the presence of double bonds within this chain. Saturated fatty acids 
contain no double bonds. Palmitic acid is a prominent dietary saturated fatty acid that is 
stored in adipose tissues (Kien, 2009). Unsaturated fatty acids contain double bonds in 
their chains. Oleic acid is a prominent monounsaturated dietary fatty acid. 
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Polyunsaturated fatty acids are those whose chains contain two or more double bonds, the 
most nutritionally significant of which are oleic acid (omega-9) and the essential fatty 
acids linoleic (omega-6) and linolenic (omega-3) (Kien, 2009). 
 The oxidation of NEFA for energy occurs within the mitochondrial matrix. To 
enable transport across the mitochondrial membranes, fatty acids must be activated. This 
occurs via esterification of a coenzyme A (CoA) unit to the carboxyl end of a fatty acid 
on the outer mitochondrial membrane, forming an acyl CoA. To cross the membrane, the 
CoA group is replaced with carnitine to form acyl carnitine. This reaction is catalyzed by 
carnitine palmitoyl I (CPTI) and allows the entry of the fatty acid across the 
intermembrane space via a translocase protein, carnitine acyl carnitine translocase. 
Carnitine palmitoyl II (CPTII) subsequently replaces the carnitine with a CoA group, 
resulting in an acyl CoA molecule present in the mitochondrial matrix (Berg et al., 2011). 
 -oxidation of saturated fats is a repeated four step process that degrades the acyl-
CoA molecule to acetyl-CoA units, which can then enter the citric acid cycle for ATP 
production. These reactions also produce the reduced species FADH2 and NADH. To 
oxidize unsaturated fatty acids, additional steps and enzymes are required that result in 
the production of acetyl CoA units, as well as the three carbon molecule propionyl-CoA 
when odd chain fatty acids are oxidized— which enters the citric acid cycle after 
conversion to succinyl-CoA (Berg et al., 2011). The ability of acetyl CoA to enter the 
citric acid cycle depends on the presence of oxaloacetate with which it condenses; 
oxaloacetate is produced from pyruvate, generated from glycolysis, and lactate and 
alanine, synthesized in peripheral tissues. Therefore, under conditions of low intracellular 
glucose (e.g. during fasting or diabetes), there is an insufficient supply of oxaloacetate 
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such that acetyl CoA entry into the citric acid cycle is diminished. In consequence, acetyl 
CoA builds up and is converted to acetoacetate and D-3-hydroxybutyrate (i.e. ketone 
bodies), which are released by the liver into blood (Berg et al., 2011). Ketone bodies 
under fasting conditions serve as alternative energy sources for the brain and heart, but if 
large quantities accumulate in the blood, they can become toxic and reduce blood pH. 
The latter is sometimes a feature of individuals who are obese and have type 2 diabetes 
(Kitabchi, Umpierrez, Miles, & Fisher, 2009). 
 NEFA can be synthesized in the body, both in the liver and adipose tissue, via the 
process of lipogenesis. Lipogenesis takes place in the cytoplasm of these cells under fed 
conditions, when energy demands are low and the body attempts to store excess 
substrates as energy (Jensen-Urstad & Semenkovich, 2011). The process begins 
irreversibly when acetyl CoA is carboxylated to malonyl CoA by the enzyme acetyl CoA 
carboxylase (ACC). Eight, two-carbon units are conjugated sequentially to form 
palmitate (Berg et al., 2011). Oleic acid is formed when palmitate is elongated to stearic 
acid and then desaturated by stearoyl-CoA desaturase (Kien, 2009). The enyzme 
malonyl-CoA decarboxylate can convert malonyl-CoA back into acetyl CoA (Muoio & 
Newgard, 2006). 
  Abnormally decreased -oxidation, as well as increased levels of malonyl CoA, 
are thought to contribute to insulin resistance observed in the metabolic syndrome via 
lipotoxicity (Muoio & Newgard, 2006). Lipotoxicity occurs when lipid molecules and 
their intermediates negatively impact insulin signaling (particularly in skeletal muscles), 
decreasing that tissue's ability to take up glucose. Obese individuals show an increased 
concentration of intracellular TAG stores in muscular tissue (Muoio & Newgard, 2006). 
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Intermediates associated with TAG, most notably diacylglycerol (DAG) and ceramide, 
accumulate when -oxidation is compromised. The latter have been suggested to 
negatively impact insulin signaling, and studies have shown TAG levels correlate more 
closely with insulin resistance than BMI or total adiposity (Muoio & Newgard, 2006).  
 The type of fatty acids consumed in the diet (i.e. saturated vs. unsaturated), affects 
the degree of insulin resistance. Studies in humans have shown that diets low in oleic acid 
and high in the saturated fatty acid palmitic acid lead to insulin resistance via 
inflammation and the accumulation of intracellular lipids (Kien, 2009). Likewise, glucose 
uptake by muscle cells in vitro increased when cells were incubated with oleic, 
pamitoleic (monounsaturated), linoleic, or alpha-linolenic acid (Kien, 2009). 
Accumulation of unsaturated fatty acids in muscle cell membranes increases fluidity and 
the number of insulin receptors, the affinity of insulin to its receptor, and glucose 
transport rate (Jans et. al). Unsaturated fatty acids have also been shown to favor fat 
oxidation over storage. 
AMP-Activated Protein Kinase (AMPK) 
AMP-activated protein kinase is a multi-component enzyme that serves an 
essential first step in the regulation of energy metabolism within all cells in nature. In 
eukaryotic cells, AMPK activation has pleiotropic effects in many tissues, including 
adipose tissue, liver, skeletal muscle, and the hypothalamus. AMPK acts as a “metabolic 
master switch” that serves an essential role in intracellular energy-sensing by detecting 
cellular energy status in order to maintain energy balance within every cell (Hardie, 
2004). AMPK is an intracellular energy sensor that, when activated, induces catabolic 
processes to rapidly produce more ATP.  
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AMPK is a heterotrimeric protein consisting of a catalytic alpha, regulatory beta, 
and gamma subunits. It is allosterically activated by an increase in the intracellular AMP: 
ATP ratio as well as by phosphorylation on Thr172 by upstream kinases. LKB1 and 
Calcium/calmodulin-dependent protein kinase kinase (CaMKK) are two upstream 
regulators of AMPK kinase (Viollet et al., 2006). 
Upon activation, AMPK initiates a cascade of catabolic ATP-generating pathways 
(e.g. fatty acid oxidation and glucose utilization) while switching off anabolic ATP-
consuming pathways (e.g. protein synthesis and gluconeogenesis). When enough ATP 
has been generated to restore balance, ATP competitively inhibits AMP from further 
activation of AMPK and turns it off (Carling, 2004). In addition to immediate activation 
of ATP-generating pathways, AMPK also has long-term effects through alteration of 
gene expression and protein synthesis.  
Leptin and Adiponectin as Upstream Regulators of AMPK. 
Leptin is a hormone that regulates energy homeostasis by modulating food intake, 
energy storage, and expenditure (Friedman & Halaas, 1998). In a healthy person, leptin 
promotes satiety and plays a role in maintaining constant fat stores (Spiegelman & Flier, 
2001). Therefore, Ob/ob leptin knockout mice show physiological signs of starvation 
such as hyperphagia, low body temperature, decreased physical activity, immune 
function and infertility (Friedman & Halaas, 1998). Leptin resistance during obesity is 
one mechanism by which energy sensing in obese humans and animals is impaired. 
While high leptin levels should reduce food intake, and thus obesity, obese humans and 
animals experience hyperphagia despite high levels of leptin. This implies that the leptin 
signal fails to reach the brain or that the signal is not transmitted beyond the leptin 
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receptor (Enriori, Evans, Sinnayah, & Cowley, 2006). In C57BL/6J mice, four or eight 
weeks of a high fat diet resulted in insulin resistance and a lack of response to 
intraperitoneal (IP) leptin injections (Prpic et al, 2003). Despite the state of energy excess 
that exists during obesity, leptin resistance impairs the signaling mechanism(s) to stop 
eating, resulting in hyperphagia and obesity. 
        Adiponectin is another hormone secreted by white adipose tissue. It has been 
shown to stimulate AMPK activation in the peripheral tissues in turn, stimulating fatty 
acid oxidation. Fasting mice exhibited high adiponectin levels to stimulate AMPK and 
food intake, and after re-feeding, adiponectin returned to previous fed state levels 
(Carling, 2004). 
Upon activation of AMPK, glucose uptake by myocardial cells increased by 
upregulation of glucose transporter 4 (GLUT4) (Russell et al., 1999). Leptin has a tissue-
specific effect on AMPK: in skeletal muscle, leptin stimulates AMPK whereas in the 
hypothalamus, leptin decreases AMPK activation (Carling, 2004). These opposite effects 
of leptin both contribute to its overall effect on energy homeostasis, leading to an 
increase in fatty acid oxidation in peripheral tissues and reduction in appetite through 
action on the hypothalamus.  
AMPK Inhibits NEFA Synthesis. 
NEFA, stored as TAG, are the most significant source of stored energy that 
generate ATP. When AMPK is activated, NEFA synthesis, an anabolic pathway, is 
inhibited while NEFA oxidation, a catabolic process, is activated. AMPK reduces NEFA 
synthesis by inhibiting acetyl-CoA carboxylase (ACC) through phosphorylation, thus 
reducing the synthesis of malonyl CoA, the initial template for NEFA synthesis. In 
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addition, because malonyl-CoA is an allosteric inhibitor of the carnitine 
palmitoyltransferase-1 (CTP1), which is a carnitine shuttle for the transport of fatty acids 
into the mitochondrial matrix for oxidation, the lower levels of malonyl-CoA result in 
less inhibition of NEFA oxidation. Meanwhile, the inhibition of ACC stimulates transport 
of fatty acids into the mitochondria where they are oxidized to generate ATP (Tong, 
2005).  
AMPK activation in skeletal muscle increases glucose uptake and fatty acid 
oxidation (Carling, 2004). In the liver, AMPK activation inhibits glucose, fatty acid, and 
cholesterol synthesis. In adipose tissue, AMPK activation inhibits fatty acid synthesis and 
increases lipolysis, thus leading to breakdown of TAG and subsequent increased release 
of NEFA into the plasma (Carling, 2004). These changes in NEFA and TAG 
concentrations in mice treated with AICAR compared with the Control mice can be 
measured via metabolomics as described later. 
The central nervous system is involved in dietary regulation of appetite and 
food choices (Morton et al, 2006). Because AMPK is present in the hypothalamus, 
changes in activation of AMPK also lead to modulation of food intake. Morton et al. 
(2006) suggested that AMPK does affect food choice.  However, the effects of AMPK 
modulation on food choice are not fully clear, though it is expected that mice with 
increased AMPK activation will consume more of a high-fat diet if allowed (Morton et 
al, 2006). What is currently known is that increased AMPK activation in the 
hypothalamus is associated with increases in energy expenditure through increased fatty 
acid oxidation, and adipocyte lipolysis, but reduced lipogenesis. 
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The hypothalamus senses levels of NEFA and other circulating lipids, acting as an 
energy regulator and initiator of the release of hormones such as leptin, ghrelin, 
adiponectin, resistin and insulin by other tissues. As mentioned earlier, obesity related 
hyperlipidemia causes lipid build up and eventually lipotoxicity in non-adipose tissues. In 
particular, this resulting impairment of lipid metabolism in the hypothalamus affects 
metabolic homeostasis. Although the mechanism of hypothalamic metabolic regulation is 
unknown, increased levels of malonyl-CoA in the hypothalamus have been associated 
with decreased food intake and low body fat in mice. Fasting mice results in AMPK 
activation and inhibition of ACC in the hypothalamus. The reduced levels of malonyl-
CoA and AMPK activation are associated with enhanced appetite and increased food 
intake and body weight. This indicates a change in metabolic set point where the body 
attempts to conserve energy. Refeeding decreases AMPK activation in the hypothalamus 
which leads to reduced food intake (Martínez de Morentin et al., 2010). However, this 
effect may not be apparent in previously obese mice, which indicates a metabolic imprint. 
This refeeding period corresponds to the period in which the mice in our study stop 
dieting and return to a standard diet where they consume food in excess of their non-
obese counterparts.  
AMPK in the liver. 
AMPK plays a major role in the control of hepatic metabolism through short-term 
effects on phosphorylation of regulatory proteins as well as through long-term effects on 
gene expression. Activation of AMPK in the liver also leads to the stimulation of NEFA 
oxidation and inhibition of lipogenesis, glucose production, and protein synthesis (Viollet 
et al., 2006). 
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In the liver, AMPK is activated by the metabolic challenges imposed by either a 
period of fasting or dietary energy restriction (Jiang et al., 2008). In the liver, the 
transition from the fasted to the fed state is also associated with physiological changes in 
energy dynamics. The reversal of the metabolic response to starvation includes alterations 
in enzyme phosphorylation states and changes in the concentration of key regulatory 
molecules. It has been reported that AMPK coordinates the changes in the activity and 
expression of a number of enzymes of lipid metabolism during refeeding (Munday et al., 
1991; Dentin et al., 2005). Additionally, hepatic AMPK can be regulated by ghrelin, 
endocannabinoids, glucocorticoids, resistin, and adiponectin (Viollet et al., 2009). 
Hepatic AMPK activation can be adjusted and regulated by several drugs such as 
AICAR (5-aminoimidazole-4-carboxamide-1--D-ribofuranoside), compound A-769662 
(Cool et al., 2006), polyphenols and two major classes of existing antidiabetic drugs 
biguanides (metformin and phenformin) and thiazolidinediones (TZDs) (Saha et al., 
2004). AICAR has been extensively used both in vitro and in vivo to activate hepatic 
AMPK (Viollet et al., 2006). 
AICAR (5-Aminoimidazole-4-carboxamide ribotide). 
AICAR (5-Aminoimidazole-4-carboxamide ribotide), an analog of AMP, has 
been used to pharmacologically activate AMPK. Upon exposure, cells take up AICAR 
and convert it to AICA ribotide (ZMP). ZMP serves as the analog of AMP, and thus 
activates AMPK through the same chemical pathway as AMP. AICAR has been shown to 
affect food intake, body composition, and glucose uptake and metabolism by cells.   
Researchers have found that activation of AMPK by administration of AICAR 
alters body composition by reducing both visceral and subcutaneous adiposity in rats 
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(Gaidhu et al, 2011). Jessen et al. (2003) chronically administered AICAR to rats and 
compared glucose transport in skeletal muscle fibers to rats that performed regular 
exercise, and found that both exercise and AICAR administration improved insulin-
stimulated glucose transport, suggesting that AICAR can mimic effects of exercise on 
glucose clearance.  
Previous in vitro studies with rat hepatocytes have shown that AICAR 
treatment activates AMPK, resulting in reduced fatty acid synthesis and glucose 
production by inhibition of ACC and 3-hydroxy-methylglutaryl CoA reductase (Buhl et 
al., 2002). Thus, AICAR treatment has been implicated to suppress gluconeogenesis 
through downregulation of gluconeogenic enzymes. 
AMPK and Insulin resistance. 
Insulin-resistance, or the inability of insulin to stimulate peripheral tissue uptake 
and clearance of glucose, is a hallmark metabolic feature of type 2 diabetes. During 
hypoxia, AMPK was found to be responsible for the insulin-independent rise in GLUT4 
translocation (Jessen et al., 2003). There was also an increase in membrane GLUT4 
content upon AICAR treatment. And, long-term AICAR exposure results in a significant 
decrease in plasma insulin and glucose levels. AICAR treatment also decreased 
endogenous glucose production in both normal and insulin-resistant obese rats (Halseth, 
Ensor, White, Ross, & Gulve, 2002).  Thus, AICAR may be a potential pharmaceutical 
regulator of hepatic gluconeogenesis. 
In diabetic rats, activation of hypothalamic AMPK may contribute to the rat’s 
hyperphagia and be explained by lower plasma levels of leptin and insulin in diabetic 
mice (Namkoong et al., 2005). Because AICAR has been shown in many studies to 
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improve blood glucose concentrations and lipid profiles, AICAR is an attractive 
pharmacological target for the treatment of Type 2 diabetes. 
Metabolomics  
In recent years, there has been much interest in developing metabolomics 
approaches and platforms to allow for the measurement of global metabolic changes in 
the body as a result of obesity. Metabolomics involves technologies such as nuclear 
magnetic resonance and mass spectrometry to measure metabolite concentrations, or 
products of metabolism, in different cells and tissues of the body. Because obesity 
involves systemic changes in metabolism, metabolomics can be a useful tool to identify 
dysregulations in specific organs and the whole body, and thus provide a description of 
the underlying metabolic issues that lead to and maintain the obese state (Gulston et al., 
2007). However, it is important to remember that metabolomics only provides a 
“snapshot” of the organism’s metabolic state at the specific timepoint that the organism’s 
tissue sample was collected. 
It has been found that obese animals are characterized by certain metabolites, 
including elevated plasma glucose, fumarate, malate, ribose, carnitine and pyrimidine 
nucleoside. Obese animals also have low plasma taurine levels (Gulston et al., 2007). 
There is variation between obese and normal weight animals in lipid composition and 
tissue composition. For example, the liver of obese rats has a lower ATP/ADP ratio 
compared to normal weight counterparts (Gulston et al., 2007). Additionally, 
metabolomics has improved our understanding of the dysregulations that occur in the 
insulin resistant state. Here, changes in plasma lysine, glycine, citrate, leucine, and 
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acetate were found to be the important metabolites in identifying insulin resistance 
(Shearer et al., 2008). 
However, an important distinction to make is that some changes in the 
metabolites may be due to short-term diet effects rather than a state of obesity. It has been 
found that changes in metabolites related to energy metabolism and glucose usage were 
caused by the diet, while an obesogenic state caused changes in amino acids and large 
non-polar molecules (Duggan et al., 2011). Although still a relatively new technology, 
metabolomics is an inexpensive approach to collect a large amount of data, allowing 
researchers to distinguish changes in metabolic pathways that characterize the state of 
obesity.  
Metabolic Imprinting 
A topic that is still being investigated is what factors determine an individual’s 
body weight set point. One theory is that metabolic imprinting is the mechanism that 
underpins the establishment of a given “set point”. One of the larger challenges to 
researchers is how to define the biological differences between individuals that seem to 
naturally carry more weight and those that carry less weight. An explanation to this is the 
set point theory, which was proposed by Bennet and Gurin in 1982. The theory states that 
the body has an internal regulator that controls how much fat it naturally tends to store. In 
other words, an individual’s metabolism adjusts to maintain a certain “preferred” weight. 
This preferred weight is one descriptor of the body’s “set point,” and explains why 
individuals who lose weight following diet restriction tend, over time, to regain the lost 
weight (Kahn and Flier, 2000). This set point is what appears to vary among individuals 
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of different natural body compositions (e.g. proportion of whole body fat versus lean 
tissues). 
One measure of an animal’s set point is their food efficiency. This is simply the 
amount of weight gained per calorie consumed. If an animal is more efficient in storing 
food, they will tend to deposit more fat when consuming the same amount of food than a 
less efficient animal consumes. Naturally, as a biological survival mechanism, the 
efficiency of storing food as fat is enhanced in times of diet restriction or reduced food 
availability (de Ferranti & Mozaffarian, 2008). This is the body’s biological response to a 
lack of food. Evolutionarily, this has the benefit of helping an animal survive during the 
winter when food availability and quality are poor or during famine. This increase in food 
efficiency indicates a change in the animal’s metabolic and physiological set point. 
However, many food-deprivation and weight cycling studies in animals demonstrate that 
this change is only temporary—once the animal is again given ad libitum access to food, 
their food efficiency soon returns to normal (Maclean et al., 2004).  
Food efficiency is strongly connected with the idea of a set point because some 
individuals seem naturally more food efficient than others. One may again draw on the 
example of those who fail to gain much weight and remain “thin,” even though their 
calorie intake is at unhealthy levels. This is a very perplexing problem that remains 
without a definitive solution in current research.  
Metabolic imprinting refers to the permanent changes in biological processes that 
result from exposure to a specific nutritional environment (Waterland & Garza, 1999). 
Research has demonstrated that early metabolic programming results in the establishment 
of set points for physiological and metabolic responses in adulthood. For example, 
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evidence from epidemiological studies and animal models indicate that maternal health 
and nutritional status during gestation and lactation have long-term effects on central and 
peripheral systems that regulate energy balance in the developing offspring (Hanley et al., 
2010). Perinatal nutrition also impacts susceptibility to developing metabolic disorders 
and plays a role in programming body weight set points. Thus, maternal over-nutrition, 
diabetes, and under-nutrition predispose offspring to an increased risk of developing 
obesity (Langhans & Geary, 2010). However, while prenatal nutrient restriction in rats 
increases adult obesity, postnatal nutrient restriction reversed the effect and resulted in 
normal, lean adults, showing that metabolic imprinting may also be affected by 
environmental changes after birth (Garg et al., 2012).  
Metabolic imprinting may also occur in adulthood as a result of diet-induced 
obesity. High fat diets can lead to an increased body weight and adipocyte number, which 
is correlated with elevated food intake and oxygen consumption (Corbett et al., 1986). 
Mice and rats that were fed high fat diets maintained a consistent obesity condition even 
when their diet was switched from a high to a low fat diet (Rolls et al., 1980; Guo et al., 
2009). When obese rats were subsequently given unrestricted access to the low fat diet, 
they returned to the same elevated weight and had greater fat stores than the control rats 
(Rolls et al., 1980). Additionally, obese people who diet or food-restrict tend to gain back 
the weight that they lose. This may occur because the state of obesity leaves a metabolic 
imprint, or permanent change in the metabolism of the body, that raises the body’s set 
point. However, among rats who developed diet-induced obesity and were subsequently 
given unrestricted access to a normal diet, rats bred to be diet-resistant were able to 
reduce their intake and returned to control weights while others plateaued at elevated 
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weights (Levin & Keesey, 1998). Therefore, there is an interaction between genetic 
predisposition and diet in the development of a consistent state of obesity.  
Long-term caloric restriction in humans has shown that fatty acid mobilization 
and oxidation during the fasting state is increased. In addition, calorie restriction led to 
increased insulin sensitivity (Huffman et al., 2012). A 3-week period of calorie restriction 
in rodents has previously been shown to lower plasma insulin, triglyceride, and 
cholesterol levels (Anson et al., 2003).  The reduction of these metabolites leads to 
reduced risk of diabetes and atherosclerosis. Chen et al. (2005) showed that in addition to 
the reduction of these plasma metabolites, there was increased physical activity in calorie 
restricted mice presumably due to increased foraging activity. Other studies have shown 
that calorie restriction reduces glucose levels and elevates ketone bodies (Greene, et al., 
2003). Thus, calorie restriction has been shown to have a wide range of health benefits. A 
previous study conducted by Duarte et al. (2012) which used a high fat diet to induce 
obesity resulted in increased fatty liver, increased adiposity, and circulating levels of 
leptin compared to the control mice. Subsequent calorie restriction did not reverse the 
metabolic changes from the high fat diet induced obesity, except a small decrease in fat 
mass.  However, upon refeeding, this decrease in fat mass was reversed, and the mice 
maintained the metabolic profiles of obesogenic mice.   
Most obese humans seem only to be able to increase their body weight set point 
permanently, while periods of calorie restricted weight loss are only temporary (Levin, 
2010). The change in set point caused by a state of obesity, together with genetic 
predisposition, causes metabolic changes that work to defend the high weight. Therefore 
even when obese rats are calorie restricted, their metabolism is adjusted in order to regain 
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the weight lost, characterized by reduced energy expenditure, increased drive to eat, 
higher food efficiency, lipid accumulation in adipose tissue, and altered neuronal signals 
(Maclean et al., 2006). Levin and Keesey (1998) showed that when obese rats that were 
not diet-resistant were calorie restricted to reach the weight of the control rats, their leptin 
and insulin levels dropped below the controls. However, when these rats were given 
unrestricted access to food, their food intake, food efficiency, and leptin and insulin 
levels rose to obesogenic levels again (Levin & Keesey, 1998). When lean and obese 
mice are calorie restricted, leptin expression decreases in obese mice but increases in lean 
mice, suggesting a metabolic imprint associated with their differing diets and weights 
(Kurki et al., 2012).  
Levin (2005) suggests that persistent obesity could be due to neuronal changes in 
the sections of the brain that regulate metabolism, such as the hypothalamus, amygdala, 
nucleus tractus solitaries, and striatum. These neurons sense metabolic substrates such as 
glucose, fatty acids, lactate and ketone bodies, and hormones, and use this information to 
alter energy intake and energy expenditure. In particular, previous studies have elucidated 
the connection between the hypothalamus and body weight control. Tanaka et al. (1978) 
conducted hypothalamic lesion studies in which the ventromedial nucleus was removed 
from birthing mice. They observed that while 3% of control mice developed obesity, 92% 
of treated mice whose ventromedial nucleus of the hypothalamus was removed developed 
morbid obesity, implicating that the hypothalamus plays a crucial role in feeding 
behavior and weight control.   
As with most neurons in the brain, the hypothalamic neurons are constantly being 
rewired in a process known as synaptic plasticity. Diet during prenatal and postnatal 
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development can have long lasting effects in the hypothalamus, causing changes in 
energy regulation (Levin, 2010). Horvath (2006) showed that during high fat diet-induced 
obesity in mice, the synaptic plasticity of the hypothalamic neurons was influenced by 
many factors, particularly leptin. This leptin-mediated plasticity of the hypothalamus, 
therefore, is altered during high fat diet-induced obesity, and the hypothalamus changes 
in response to leptin released in the obesity state (Horvath, 2006). Additionally, rats that 
are obesity-prone have dysregulated hypothalamic pathways and a reduced response to 
leptin (Bouret et al., 2008).  
Another important theory relevant to this project is the “thrifty gene” hypothesis. 
Maintaining energy homeostasis by balancing food intake and energy expenditure 
through exercise and basal metabolism is crucial for survival (Spiegelman & Flier, 2001). 
A complex array of physiological processes regulates the rate of catabolic processes that 
generate energy and anabolic processes that consume energy. These physiological 
mechanisms maintain body weight and energy stores in homeostasis. In addition to 
regulating the energy balance of daily activities, such as exercise and food intake, an 
organism must be able to store energy for prolonged periods of food scarcity. The “thrifty 
gene” hypothesis describes how natural selection favored the advantageous traits of 
effective energy storage during periods of excess to allow survival during periods of 
famine (Spiegelman & Flier, 2001). In order to maintain energy homeostasis, metabolism 
is regulated at the gene transcription and translation, cellular and tissue, and whole 
organism levels.  
For optimal health and survival of humans and animals, a balance between 
catabolic and anabolic processes must be maintained. Catabolic processes include 
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carbohydrate, amino acid and fatty acid oxidation. Anabolic processes, such as fatty acid, 
protein, and cholesterol synthesis, are necessary for normal cellular division and growth, 
and for health and survival. In humans, it is critical to the maintenance of a constant body 
weight that the balance between these energy-generating and energy-consuming 
processes be maintained, otherwise, under-nutrition or overweight and obesity will ensue.
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Chapter 3 - Methodology  
Experiment 1 Rationale 
The aims of this experiment were: 1) to characterize the developmental timeline 
for the attainment of obesity and related metabolic derangements in C57BL/6J mice and 
2) to determine whether establishment of this obese state and resultant metabolic 
syndrome entrains an ‘imprint’ that establishes certain metabolic set points (e.g. AMPK 
activation, glucose and fatty acid metabolisms) that remain despite a period of weight 
loss.  
Experiment 1 Methodology 
University of Maryland’s Institutional Animal Care and Use Committee (IACUC) 
approved all experimental procedures (R-11-42). Male C57BL/6J mice (n = 54, Charles 
River, Wilmington, MA) were acquired at 3 weeks of age. Upon arrival, mice were 
housed in plastic cages in groups (n = 6 mice/group) during which they were fed ad 
libitum a standard diet (TD.06416, TekLad), had free access to water provided by an 
automatic dispenser system and were kept on a 12 hour light/12 hour dark cycle in the 
Department of Animal and Avian Sciences Animal Wing at the University of Maryland. 
At 8 weeks of age, 48 mice were placed into individual plastic cages and randomly 
allocated to either a Control or Diet Induced Obesity (DIO) Group. The Control mice 
were fed a standard diet (2018 Teklad Global 18% Protein Rodent Diet). The standard 
diet had an energy density of 3.1 kcal/g, with 24% of energy from protein, 18% from fat, 
and 58% from carbohydrates. The DIO mice were fed a high fat diet (Teklad Rodent Diet 
TD.06414). The high fat diet had an energy density of 5.1 kcal/g, with 18% of energy 
from protein, 60% from fat, and 21% from carbohydrates. The remaining mice (n = 6), 
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which served as baseline controls, were given a glucose tolerance test (GTT) after which 
blood and tissues were collected and analyzed as described below. 
The experiment lasted 13 weeks (Figure 3-1). After 4 and 8 weeks on both 
Control and experimental diets, groups of mice (n=6, n=6) were fasted for 4 h, after 
which they were given the GTT and subsequently euthanized by CO2 asphyxiation, and 
blood and tissues were removed for later analysis. At week 8, the remaining mice in the 
Control group continued to consume the basal diet ad libitum while the remaining mice in 
the DIO group were food restricted (20% less energy intake) on the basal diet for 2 weeks 
and then allowed to consume the basal diet ad libitum for the final 3 weeks of the study. 
Subsequently, at weeks 10 and 13, groups of mice (n=6, n=6) were fasted for 4 h after 
which they were given the GTT and subsequently euthanized by CO2 asphyxiation, and 
blood and tissues were removed for later analysis. See below for descriptions and 
explanations of laboratory analyses.  
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Figure 3-1. Experiment 1 design and treatment arrangements. 
 
Experiment 2 Rationale 
The aims of this experiment were: 1) to characterize the influence of AMPK 
activation on the obesogenic state of the C57BL/6J mice and 2) to determine whether 
increasing AMPK activation affects the metabolic profile encountered due to obesity and 
subsequent weight loss.   
Experiment 2 Methodology 
University of Maryland’s Institutional Animal Care and Use Committee (IACUC) 
approved all experimental procedures (R-11-42). Male C57BL/6J strain mice (n=48), 
(Charles River, Willmington, MA) were acquired at 6 weeks of age. Upon arrival, mice 
were housed in stainless steel cages (n=6 mice/cage) during which they were fed ad 
libitum a standard diet (TD.06416, TekLad), had free access to water provided by an 
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automatic dispenser system and were kept on a 12 hour light/12 hour dark cycle in the 
Department of Animal and Avian Sciences Animal Wing at the University of Maryland. 
At 8 weeks of age, 48 mice were placed into individual plastic cages and randomly 
allocated to either the standard (Control, n = 18) or the high fat (DIO, n = 24) diet. The 
composition of the standard (2018 Teklad Global 18% Protein Rodent Diet) and the high 
fat diets (Teklad Rodent Diet TD.06414) were the same as in Experiment 1. The 
remaining mice (n=6) served as baseline controls and were given a glucose tolerance test 
(GTT) and blood and tissues were collected following euthanasia as described below. 
The Control and DIO groups were fed their respective diets ad libitum for 8 
weeks (Figure 3-2). In Experiment 1, the results indicated that 8 weeks was a sufficiently 
long enough period to induce a state of obesity and to reduce the ability of the mice to 
clear blood glucose as determined by the GTT. After 8 weeks on standard and high fat 
diets, mice (n=6) from each dietary group were fasted for 4 h, after which they were 
given the GTT and subsequently euthanized by CO2 asphyxiation. Blood and tissues were 
removed for later analysis as described below. The remaining mice in the DIO group 
were allocated to three treatment groups (n = 6 per group) that received either 1) the DIO 
ad libitum plus intraperitoneal (IP) administration of buffered (pH 7.4) sterile saline, 2) 
the DIO ad libitum plus IP administration of 5-amino-4-imidazole carboxyamide riboside 
(AICAR, 0.5 mg/g body weight), or 3) the standard diet at 80% of previous 
metabolizable energy intake plus IP administration of buffered sterile saline. The mice 
remaining from the Control group continued to be fed the standard diet ad libitum and 
were allocated two treatment groups (n = 6 per group) that received either 1) IP 
administration of buffered (pH 7.4) sterile saline or 2) IP administration AICAR (0.5 
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mg/g body weight), Mice received the IP injections of buffered (pH 7.4) sterile saline 
(0.28 mL per injection) or AICAR (dissolved in 0.28 mL saline per injection) three times 
per week for 2 weeks. After 2 weeks, mice were fasted for 4 h, after which they were 
given the GTT and subsequently euthanized by CO2 asphyxiation. Blood and tissues were 
removed for later analysis as described below. 
  
 
Figure 3-2. Experiment 2 design and treatment arrangements 
 
Treatment and Analysis for Experiments 1 and 2 
The subsequent sections outline the treatment and analysis performed on mice at 
the aforementioned time points labeled in Figures 3-1 and 3-2. Mice in Experiments 1 
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and 2 were subjected to the following methods relating to feeding, body weight analysis, 
glucose clearance, tissue collection, AMPK analysis, fat content and metabolomics.  
Feeding. 
When mice were fed ad libitum, a known amount of feed was placed in food 
hoppers at the beginning of each week. Hoppers were checked daily and extra feed was 
added as needed. The amount of feed consumed by each mouse was recorded at the end 
of the week. The food hoppers were designed to allow easy access to feed by the mice yet 
prevent feed spillage.  
During the calorie restriction phase for the mice previously fed the HFD, a fixed 
amount of feed was placed into a glass tube feeder and feed remaining the next day was 
weighed and recorded. The feeder consisted of a glass test tube with a smoothed hole 
near the bottom to allow easy access yet prevent feed spillage. 
Body Weight. 
At the end of every week, all mice were weighed and body weight was recorded. 
A small beaker (250 mL) was placed on a standard laboratory scale. The mouse was 
placed inside the beaker, and the weight was recorded in grams (0.1 g). 
Glucose Tolerance Test (GTT). 
The GTT was performed on mice (n = 5-6) from both the Control and DIO mouse 
groups at 4, 8, 10, and 13 weeks to determine changes in pancreatic function (i.e. insulin 
secretion) and the ability of tissues (mainly muscle) to clear blood glucose. The GTT is a 
standard test conducted to diagnose type 1 diabetes and the development of metabolic 
syndrome associated with obesity. The GTT was performed after fasting the mice for 4 
hours beginning at the onset of the light cycle. Prior to intraperitoneal injection of the 
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glucose dose, a sterile surgical blade was used to nick the tip of the tail to acquire a drop 
of blood for measurement of baseline blood glucose concentration using a hand held 
glucometer (AlphaTRAK, Abbott Labs, Inc.). Immediately after the baseline blood 
glucose sample, a bolus dose of a sterile solution of glucose (2g glucose/kg body weight) 
was administered by intraperitoneal injection. At 30, 60, 90 and 120 min after the glucose 
bolus, glucose concentration was measured in a drop of blood from the tail by gently 
removing the clot over the incision and massaging the tail vein (Andrikopoulos, Blair, 
Deluca & Fam, 2008). 
Euthanasia and Tissue Collection. 
After the GTT, mice were placed individually into a sealable polycarbonate 
chamber and the chamber purged with CO2 until breathing had stopped for at least one 
minute. Euthanasia by CO2 asphyxiation leads to rapid death without severe distress or 
pain (Hackbarth, Kuppers & Bohnet, 2000). After euthanasia, the peritoneal cavity and 
posterior vena cava of the mice was exposed by blunt dissection through the abdominal 
cavity and a blood sample (approximately 0.5 ml) withdrawn into a tuberculin syringe 
(27 ga needle, 0.5 mL) containing ethylenediaminetetraacetic acid (EDTA) to prevent 
blood clotting. Whole blood was aliquotted (150 µL) into three tubes and placed on ice 
prior to storage at -20 C. Removal of this quantity of blood also ensured death by 
exsanguination. Immediately following blood sampling, the mice were decapitated and 
the whole liver was removed, weighed, sliced into 200-400 mg amounts, and wrapped in 
aluminum foil prior to plunging the sample into liquid nitrogen. The empty carcass 
(minus visceral organs, lungs and heart) was weighed, placed into a ziplock freezer bag 
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on ice, and within 2 h stored at -20 C.  Liver samples were also stored at -20 C for 
metabolomics and AMPK analyses. 
Measurement of AMPK activation. 
AMPK activation was measured in liver samples from mice. Once removed from 
the freezer, liver samples were kept on ice. For processing, liquid nitrogen was poured 
over a sample (approximately 0.6-0.7 g) to allow the sample to be crushed. The crushed 
sample was transferred to a 2 mL snap cap tube placed in ice, and 0.5 mL of extraction 
solution added followed by homogenization for 1 min (Brinkman POLYTRON 
Homogenizer, Brinkman Instruments, Inc., Westbury, NY). The protein extraction 
solution consisted of 20 mM Tris-HCl, 150 mM NaCl, 1 mM EGTA (ethylene glycol 
tetraacetic acid), 1% Triton-X-100, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride 
in isopropanol, and 1x Halt
TM
 Protease and Phosphate Inhibitor Cocktail (Thermo 
Scientific). After homogenization, samples were centrifuged at 15,000 ×g for 10 min at 4 
C. The supernatant was removed and stored at -20 C. 
Protein concentration in liver extracts was determined using the Bradford assay. A 
standard curve was constructed for each 8 by 12 well plate. A standard curve of bovine 
serum albumin at 0, 8, 16, 24, 44, and 64 μg/ml was used. One sample from each 
treatment group was diluted 1:50, 1:250, 1:500, and 1:1000 to establish the proper 
dilution that falls on the standard curve. For samples from week 8 and 10 mice, a 1:500 
dilution was required whereas for week 13 samples a 1:1000 dilution was necessary. To 
each protein extract (160 μl of diluted sample) was added 40 ul of Coomassie Brilliant 
Blue G-250 dye and absorbance measured at 595 nm using a UV-Vis spectrophotometer. 
All samples were run in triplicate. 
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For determination of phosphorylated AMPK α (AMPK activation) in liver, about 
50 µg of total protein was analyzed (AMPK α [pT 172] immunoassay kit, Invitrogen 
Corp., Camarillo, CA) according to the manufacturer’s protocol. Absorbance was 
recorded at 450 nm using a microplate reader (ThermoElectron, San Jose, CA). Final 
AMPK activation was calculated using standards supplied with the kit. 
Fat Content. 
The fat content of the carcasses was determined by Soxhlet extraction. The 
carcass consisted of the decapitated and eviscerated mouse. Frozen carcasses were 
pulverized under liquid nitrogen in a freezer mill (model 6850, Spex Certiprep, 
Metuchen, NJ), weighed and lyophilized to dryness (FreeZone 12 L Freeze Dry System, 
Labconco Corp, Kansas City, MO). After drying (3-4 days), samples were weighed for 
calculation of carcass water and dry matter contents. Fat extractions were performed in 
triplicate on 1 gram samples.  
Briefly, samples (1 g) were weighed into a porcelain extraction thimble, covered 
with a piece of gauze and continuously extracted in petroleum ether over approximately 
18 h. The process extracts all compounds dissolvable in ether, including tissue 
triglycerides, fatty acids and other lipid compounds (e.g. phospholipids). After extraction 
and complete evaporation of residual ether, the whole thimble was weighed and recorded. 
The difference between the initial and final weight of the thimble represents the loss of 
lipid, which was then extrapolated to a fresh (wet) carcass weight after correction for 
water loss following lyopholization.  
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Metabolomics. 
Metabolomics analysis on whole blood and frozen liver was performed on all 
samples. Polar and non-polar metabolites (e.g. fatty acids, glucose, amino acids, Krebs 
cycle keto-acids, glycolytic intermediates) were extracted and derivatized for gas 
chromatography-mass spectrometry (GC-MS, Agilent, Palo Alto, CA) analysis.  
For blood samples, to a known weight of thawed chilled whole blood (0.1 g) was added a 
known weight (0.05 g) of a solution containing the internal standard norleucine (1.3 
mM). Next, ice-cold methanol (1 mL) was added, and the samples were vortex mixed for 
15 min on an orbital shaker. At room temperature, the methanolic supernatant was 
separated following centrifugation (15,000 ×g, 15 min at 4 C), transferred to a glass v-
vial and reduced to dryness under a gentle stream of nitrogen gas. 
For liver samples, to a known weight of chilled liver (0.05 g) was added a known 
weight (0.05 g) of a solution containing the internal standard norleucine (3.8 mM). Next, 
an ice-cold mixture of methanol: chloroform: water (5:2:2) was added (1 mL), and the 
samples were homogenized on ice for 2 min. The samples were vortexed for 15 minutes, 
the organic supernatant was separated following centrifugation (15,000 ×g, 15 min at 
4C), transferred to a glass v-vial, at room temperature, and reduced to dryness under a 
gentle stream of nitrogen gas. 
For both the blood and liver dried extracts, metabolites were derivatized by the 
additions of 60 uL of O-methoxylamine in pyridine (30 mg/mL) and 60 uL of N,O-
bistrimethylsilyl trifluoro-acetamide (containing1% trimethylchlorosilane) with heating 
in a microwave (200 W for 90 seconds). Derivatized metabolites were separated by GC 
(HP6890 GC, HP50+ midpolarity capillary column) and full scan monitoring (50-650 
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molecular weight) of metabolite ions was performed on an MS (HP5973 Mass Selective 
Detector) under electron impact mode.  
Individual metabolite data was extracted from RAW GC-MS spectra using 
AMDIS Version 2.71 (http://chemdata.nist.gov/mass-spc/amdis). Metabolite values were 
normalized to norleucine internal standard using G3835AA MassHunter Mass Profiler 
Professional (Agilent Technologies, Santa Clara, CA) following manufacturer’s software 
instructions. Metabolites were identified in Mass Profiler Professional using the Fiehn 
Library (G1676AA). 
Statistical Analysis 
Differences between data were analyzed using Student’s t-tests, and in the case of 
unequal variance, a Welch’s t-test. Body weight, food and energy intake, body 
composition, and glucose clearance were analyzed in excel using Welch’s 2-tailed t-test, 
with P < 0.05, as well as Chi Squared tests. Metabolomics data was analyzed in 
SAS/STAT® Software. Experiment 1 metabolomic data was analyzed using pooled 
student’s t-test or Satterthwaite t-test. Experiment 2 metabolomic data was compared 
using Tukey multiple mean comparison test with ANOVA.  
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Chapter 4 - Experiment 1 Results and Discussion 
Weight and Energy Consumption 
Weight gain and Food efficiency. 
The high fat diet successfully induced a steady weight gain in the DIO group up 
to week 8 (Figure 4-1). From weeks 4 to 8, the rate of weight gain was higher in the DIO 
group compared to the Control group. Previous studies with mice fed a similar HFD diet 
demonstrated that this pattern of body weight and fat gain continues beyond 8 weeks. The 
stability of this growth rate relative to the Control group (Figure 4-2) results from the 
higher energy density of the HFD (5.1 kcal/g), (i.e. about the energy-density of an 
average brownie). The DIO group gained weight mainly in the form of fat as opposed to 
protein (Figure 4-9), confirming that consuming the HFD diet for 8 weeks was adequate 
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Figure 4-1. Experiment 1: Weekly body weight. Control mice were allowed ad libitum intake of 
the standard diet (SD) from week 0 to 13. From weeks 0 to 8 the DIO mice were allowed ad 
libitum intake of the high fat diet, from weeks 8 to 10 the DIO mice were fed the SD diet at 80% 
of caloric intake compared to the ad libitum period and from weeks 10 to 13 the DIO mice were 
allowed  ad libitum intake of the SD. Individual data points represent the means of: Control: n=20 
for weeks 1-4,  n=14 for weeks 5-8, n=9 for weeks 9-10 and n=5 for weeks 11-13; DIO: n=21 for 
weeks 1-4,  n=15 for weeks 5-8, n=10 for weeks 9-10, and n=5  for weeks 11-13. * indicates a 
significant (P<0.05) difference between groups. Error bars represent the standard error of the 
mean. 
 
After switching to the SD diet and being fed at 80% of energy intake at the 
beginning of week 9, the DIO group immediately and steadily lost weight, indicating that 
the mice were not able to sustain their high body fat when fed the Control diet.  
We quantified how well the two groups stored energy from food as body weight 
(i.e. how readily the body gained weight under a normal diet). This measurement, called 
“food efficiency,” would help detect an obesity-induced change in the body’s preferred 
amount of fat.  
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Figure 4-2. Experiment 1: Weekly food efficiency. Values represent the ratio of weight gained to 
calories consumed per week. Refer to Figure 4-1 for the descriptions of the 3 dietary periods for 
the DIO mice. Individual data points represent the means of: Control: n=20 for weeks 1-4, n=14 
for weeks 5-8, n=9 for weeks 9-10 and n=5 for weeks 11-13; DIO: n=21 for weeks 1-4,  n=15 for 
weeks 5-8, n=10 for weeks 9-10, and n=5  for weeks 11-13. Error bars represent the standard 
error of the mean. 
 
We expected that following the period of food restriction, the DIO mice would 
retain a “metabolic imprint” that would eventually lead them to naturally continue to 
store dietary energy more efficiently once the mice were offered ad libitum intake of the 
SD diet. 
The food efficiency plot in Figure 4-2 reports this as the ratio: 
                                  
                                  
. However, this ratio is not meaningful when the caloric 
intake is very different between the groups; the DIO mice have higher food efficiency 
values up until the diet switch only because they are rapidly gaining weight as a result of 
their diet. The higher values do not necessarily imply that they are naturally better at 
Chapter 4 – Experiment 1 Results and Discussion 53 
storing fat. Food efficiency as a measure of a natural ability to store fat is likewise not 
very meaningful during the weight loss period, when the ratio is negative (Figure 4-2). 
The weight of the DIO group would need to stabilize before food efficiency could 
demonstrate a metabolic imprint (by consistently remaining higher than the Control 
group’s food efficiency). However, because the body weight of the food restricted DIO 
mice fed ad libitum never fully stabilized over the 3-week period, the food efficiency 
measurements failed to fully capture the metabolic imprint of the DIO group. The 
eventual increase in food efficiency over the final week of ad libitum intake, however, is 
promising because it means that weight loss was slowing and eventually reverting back to 
weight gain—possibly reflecting an imprint that predisposed the post-obese mice to 
maintain a higher body weight. Unfortunately, our study did not continue longer than the 
3 weeks of ad libitum intake of the SD diet to further emphasize possible long-term 
changes in body weight and fat set points. The potential of obesity to cause this kind of 
metabolic imprinting will need to be investigated over longer periods of time than what 
was possible in the present study. 
The nature of the diet: Food Intake vs. Energy intake.  
When comparing food intake (Figure 4-3) to caloric intake (Figure 4-4), the 
difference between the two diets immediately becomes clearer. 
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Figure 4-3. Experiment 1: Weekly food consumption. Weekly values represent the average intake 
(as-is basis) of each group. Refer to Figure 4-1 for the descriptions of the 3 dietary periods for the 
DIO mice. Individual data points represent the means of: Control: n=20 for weeks 1-4, n=14 for 
weeks 5-8, n=9 for weeks 9-10 and n=5 for weeks 11-13; DIO: n=21 for weeks 1-4, n=15 for 
weeks 5-8, n=10 for weeks 9-10, and n=5 for weeks 11-13. * indicates a significant (P<0.05) 
difference between groups. Error bars represent the standard error of the mean. 
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Figure 4-4. Experiment 1: Weekly energy consumption. Values represent the energy (kcal) 
consumed per week for each group. Refer to Figure 4-1 for the descriptions of the 3 dietary 
periods for the DIO mice. Individual data points represent the means of: Control: n=20 for weeks 
1-4, n=14 for weeks 5-8, n=9 for weeks 9-10 and n=5 for weeks 11-13; DIO: n=21 for weeks 1-4,  
n=15 for weeks 5-8, n=10 for weeks 9-10, and n=5  for weeks 11-13. * indicates a significant 
(P<0.05) difference between groups. Error bars represent the standard error of the mean. 
 
The DIO group consumed less food than the Control group during the first eight 
weeks, but consumed much more energy. This is possible due to the very high energy 
density of the DIO diet: 5.1 kcal/g for HF diet versus 3.1 kcal/g for the SD diet. This 
difference in energy density resulted in the DIO mice consuming less compared to the 
Control group. Thus, when the DIO mice were energy restricted after the switch to the 
SD diet, their weekly food intakes increased by 3.5 g (week 9, Figure 4-3) to a level that 
was similar to the Control mice. 
Our methodology intended a two-week caloric restriction period (on the SD) 
starting the beginning of week 9 and then a switch to ad libitum feeding of SD for the 
next three weeks. Our plot of food intake however reveals that DIO mice did not eat 
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significantly more once given ad libitum access to the diet. For this reason, we executed 
an effective methodology, which consists of an eight week HFD feeding period followed 
by a five week “diet phase” for DIO mice.  
Energy consumed over body weight. 
There is also a relationship between food consumption and body weight (Figure 
4-5). Each point represents the mass of food consumed and body weight of a single 
mouse during one week. The positive correlation coefficients, Control R=0.45 and DIO 
R=0.63, demonstrate a trend towards heavier (not necessarily DIO) mice consuming 
more food, as anticipated. The slopes of this relationship are nearly the same between 
Controls (slope=0.48) and the DIO (slope=0.49), implying that a given difference in body 
weight will, for each group, correspond to the same difference in food intake. Since the 
Control mice (blue line) lie above the DIO points (orange), the average food consumed 
per gram body weight is not equal between the groups; the Controls each consumed more 
per gram body weight.  
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Figure 4-5. Experiment 1: The relationship between body weight and food consumed. This 
correlation relates food mass consumed in one week to body weight at the end of that week. Each 
value represents a single mouse at a given week, and mice at all time points are plotted. Mice are 
generally observed to eat in proportion to their body weight for both groups. 
 
In a plot relating energy (kcal) consumed to body weight (Figure 4-6), the 
difference in dietary energy density resurfaces. The DIO points now lie above the Control 
group points; DIO mice took in more calories per gram body weight than Controls, on 
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average. This scaling effect on the energy also causes the slope of the DIO group linear 
fit to be notably larger. The larger slope means that a given difference in body weight 
will correspond, within the DIO group, to a larger difference in caloric intake. Likewise, 
within the Control group, the same difference in body weight would correspond to a 
lesser difference in caloric intake. This fact has significant implications for an 
understanding of obesity and will be addressed later. 
 
Figure 4-6. Experiment 1: Energy consumed correlated to body weight. Different dietary energy 
densities resulted in a scaling effect on the slopes of the plot. Between a light and heavy mouse in 
the DIO group, there is a greater difference in energy intake. 
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Finally, in a plot relating the ratio
               
          
  to body weight (Figure 4-7), 
we find that the kcals consumed per gram body weight tends to decrease as body weight 
increases. That is, although heavy (not necessarily DIO) mice ate more food, they 
consumed a relatively smaller proportion of their body weight compared to lighter mice. 
Taken together, these trends (Figures 4-5, 4-6, 4-7) may shed some light on the 
mechanism underlying the development of obesity. It is assumed that when provided ad 
libitum access to food, mice will consume to the point of satiation. How much food is 
satiable for each mouse is more or less proportional to their body weight, demonstrated 
by Figure 4-5. However, when the heavier mice in the DIO group ate to satiety (i.e. 
intake proportional to their body weight), they consumed energy disproportionately due 
to the high energy density of the diet. Thus, since food (mass) consumption is 
proportional to body weight and an energy-dense diet causes a scaling effect on energy 
intake, when the more energy-dense diet is fed, there is a greater caloric excess for heavy 
mice than for light mice. This fact is best demonstrated in Figure 4-7. If we consider the 
linear fit for the Control group to be a healthy ideal—a prescription for healthy energy 
consumption based on body weight—we see that there is a greater deviation from this 
ideal for heavy members of the DIO group than for light members, suggesting that a high 
energy diet is worse for heavy individuals because it tends to result in a greater deviation 
in caloric intake from a healthy ideal. These conclusions can help explain how obesity 
can develop; for heavy individuals, a satiable amount of food often translates to a 
disproportionately greater intake of calories—if that food is energy-dense.  
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Figure 4-7. Experiment 1: Energy consumed per gram body weight vs. body weight. The plot 
indicates that as mouse body weight increased, they consumed less energy per unit body weight. 
For DIO mice on the heavy end, there is a greater upwards deviation from their Control 
counterparts. If one considers the Control group’s linear fit a healthy ideal, this implies that a 
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Body composition 
Group totals over time. 
 Changes in body composition (lean dry mass, water and fat mass) are illustrated 
in Figure 4-8. For both groups, lean dry mass remained largely constant over the course 
of the 13 week experiment such that changes in weight were attributable to fluctuations in 
body fat and water mass. At week 4, there was not a significant difference in fat content 
between the DIO and Control groups. By week 8, however, the DIO group displayed a 
higher (P < 0.005) proportion of body fat (DIO, 43.34% vs. Control, 22.66%) and, in 
turn, a lower body water percentage. The DIO group’s rise in fat mass with no change in 
lean dry mass from week 4 to 8 suggests that the steady weight gain shown in Figure 4-1 
was due almost exclusively to accumulation of fat mass. Evidently, consumption of the 
HFD diet by the DIO mice resulted in a linear increase in fat mass (R = 0.996), while lean 
mass gain remained constant. The slope of a linear fit over the 8 weeks of consuming the 
HFD diet (Figure 4-9) indicates an average growth rate of 1.80 (± 0.08) g per week. A 
chi
2
 test comparing data to the fit yields P=0.90, indicating excellent agreement of DIO 
weight gain with a linear model. 
 Following two weeks of calorie restriction, while the DIO mice lost body weight, 
body fat percentage was not affected.  Because the Control group increased their body fat 
content over this same period to 32.47% (P<0.005), there was a large but not significant 
difference between the DIO and Control groups over the 2 week period the DIO mice 
were energy restricted (DIO 41.13%, Control 32.47%, P=0.087). 
After 3 weeks of consuming the SD diet ad libitum, there was a reduction 
(P<0.05) in body fat content of the DIO mice compared to values of the DIO mice at the 
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end of the initial 8 week period of consuming the HFD diet. This surprising decrease in 
body fat even after 3 weeks of ad libitum intake of the SD diet may be due to the 
continued weight loss of the DIO group during the first 2 weeks of consuming the SD 
diet ad libitum, during which the DIO mice maintained the same caloric intake as during 
the calorie restriction period. Over this same time period, the Control mice reduced their 
body fat content from 32.57 to 27.62%. It is unclear why the Control group showed a 
spike in fat content at week 10. 
 
Figure 4-8. Experiment 1: Body composition. Dry lean mass represents dehydrated and fat-
extracted non-visceral tissue, fat mass represents all ether extractable lipids and water mass is the 
loss in carcass weight after samples were lyophilized. DIO mice had a greater (P<0.005) 
proportion of body weight as fat mass after consuming the high fat diet for 8 weeks compared to 
Control mice consuming the standard diet and compared to the DIO mice at week 4 and week 13. 
This excess fat impinges on body water while dry lean mass is fairly constant.  
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Figure 4-9. Experiment 1: Linear weight gain of DIO mice when consuming the high fat diet. A 
χ² test of linear fit yields P = 0.9; R=0.996. This constant growth rate is hypothesized to be 
primarily due to fat gain. Error bars represent the standard error of the mean. 
 
Glucose Clearance 
The following figure shows the results of the glucose tolerance test at weeks 4, 8, 
10, and 13. The blood glucose concentration at each time point represents the mean (n=5-
6) value for each group.  
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Figure 4-10. Experiment 1: The mean of blood glucose concentrations following administration 
of 2g/kg glucose dose. Higher (P < 0.05) blood glucose concentrations were observed in DIO 
mice at weeks 4 and 8 compared to Control mice, clearly indicating impairment in the ability of 
the DIO mice to clear blood glucose. The DIO curve appears to be translated downward for the 
two test points after the diet switch (weeks 10, 13), indicating a progressively improving glucose 
clearance. Error bars represent standard error of the mean. (Control n=4-6, DIO n=6)  
 
 Chi-squared tests were used to evaluate the goodness of fit of the DIO mice to the 
Control mice at every data collection point. The curves differed (P < 0.001) at all time 
points except week 10. Upon integration, we saw a downward trend in blood glucose 
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weeks. From weeks 8 to 13, the DIO groups’ glucose concentration curve crosses over 
that of the Control group (Figure 4-10). The maintenance of the downward translation of 
the curve indicates a steady increase in glucose clearance in the DIO group. Hence, the 
DIO group developed a greater ability to clear blood glucose following the 2-week period 
of energy restriction on the SD diet. However, by week 13, the DIO glucose curve 
appears to over compensate given that the curve is lower than the Control curve at all 
time points after t=0. This downward deviation is significant (χ²=18.0, P=0.001) and may 
represent a hysteresis effect caused by the period of obesity.  
 
Figure 4-11. Experiment 1: Area under the curve of blood glucose concentrations during the 120 
min period following administration of a 2g/kg glucose dose. Glucose clearance for the Control 
mice remained similar throughout the 13 week experiment. In contrast to the Control mice, 
glucose clearance by the DIO mice at weeks 4 and 8 was lower (P<0.05). After 2 weeks of calorie 
restriction, however, the DIO mice improved (P<0.05) their ability to clear blood glucose. There 
was no significant difference between the Control and DIO groups at week 13. Error bars 
represent the standard error of the mean. (Control n=4-6, DIO n=5-6) 
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 Figure 4-11 provides another comparison between the DIO and Control groups. 
Each bar represents the area under the curve of the data from Figure 4-10. Higher values 
indicate a reduced ability to clear blood glucose, a sign of insulin resistance. At weeks 4 
(P < 0.05) and 8 (P < 0.005), the DIO group had higher integrated values compared to the 
Control group, thus the DIO mice were displaying symptoms of the metabolic syndrome 
of obesity. By contrast, there were no differences in glucose integrated values between 
the DIO and Control groups at weeks 10 and 13, (i.e. 2 and 5 weeks after the diet switch). 
The DIO integrated values were not different when comparing week 4 to 8 and week 10 
to 13. However, the values decreased (P < 0.005) for the DIO group between weeks 8 and 
10  when the DIO mice were switched from ad libitum consumption of the HFD diet to 
energy restricted intake of the SD diet. 
 The results agree with our previous expectations of the effect of a high fat diet 
and high body fat on glucose clearance. After 4 weeks on a high fat diet, the DIO group 
exhibits significantly elevated glucose intolerance, a sign of diet induced insulin 
resistance. The glucose intolerance progresses as the group gains weight, from week 4 to 
8. Finally, the sudden reduction in the DIO group’s dietary NEFA after week 8 induces a 
rapid improvement in glucose clearance implying that a change in diet has powerful 
effects on the body’s ability to metabolize glucose.  
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Glucose Clearance and Body Composition.  
 
Figure 4-12. Experiment 1: Correlation of integrated glucose concentration with percent body fat 
in dry matter. There is virtually no correlation between these two variables. Group means are only 
significantly separated in the dimension of percent body fat. Error bars represent standard error.  
 
Although the glucose clearance trend correlates strongly with increases and 
decreases in weight and percent body fat, investigating whether the glucose clearance 
values are tied to the fat stores of mice requires a plot relating integrated glucose values 
to percent body fat (Figure 4-12). Each point represents an individual mouse’s integrated 
glucose curve value and percent body fat by mass in the dehydrated carcass. The plot 
reveals a poor relationship (R=0.0019) and a relatively low, positive slope.  
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Figure 4-13. Experiment 1: Integrated glucose concentration per unit lean body mass. We observe 
no correlation between these two variables. Groups are not separated in the dimension of lean 
body mass. Black marks are placed to the side to illustrate group means (in glucose integrals) and 
relative variances. Error bars represent standard error.  
 
Glucose clearance correlates poorly with lean body mass, the sum of dehydrated lean 
mass and water mass (Figure 4-13). Since blood glucose is primarily taken up by muscle, 
a major form of lean tissue, the integrated curve values should decrease as lean mass 
increases. However, there is virtually no correlation. Due to the lack of dependence on 
lean mass, the glucose concentration measurements were not standardized. Any attempt 
to standardize glucose concentration values to lean mass would increase the slope of the 
data since mice with lean mass have presumably lower readings of blood glucose 
concentrations.  
Figures 4-12 and 4-13 and Figures 4-8, 4-8, and 4-11 above show a lack of a 
strong correlation between glucose clearance and percent body fat or lean mass on an 
individual basis and group average basis respectively. The DIO group’s glucose clearance 
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dramatically improved, with little change in body composition. The results suggest that 
the diet composition, particularly the rich saturated fat content in the HFD, likely exerts a 
greater metabolic influence on glucose clearance. The overcompensated glucose 
clearance in the DIO group can be attributed to a hysteresis effect (i.e. imprinting) due to 
the diet history of the DIO group. Weight and body composition are vastly different at 
week 10, after 2 weeks of diet, however, glucose clearance equalizes between the two 
groups. The analysis of dietary fat on glucose clearance and liver NEFA was investigated 
using metabolomics in subsequent sections. 
Metabolomics 
Review of Diet Composition.  
The standard diet and HFD have energy densities of 3.1kcal/g and 5.1kcal/g, 
respectively. For mice in the Control group, caloric intake is divided into three parts to 
reflect healthy nourishment for mice. The Control group derives 24% of calories from 
protein, 58% from carbohydrates, and 18% from fat. For the DIO mice, 18% of calories 
come from protein, 21% from carbohydrates, and 60% from fat. The high dietary fat 
content consists mostly of saturated fats that are broken down into NEFA, which 
subsequently accumulate in the liver, blood, muscle, and adipose tissue. The results 
indicate that the amount of hepatic NEFA varies with diet composition and correlates 
significantly with the state of glucose clearance. 
Dietary fat, glucose clearance, and insulin resistance. 
The accumulation of triglyceride stores in muscle and elevated amounts of 
circulating NEFA are strongly associated with impaired insulin action. However, 
postulates that describe the influence of high lipid availability on glucose metabolism 
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vary greatly. Literature suggests an impairment of glucose transport due to the down 
regulation of GLUT-4, decreased activation of insulin receptor tyrosine kinase, 
overstimulation of glucose production by the liver, and inhibition of glucose oxidation 
through a variety of pathways (Kahn & Flier, 2000).  
Research studies acknowledge the competition for respiration between glucose 
and fatty acids, which leads to a reciprocal relationship between their metabolisms 
(Randel 1999). Elevated NEFA and muscle triglyceride stores cause increased fatty acid 
oxidation, which impairs whole-body glucose oxidation and induces insulin resistance 
though a number of mechanisms (Storlien et al., 2006). Authors have shown that insulin 
sensitivity is inversely correlated with muscle triglyceride accumulation. Conversely, 
high blood glucose tends to inhibit fatty acid oxidation (Storlien, Jenkins, Chisholm, 
Pascoe, Khouri, & Kraegen, 1990). Fatty acids also play a central role in the development 
of insulin resistance. Prolonged exposure of islet β-cells to high circulating NEFA leads 
to attenuation of the secretory response to glucose. NEFA also induce the downregulation 
of GLUT-4 in myocyte membranes and thus prevent rapid glucose uptake. Finally, 
insulin resistance may also be caused by elevated transport of NEFA into mitochondria 
(Kien, 2009). 
Liver NEFA and glucose clearance on an individual basis. 
In individual mice, the results showed a weak and unexpectedly negative 
correlation between total NEFA levels (a sum over all NEFA investigated) and glucose 
clearance (Figure 4-14). 
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Figure 4-14. Experiment 1: Integral of glucose curve and total liver NEFA index. Total liver 
NEFA index (a sum) is intended to be an indicator of generally elevated NEFA concentrations.  
 
Since higher glucose curve integrals represent a relative inability to clear glucose, a 
positive correlation with total NEFA levels in both groups is expected. However, the 
outcome of this correlation may be complicated by the fact that not all dietary NEFA 
produce a deleterious effect on glucose clearance. Polyunsaturated fats such as linolenic 
(Ω-3) and linoleic acids (Ω-6) can, when introduced into a diet rich with saturated fats, 
lead to improved insulin sensitivity and may even prevent the development of insulin 
resistance (Storlien, Jenkins, Chisholm, Pascoe, Khouri, & Kraegen, 1990). Our 
experiment indicates a large variance in total NEFA within a given group (e.g. DIO week 
8 or Control week 8); this is possibly due to the high sensitivity of metabolomics to 
conditions preceding measurement.  Despite the lack of a positive correlation between the 
total NEFA in an individual mouse and its glucose curve integral, group averaged NEFA 
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levels (covered in next section) reveal significant changes during dieting that correlates 
strongly with the improved glucose clearance of the DIO group. Reduced circulating 
NEFA, and subsequent improved insulin sensitivity, suggests an explanation for the rapid 
improvement in DIO glucose clearance. 
NEFA over time. 
We observed the largest group differences in liver NEFA at weeks 4 and 8.  
Figure 4-15 shows group average metabolite peak areas for the four fatty acids 
investigated. At the first two test points (pre-diet phase), DIO livers have notably higher 
levels of linolenic, palmitic, and linoleic acids. They have lower levels of oleic acid. 
After two weeks on the standard diet (week 10), several DIO fatty acid levels aligned 
with Control levels, none, however, proved significantly different (Figure 4-18). This is 
clearly the result of the severe reduction in dietary fat intake of the DIO group. The 
realignment of DIO liver fatty acid levels after dieting and relative fixity of their fat 
stores demonstrates that dietary fat intake contributes heavily to liver NEFA levels 
(Figure 4-18).  
Palmitic acid is the main component of dietary saturated fat and adipose tissue 
stores. The observed significantly elevated DIO concentrations of palmitic acid are thus 
consistent with our expectations for a diet high in saturated fat. An excess of palmitic 
acid in both blood and liver fat stores is associated with the development of insulin 
resistance. Figures 4-10 and 4-15 demonstrate a high correlation between the DIO 
group’s relative glucose clearance and concentration of palmitic acid in liver. Glucose 
clearance worsens at test points where palmitic acid is high. The shift in Control levels 
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versus DIO levels of palmitic acid mirrors that of glucose clearance, although neither 
trend is significant.  
Oleic acid is a cis monounsaturated fatty acid and essential dietary fat component. 
Several mono- and poly- unsaturated fatty acids, including oleic acid, have been shown to 
markedly improve insulin sensitivity when included in a diet high in saturated fat. Diets 
low in oleic acid have been associated with insulin resistance. The relatively high Control 
group levels of oleic acid and low DIO levels are likely due to respective diet 
composition. The lack of this essential fatty acid in HFD for the first 8 weeks may have 
contributed to insulin resistance in the DIO group (Figure 4-15). 
 
Figure 4-15. Experiment 1: Relative levels of liver non-esterified fatty acids. Bars represent the 
means (Control n=4-6, DIO n=5-6) of each group and error bars represent the standard error of 
the mean. 
Chapter 4 – Experiment 1 Results and Discussion 74 
Principle Component Analysis of NEFA metabolic profiles. 
To gain an understanding of the NEFA profile of the group as a whole, we 
performed a Principle Component Analysis (PCA) of the collection of individual NEFA 
profiles. In PCA, each mouse’s profile is represented by a point in an n-dimensional 
space where the position along each dimension is the liver concentration of a different 
fatty acid (n=6, fatty acids). The space is compressed mathematically into a 3-
dimensional space where the original points are represented, with some loss of 
information. This assumes that within a group, proximity of NEFA levels along any set of 
dimensions will emerge as spatial clustering in the 3-dimensional “projection.” Hence, 
when members of a group are similar in at least some of their NEFA levels, the 3D 
representation will manifest a spatial nearness. 
Figure 4-16 shows the 3D representations of individual NEFA profiles of mice at 
each test point. The plus signs represent the center of mass of each group, and the spheres 
represent the standard deviation of the points from their center of mass. The spatial 
separation of the centers of mass (in distance) is used as a metric to evaluate differences 
between the NEFA profiles of the groups as a whole. Therefore, greater separation of the 
groups’ clusters signifies a greater difference between their respective metabolic profiles. 
More tightly clustered groups (smaller spheres) have members that are more similar in 
their NEFA levels.  
This depiction of data allows the ability to test significance in the difference 
between our groups’ metabolic profiles. We found that Control and DIO clusters are 
significantly spatially separated, and thus have significantly different NEFA profiles, at 
all weeks except week 10. The corresponding P-values are: P4=0.0087, P8=0.0568, 
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P10=0.109, and P13=0.0761 using α=0.10. The constant α is set at 0.10 because spatial 
clustering is difficult to produce unless several metabolites differ between the groups. 
The distance between the “means,” or in this case the centers of mass, produces a test 
statistic for a Welch’s T-test. The standard deviations are the sphere radii allowing 
statistical testing of the spatial separation of data clusters in 3D.  
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Figure 4-16. Experiment 1: Three-dimensional projections of metabolic profiles at each test point. 
All axes are effectively dimensionless. Plus signs are the centers of mass for each group, and 
sphere radius represents the standard deviation of points from their center of mass. Each point 
represents an individual mouse’s metabolic profile (its position determined by the unique 
amounts of each NEFA in its liver sample). Tighter clustering of a group represents closeness of 
the members’ NEFA profiles. Spatial separation of centers of mass implies systematic deviation 
of the group members from each other. Groups are significantly different at weeks 4, 8, 13 
(P<0.1). 
 
The PCA analysis reveals that members of the Control group differ systematically 
from their DIO counterparts in NEFA levels. For a given NEFA, members of each group 
tend to have similar levels amongst themselves and to differ systematically from 
members of the other group. That is, members of a group vary together across multiple 
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NEFA. This is the best evidence the difference in glucose clearance seen at weeks 4, 8, 
and 13. 
Energy Pathways and Glucose Metabolism 
Lactic Acid. 
 The trend of hepatic lactic acid levels from weeks 4 to 13 was established in a 
similar fashion as the fatty acid trends previously discussed. This trend was indicative of 
notable metabolic differences established between the DIO and Control groups, persisting 
during food restriction and increasing during subsequent ad libitum dieting periods. 
 Hepatic concentrations of lactic acid were similar for the DIO and Control groups 
at week 4, as shown in Figure 4-17. By week 8, when differences in energy intake, body 
weight, body fat proportion, and glucose clearance were largest compared to the Control 
group, hepatic lactate levels deviated slightly but in opposite directions relative to week 
4. After the 2 week food restriction period of the DIO group, hepatic lactic acid levels 
remained fairly constant in both groups relative to their respective levels in week 8. After 
3 weeks of ad libitum intake of the SD by the food restricted DIO group, hepatic lactic 
acid levels were significantly higher (P< 0.0005) than in the Control group. Similarly, 
metabolomics analysis of blood showed that lactic acid was also higher (P < 0.002) in 
blood of the DIO group after 3 weeks of ad libitum consumption of SD diet compared to 
the Control group. 
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Figure 4-17. Experiment 1: Liver lactic acid levels. Liver lactic acid was higher (P<0.05) in the 
DIO mice at week 13 following a 3 week period of consuming the standard diet ad libitum. Error 
bars represent standard error. (Control n=4-6, DIO n=5-6) 
 
 Prior studies have shown that the concentration of lactate in blood and liver is 
elevated in DIO mice compared to their lean counterparts (Xie, Waters, & Schirra, 2012). 
This elevation of lactate was suggested to occur because anaerobic glycolysis is up-
regulated in obese mice, which may cause the elevation of lactate levels. Also, lactate 
release from adipose tissue is increased because of increased mass in obese individuals. 
 Hepatic gluconeogenesis is up-regulated during fasting or periods of starvation 
when blood glucose levels are low. And, in animal models of insulin resistance and 
metabolic syndrome brought about by DIO, hepatic gluconeogenesis is also up-regulated. 
Blood lactate, derived mostly from muscle metabolism of glucose, is a major 
gluconeogenesis precursor taken up by the liver as part of the Cori Cycle. Elevated 
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lactate suggests an up-regulation of lactate uptake by the liver. It has been suggested that 
blood lactate may even serve as a suitable marker for overall dysregulation of hepatic 
glucose production (Xie et al., 2012). While the latter would seem to be compatible with 
our findings of elevated blood glucose (P=0.057) but lower hepatic glucose (P=0.0512) in 
the DIO group at week 13 (decreased hepatic glucose signifies a need for up-regulated 
glucose production), it is at odds with the fact that glucose clearance improved once DIO 
mice were food restricted and subsequently fed ad libitum the SD diet for 3 weeks. 
However, because of the persistent elevation and increase over time of lactate, and the 
elevation of other gluconeogenic substrates (see below), gluconeogenesis as a viable 
indicator of derangement in the obese state should be considered a potential indicator of 
persistent metabolic dysregulation. 
 With respect to liver AMPK, it is notable that AMPK activation in the DIO was 
considerably elevated after 3 weeks of consuming the SD diet ad libitum. As noted 
above, when hepatic AMPK is activated, gluconeogenic gene expression and hepatic 
glucose production are reduced. Thus, we would have hypothesized that if there is higher 
hepatic AMPK activation of the ad libitum fed DIO mice, signaling the need for ATP 
generation, then gluconeogenesis would be reduced to allow for the partition of substrates 
toward the Krebs cycle for oxidation. The fact that hepatic levels of gluconeogenic 
substrates remain elevated through week 13 suggests some disruption in this progression 
prevents oxidation of Kreb’s cycle intermediates. Perhaps some upstream or downstream 
components of the AMPK signaling pathway and/or metabolic pathways regulated by 
AMPK (i.e. gluconeogenesis) have been altered long term such that the metabolic 
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signature of the obese state continues to persist even when the mice were fed a standard 
lower fat diet.  
Previous studies have shown that NEFA concentration is positively associated 
with greater rates of gluconeogenesis, possibly due to increased ATP and NADH 
production via pyruvate carboxylase activity, a key enzymatic step to ensure high rates of 
acetyl-CoA and thus fatty acid oxidation (Consoli, Nurjhan, Reilly, Bier, & Gerich, 
1990). Our findings that several liver fatty acids are persistently elevated in the DIO 
group seem to support this view. Such patterns of dysregulation may be involved in some 
general change in metabolic set point that is suggested by our findings. Again, specific 
components in these pathways as well as others regulating gluconeogenesis must be 
examined to further confirm this view. 
Succinic Acid, Malic Acid and Pyruvic Acid. 
Figure 4-18. Experiment 1: Metabolome profile of mouse livers. Only those metabolites that were 
statistically different or tended (dotted) to be different between groups are shown. Values 
represent the level of significance when comparing DIO and Control mice at weeks 4, 8, 10 and 
13. Metabolites shaded orange were higher in the DIO group, while those shaded blue were lower 
in the DIO group. (Control n=4-6, DIO n=5-6) 
 
Metabolite Week 4 Week 8 Week 10 Week 13
lactic acid - - - 0.0017 down regulated in DIO
succinic acid - - 0.0882 0.0214 up regulated in DIO
β-hydroxybutyric acid - 0.1455 - -
glucose 1 - - - 0.0571 significant difference
glucose 2 - - - 0.0907 nonsignificant trend
glutamic acid - - 0.0789 - - no significant difference
3-phosphoglyceric acid - 0.0648 - -
tryptophan - - 0.0834 -
palmitoleic acid 0.0004 0.0008 0.0156 -
oleic acid 0.1241 - - 0.0563
linoleic acid - - - 0.019
palmitic acid 0.0815 0.0771 0.0342 0.0407
aspartic acid 0.1446 0.101 0.12 -
lysine - 0.1394 - -
tyrosine - - 0.0839 0.0333
methionine 0.0708 0.0315 - -
glycine 0.0095 - 0.025 -
malic acid - - - 0.057
alanine - - - 0.0411
hydroxyaspartic acid - - - 0.1257
pyruvic acid - - - 0.1214
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Figure 4-19. Experiment 1: Metabolome profile of mouse blood. Only those metabolites that were 
statistically different or tended (dotted) to be different between groups are shown. Values 
represent the level of significance when comparing DIO and Control mice at weeks 4, 8, 10 and 
13. Metabolites shaded orange were higher in the DIO group, while those shaded blue were lower 
in the DIO group. (Control n=4-6, DIO n=5-6) 
 
 Metabolomics analysis of blood revealed that concentrations of succinic acid 
(P=0.0214) and malic acid (P=0.057) were higher in the DIO group compared to the 
Control group at week 13 (Figure 4-20). And, though not reaching a level of 
significance, pyruvic acid was numerically higher in the blood of DIO mice in week 13. 
Succinic acid was numerically higher in the blood of DIO mice in week 10. All three of 
these metabolites are intermediates of the Krebs Cycle, and that these were elevated in 
the blood of DIO mice fed the SD diet ad libitum suggests that the Krebs cycle fluxes in 
tissues, perhaps the liver, have been reduced.  
 Previous metabolomic research with DIO mice has observed elevated succinate 
and pyruvate after 12 weeks of feeding a HFD (Duggan, Hittel, Hughey, Weljie, Vogel, 
& Shearer, 2011). In that study, diet-induced metabolic changes were clearly 
distinguishable in obese mice even after they were subsequently switched to a standard 
Metabolite Week 4 Week 8 Week 10 Week 13
lactic acid - - 0.1057 0.0004 down regulated in DIO
succinic acid 0.03 - - - up regulated in DIO
glucose 1 0.0651 - - 0.0152
glucose 2 0.0273 - - 0.01 significant difference
glutamic acid 0.0253 - - - nonsignificant trend
palmitoleic acid 0.0003 0.0231 0.0352 0.0543 - no significant difference
oleic acid 0.0174 0.0072 0.1167 0.1413
linoleic acid 0.0009 0.0431 - -
linolenic acid 0.0683 - - -
palmitic acid - - - 0.0916
serine 0.0818 - - 0.0063
tyrosine 0.0483 - - -
methionine - 0.0876 - -
valine 0.0944 - - 0.0079
threonine 0.0358 - - -
glycine 0.0011 - - -
oxalic acid - - - 0.0145
alanine - 0.092 - -
phenylalanine 0.0948 - - -
glutamine 0.0961 - - -
beta-alanine - - 0.0729 0.0219
glycerol 1-phosphate - - - 0.1305
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balanced diet for one week. Although both succinate and pyruvate were found to be diet-
dependent in that study, our study corrected for the influence of diet by food restricting 
the DIO for 2 weeks on a standard diet and then allowing these mice to consume the 
standard diet ad libitum for three weeks. This discrepancy requires further investigation 
but possibly suggests that some obesity induced metabolic dysregulation preceding the 
potential weight gain during the rebound period is causing the energy-related metabolism 
to behave as if the animals were consuming a high-fat diet (and hence a diet-dependent 
response in various metabolites). 
 Blood pyruvate was also found to be elevated in a metabolic profiling study of 74 
obese subjects versus 67 lean subjects (Newgard, 2009). These authors implicated the 
higher pyruvate in plasma as a possible contributor to the impairment in glucose 
clearance. This possibility is discussed further later in the paper.  
Subsequent studies are needed to confirm the cause and role of both elevated 
plasma pyruvate and succinic acid in DIO metabolism, although their presence in the 
literature is encouraging. No previous studies have found notably elevated malate in DIO 
obese individuals. The relation of malate to DIO metabolism, if any, can therefore not be 
discussed further without further study. 
Alanine. 
 In addition Krebs Cycle intermediates, we also observed elevated blood alanine 
(P=0.0411) in the DIO group following ad libitum consumption of the SD diet for 3 
weeks.  
 In the studies of Duggan et al. (2011) and Newgard et al. (2009) mentioned 
above, plasma alanine was also found to be elevated in the DIO mice and in obese 
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subjects. After blood lactate, blood alanine is a significant precursor removed by the liver 
for gluconeogenesis, as part of the alanine cycle. In a study of insulin-resistant diabetic 
patients, plasma alanine was elevated by 40% compared to non-diabetic patients, and the 
recycling and use of plasma alanine for glucose synthesis was greater by one-third 
(Consoli et al., 1990). Herein, the elevated blood alanine observed in the DIO mice fed 
the SD diet ad libitum provides further support that gluconeogenesis is elevated and that, 
perhaps there is a persistent metabolic dysregulation present.  
 Newgard et al. (2009) suggests that elevated plasma alanine may arise from 
increased BCAA catabolism and glutamate accumulation. In conjunction with increased 
pyruvate formation, these authors hypothesized that this elevation in plasma alanine may 
negatively impact glucose clearance. 
AMPK Activation in the Liver 
There is an increase in AMPK activation in DIO mice from week 8 to week 10 
(P=0.056), and from week 10 to week 13 (P=0.0104) (Figure 4-21). At week 13, liver 
AMPK activation is elevated in the DIO group compared to the Control group 
(P=0.0035). This elevation in AMPK activation in DIO mice even after 3 weeks of ad 
libitum feeding on a balanced standard diet shows that mice are perceiving a low energy 
state, i.e. a high AMP:ATP ratio. One possible explanation for why mice fed ad libitium 
falsely perceive a low energy state is because of the metabolic imprint left by diet 
induced obesity and weight loss. Previous literature confirms this inclination to regain 
body fat after weight loss, increased food intake, thrifty metabolism (decreased energy 
expenditure), and increased fat storage in adipose tissues (Summermatter et al., 2007).   
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Figure 4-20. Experiment 1: AMPK activation in the liver at weeks 8, 10, and 13. Liver AMPK 
activation was greater (P<0.05) in DIO mice at weeks 8 and 13 compared to Control mice at 
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Relationships to food intake and body composition. 
 
Figure 4-21. Experiment 1: Correlation between liver AMPK activation and either food intake, 
lean body mass, or percent body fat. Liver AMPK activation did not correlate with any of these 
parameters.  
 
AMPK activation was compared on an individual mouse basis to percent body fat 
in dry matter, wet lean mass, and food intake (Figure 4-21). Strong correlations were not 
observed with any of these variables.  
AMPK activation is most responsive to changes in the intracellular AMP:ATP 
ratio due to external metabolic stresses such as exercise or fasting. This short-term 
variation in AMPK activation affects the measured value of AMPK activation. Thus, 
AMPK activation can vary due to transient low energy conditions such as food 
restriction. The overall energy status of the body such as an abundance of energy due to 
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obesity or long-term nutrient scarcity due to a famine is also a factor in AMPK activation 
(Osler & Zierath, 2008). 
Food intake should not be presumed to be a strict function of AMPK activation 
(or vice versa). A number of upstream hunger and satiety factors such as ghrelin and 
leptin, which target many downstream effector proteins other than AMPK are also 
important. The variable most closely associated with food intake is in fact body weight 
(Figure 4-5). The lack of AMPK correlation with food intake, lean body mass, and body 
fat percentage does not however assure a total lack of dependence. A more complete 
explanation of AMPK’s potential role is postponed until a later section. Finally, it is 
possible that the potential dependence of AMPK on each of these bulk measurements is 
too small to detect within the limits of our (relatively large) uncertainty.  
AMPK and glucose clearance 
In performing a similar correlation with glucose curve integrals, we found no 
strong relationship (Figure 4-22). The DIO group’s average AMPK activation increases 
from week 8 to 10 alongside its glucose sensitivity (Figures 4-20 and 4-11). This 
relationship between AMPK activation and glucose clearing has been shown in previous 
studies where AMPK activation is associated with increased glucose uptake by the liver 
and decreased hepatic gluconeogenesis (Carling, 2004). The fluctuation in Control mice 
AMPK seems without adequate explanation given our data. We would expect it to be 
rather constant, and the result remains unclear.  
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Figure 4-22. Experiment 1: Integral of glucose curves over AMPK activation. No dependence of 
glucose clearance on AMPK activation was observed for either group. 
 
AMPK Dysregulation factors: Leptin resistance. 
We may be able to explain the link between AMPK activation and glucose 
clearance by gathering the aspects of metabolic syndrome of which both glucose 
intolerance and AMPK malfunction are symptoms. Leptin resistance is one such feature. 
It is a disruption of the normal function of the hormone leptin, which has direct 
consequences for AMPK, a downstream effector protein, as well as glucose absorption. 
Leptin resistance may be responsible for the high food intake during obesity despite the 
abundance of energy available. 
Leptin is an adipocyte-derived hormone that is released following a meal and 
functions as a satiety factor and promoter of lipid oxidation. Its circulating concentration 
is directly proportional to body fat mass, and it has a role in preventing fat accumulation 
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Similar to insulin resistance, leptin resistance is characterized by high circulating 
concentrations of leptin and a blunted metabolic response to peripherally and/or centrally 
injected leptin.  
Several studies have demonstrated that rodents fed a high fat diet will develop a 
resistance to leptin that appears in as little as 16 days and is very progressive (Enriori et 
al., 2007). In leptin resistant mice, both endogenous and high-administered doses of 
leptin fail to reduce appetite, do not decrease energy expenditure, and do not reduce body 
fat (Van Heek et al., 1997). 
Desensitization to leptin is often conceived as resulting from repeated exposures 
to high circulating concentrations of leptin. These abnormally high levels are created 
when adipocytes naturally secrete more leptin in response to a high fat diet. The chronic 
elevation of circulating leptin has been shown to create a deficiency in adipocyte leptin 
receptors (ObRb) in peripheral tissues, leading to reduced metabolic response to leptin. 
The effect is not necessarily permanent and can be ameliorated by diet modification. Van 
Heek et al. (1997) found that food restriction and fasting produce a rapid decline in the 
normally stable concentration of circulating leptin. Observing this trend over time, 
Enriori et al. (2007) found that the leptin resistance accrued after 20 weeks on a high fat 
diet (at which point mice are fully obese) is completely reversible within at most 17 
weeks after returning to a standard diet.  
The body composition results shows that differences in body weight among DIO 
mice are largely due to increased adipose tissue mass (a combination of hypertrophy and 
hyperplasia of adipocytes). The state of DIO body fat at the peak of obesity is sufficient 
to presume correspondingly high levels of circulating leptin and we may safely consider 
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them leptin resistant. This assumption of leptin resistance is supported by the fact that 
elevated leptin is only symptomatic of leptin resistance, and several similar studies 
utilizing diet induced obesity have induced leptin resistance by 8 weeks. 
Minokoshi et al. (2002) have discovered that leptin mediates its functions (fatty 
acid oxidation, hunger suppression, and prevention of lipid accumulation in non-adipose 
tissues) primarily via AMPK. This was until recently an unestablished pathway. Leptin 
promotes AMPK activation by phosphorylation of the α2 subunit of AMPK. This finding 
lead to the realization that leptin acts directly on muscle, utilizing AMPK to inhibit 
Acetyl-CoA carboxylase (ACC), and thus promotes fatty acid oxidation during ATP 
shortage. Leptin is thereby found to be a principle upstream modulator of AMPK 
activation (Minokoshi et al., 2002). 
Leptin resistance, initially caused by a deficiency in ObRb receptors, should then 
correspond to lower AMPK activation in both muscle and liver (Minokoshi et al., 2002). 
At least, it should impose a limit on the maximum activity of AMPK during states of rest 
(strenuous exercise stimulates AMPK). The DIO mice leptin resistance at week 8 is 
therefore one way to explain their low AMPK levels.  
Once DIO mice are switched to a standard diet, AMPK activation is expected to 
increase. Following the diet switch, DIO mouse body fat is in a state of flux; the mice are 
shedding excess fat that apparently can no longer be maintained under the standard diet. 
In this state of weight loss, AMPK plays a critical role in orchestrating fatty acid 
oxidation and other catabolic processes required for lipid utilization. AMPK levels in 
DIO mice may have increased after the change to a standard diet due to the increased 
Chapter 4 – Experiment 1 Results and Discussion 90 
demand for ATP, combined with an improved leptin sensitivity caused by the switch to a 
standard diet (Figure 4-20). 
AMPK and glucose intolerance 
If diet-induced leptin resistance does impose an upper limit on AMPK activation, 
this dysregulation may offer one clue into the relative inability of DIO mice to metabolize 
glucose. AMPK plays a central role in the transition from carbohydrate to lipid utilization 
during fasting and exercise. This transition is essential to a healthy metabolism, and the 
body’s ability to affect it is in fact a common gauge of metabolic fitness. Osler and 
Zierath (2008) refer to the idea of “metabolic flexibility,” or the ability to switch readily 
between glucose utilization and NEFA oxidation, to characterize metabolic fitness. Obese 
individuals are characteristically inflexible and do not make acute transitions in substrate 
utilization. They will not, for example, experience a sharp rise in glucose utilization and 
storage following a meal, whereas fit individuals will. Metabolically fit persons are also 
able to switch readily to NEFA oxidation during states of exercise, while obese 
individuals are not. The ability to activate AMPK, which orchestrates the steps needed to 
effect NEFA oxidation, factors heavily in the capacity for transitions in energy source. 
Leptin resistance-induced limitations on this ability will therefore contribute to the state 
of an individual’s metabolic fitness.  
In particular, a limitation on AMPK will likely contribute to the inability to 
uptake glucose. Insulin resistance, as opposed to leptin resistance, is recognized as the 
main cause of glucose intolerance. While both conditions are operating in obese 
individuals, leptin resistance-induced AMPK inactivity may influence insulin sensitivity. 
Schimmack et al. (2006) reported that decreases in malonyl-CoA and NEFA due to 
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AMPK activation are associated with reductions in fatty acyl-CoA, diacylglycerol, and 
ceramides. Accumulation of these lipid metabolites inhibits glucose metabolism and is 
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Chapter 5 - Experiment 2 Results and Discussion 
Food and Energy Intake 
 Weekly energy intake by the DIO mice fed the HFD for 8 weeks was higher 
(P<0.01) than that of the Control mice fed the SD diet. From weeks 4 to 5, the DIO group 
showed a large spike in food and energy consumption, which gradually reduced to 
intakes close to those of the DIO group from weeks 1 to 3. This trend, suggestive of an 
increase in energy demand and decrease in satiety in the DIO group over a two week 
period, is not readily explainable. In Experiment 1, the food and energy intake of the DIO 
group remained fairly constant over the 8 week period when the HFD was offered. 
 
Figure 5-1. Experiment 2: Weekly energy consumption. Energy consumed was constant for the 
Control group through to week 8, while energy intake was greater for DIO mice particularly from 
weeks 3 to 5. A decrease in energy consumption was observed in all groups from week 8 to 9, 
except for the DIO mice consuming the standard diet ad libitum and injected with saline 
(placebo). Individual data points represent the means of: Control: n=14 for weeks 1-8, and n=4-5 
for weeks 9-10; DIO: n=21 for weeks 1-8 and n=5-6 for weeks 9-10. Error bars represent 
standard error. 
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 Energy and food intake tended (P = 0.086) to be reduced in the DIO ad libitum 
AICAR administered group compared to the DIO ad libitum saline group at week 10. 
Thus, altering AMPK activation in the whole body with AICAR changed the mice’s 
perception of energy demands and satiety. It is important to note that intravenous, oral, 
and intraperitoneal administration affects all tissues except the brain, since AICAR 
cannot considerably cross the blood-brain barrier (E. Spangenburg, personal 
communication, November 11, 2012). Thus, the effects on AMPK activation in other 
tissues resulted in effects on food intake via indirect neuronal and/or hormonal 
mechanisms. This trend suggests an ability of AMPK to alter the body's perceived energy 
status, part of a generalized metabolic set point. This data also lends support to our 
assumption that the weight loss trend observed in the DIO ad libitum AICAR group 
would continue this trend beyond the two weeks of AICAR treatment (Figure 5-2).   
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Figure 5-2. Experiment 2: Weekly food consumption. The Control mice consumed the standard 
diet (SD) ad libitum throughout the experiment, and from week 9 to 10 the Control mice were 
given an IP injection (3 times/wk) of either saline or AICAR. The DIO mice consumed the high 
fat diet (HFD) ad libitum for 8 weeks, after which they were allocated to 1 of 3 treatment groups 
for 2 weeks: HFD ad libitum + saline IP, HFD ad libitum + IP AICAR, or SD at 80% of energy 
intake + IP saline. Individual data points represent the means of: Control: n=14 for weeks 1-8, 
and n=4-5 for weeks 9-10; DIO: n=21 for weeks 1-8 and n=5-6 for weeks 9-10. Error bars 
represent the standard error of the mean. For the Control mice, food consumption was constant 
through to week 8, while food consumption by the DIO mice was greater, particularly from 
weeks 3 to 5. A decrease in food intake was observed for all groups from week 8 to 9 except the 
DIO ad libitum saline group.  
 
It is firmly established in the literature that regulation of food intake and satiety 
involves hypothalamic AMPK; as previously discussed, its inhibition is associated with 
decreased food intake. AICAR’s ability to cross the blood brain barrier is minimal, in 
fact, the amount (< 1%) is not substantial enough to observe its effects in the periphery 
(Marangos et al., 1990). So while AICAR may enter the hypothalamus and affect 
hypothalamic AMPK, it would not reach beyond this central effect (Gaidhu et al., 
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2011).This makes sense given that elevation of hypothalamic AMPK by AICAR would 
actually increase food intake. It also must be noted that hepatic AMPK levels measured 
via ELISA were inconclusive due to experimental error and therefore the efficacy of 
administered AICAR cannot be undoubtedly established. 
 It is unclear in the literature how peripherally injected AICAR affects food intake, 
as most related studies administer it via intracerebroventricular injection. In fact, few 
studies regarding the effects of AICAR on organisms as a whole have been conducted 
(Daignan-Fornier & Pinson, 2012). Several compounds, including nutrients and 
hormones, have been established as suppressors of hypothalamic AMPK and therefore 
lead to decreased food intake: leptin, elevated glucose, insulin, -lipoic acid, and others 
(Xue & Khan, 2006). Similar studies in the future measuring hypothalamic AMPK must 
be conducted to further elucidate this observed effect. 
 Energy and food consumption did not significantly change in the week 10 SD ad 
libitum AICAR group compared to the week 8 group. It is interesting that the effect of 
AICAR on body and food consumption was more prominent in the DIO group than the 
SD group, as was observed in respect to weight change (see below). This suggests that 
the effect of AICAR may have a diet-dependent component. No support has been 
established for this in the literature.  
 Another possibility for this disparate effect between the DIO and Control groups 
may involve AMPK, the target of AICAR, as a metabolism-dependent rather than diet-
dependent element. It superficially appears that AMPK may sense energy status relative 
to some “programmed” metabolic baseline; the DIO group is metabolically distant from 
this baseline, while the Control group is at or near it. AMPK activation would then be 
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regulated accordingly, or perhaps just more effectively, in the DIO group, resulting in a 
near return to the baseline level of perceived energy metabolism via changes in satiety 
and food intake (assuming those are the established intact pathways of AMPK). This 
return to the metabolic baseline would most likely involve other metabolic regulators and 
energy sensors. 
 Ideally, such an effect would lead to similar states of "perceived" energy 
metabolism between the DIO ad libitum AICAR and Control ad libitum AICAR groups 
(which both have increased AMPK). Our results happen to show such a trend. No 
statistically significant difference in energy consumption between the DIO ad libitum 
AICAR and Control ad libitum AICAR groups remained at week 10, while a statistically 
significant difference did persist between the DIO ad libitum saline and Control ad 
libitum saline groups (P=0.001). However, while our results apparently match such a 
prediction, a lack of direct evidence, an absence of a proposed mechanism, and too small 
of a sample size make this concept merely a hypothesis that should be further 
investigated in similar future studies. 
Body Weight Changes 
 As in Experiment 1, feeding the HFD replicated the diet-induced changes in body 
weight and adiposity compared to mice fed the SD diet. After 8 weeks of consuming the 
HFD, mice in the DIO group were allocated into three groups receiving the following 
treatments for 2 weeks: 1) HFD ad libitum and saline injection, HFD ad libitum and 
AICAR administration, and SD food restricted (FR) and saline injection. The final body 
weights of the DIO group fed the HFD ad libitum and given saline injections were 
significantly higher than those of the DIO group fed the HFD ad libitum and given 
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AICAR injections group (P<0.05). This suggests that activation of AMPK by AICAR 
improved to some extent the ability to lose weight in spite of an ad libitum diet. Had this 
trend been allowed to continue beyond a two week period, AICAR may have proved to 
be an effective method in body weight reduction. The fact that the SD FR group did not 
deviate significantly from the HFD ad libitum saline group suggests that the tendency to 
maintain a set weight (i.e. body weight set point) within this two week period is not 
effectively changed by diet or energy intake. Future studies must be conducted to confirm 
if AICAR administration over a longer period of time would be successful.  
 
 
Figure 5-3. Experiment 2: Body weights. Refer to Figure 5-2 for descriptions of groups and 
treatment assignments. From week 2 onwards, DIO mice weighed more (P<0.05 ) than Controls 
DIO mice administered AICAR for 2 weeks weighed less (P<0.05) than DIO mice given saline. 
Individual data points represent the means of: Control: n=14 for weeks 1-8, and n=4-5 for weeks 
9-10; DIO: n=21 for weeks 1-8 and n=5-6 for weeks 9-10. Error bars represent the standard error 
of the mean.  
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  At the beginning of week 9, mice in the Control group were split into 2 groups 
over the final 2 week period: SD ad libitum saline and SD ad libitum AICAR. Like all 
DIO groups, both Control groups exhibited a small drop in weight over the first week. 
This phenomenon is not easily explained (it may be due to the effective methodology of 
injections, perhaps causing the mice to eat less due to stress or some related factor) and 
warrants further investigation.  
 Over the second week both Control groups steadily regained weight. Neither 
group showed a statistically significant weight change over that period. In addition, 
unlike in the DIO groups, no significant change in weight was seen between the SD ad 
libitum saline and SD ad libitum AICAR groups at the end of the two week period. This 
trend further suggests a diet-dependent or metabolic-dependent effect of AICAR, as its 
trending weight reduction effect observed in the DIO groups was not seen with the 
Control groups. 
Body Fat Composition 
 Fat proportion was calculated for week 8 and 10 time points. As in Experiment 1 
at week 8, this value was significantly higher in the DIO group (P=0.0018). This 
suggests, as previously noted, that the weight gain experienced in the DIO group over 8 
weeks was primarily fat mass accumulation due to the high fat content of the diet.  
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Figure 5-4. Experiment 2: Body composition. Refer to Figure 5-2 for descriptions of groups and 
treatment assignments. By week 8, DIO mice had a greater (P<0.05) proportion of body fat. Fat 
proportion does not change significantly within either group from week 8 to week 10. Individual 
data points represent the means of: Control: n=14 for weeks 1-8, and n=4-5 for weeks 9-10; DIO: 
n=21 for weeks 1-8 and n=5-6 for weeks 9-10. Error bars represent the standard error of the 
mean.  
  
At the end of 10 weeks, the three DIO groups showed no significant change in fat 
proportion relative to each other or to those of week 8. Likewise, no significant change in 
fat proportion was seen among the Control groups. Our results show that AICAR is 
ineffective in decreasing fat mass over a 2 week period. Such findings suggest a possible 
disruption in AMPK pathways related to fatty acid metabolism and storage. Prior studies 
have shown that AMPK increases fat oxidation via inhibition of ACC, as well as 
increasing mitochondrial biogenesis and inhibiting fatty acid synthesis (Xue & Kahn, 
2006).  AMPK can also directly reduce adiposity by inducing adipocyte apoptosis, 
inhibiting lipolysis, and down-regulating adipogenic genes (Dagon, Avraham, & Berry, 
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2005).  Further investigation is therefore required to elucidate any possible deregulation 
up- or down- stream of these pathways, and whether or not residual DIO effects are at 
least partially responsible 
Insulin Resistance 
 As previously discussed, insulin resistance is a primary sign of metabolic 
syndrome resulting from obesity. Average glucose tolerance test levels and integrated 
glucose levels were completed for each group and subgroup in weeks 8 and 10. The 
integrated glucose level in the DIO group at week 8 was significantly greater than that of 
the Control group (P=0.0025), similar to the results from Experiment 1 (Figure 5-5). 
This shows that HFD diet-induced obesity significantly increased systemic insulin 
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Figure 5-5. Experiment 2: Area under the curve of blood glucose concentrations during the 120 
min period following administration of a 2g/kg glucose dose. Refer to Figure 5-2 for descriptions 
of groups and treatment assignments. Glucose clearance was lower in DIO mice after 8 weeks of 
consuming the high fat diet compared to Controls. Glucose clearance improved (P<0.05) in the 
DIO mice at week 10, but was not different between treatments administered to the DIO mice. 
Individual data points represent the means of: Control: n=14 for weeks 1-8, and n=4-5 for weeks 
9-10; DIO: n=21 for weeks 1-8 and n=5-6 for weeks 9-10. Error bars represent the standard error 
of the mean.  
 
 All DIO and SD groups showed some improvement in glucose clearance in week 
10 versus week 8. Integrated glucose levels across the DIO groups remained higher than 
those of the SD groups. Interestingly, of the DIO groups, only the FR and ad libitum 
saline groups showed a statistically significant improvement (P=.0033, P= 0.0191 
respectively), while the ad libitum AICAR group did not. There was no statistical 
difference in glucose clearance between any of the DIO groups at week 10. Likewise, the 
SD ad libitum saline group showed a statistically significant improvement (P=0.0054) 
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while the SD ad libitum AICAR group did not. There also was no statistical significance 
between the SD groups at week 10.  
 This data suggests that AICAR administration at a dose of 0.5 mg/g body weight 
three times a week over a two week period did not produce any sizeable improvement in 
insulin sensitivity. AMPK, as previously mentioned, inhibits hepatic gluconeogenesis. In 
addition, prior studies have suggested that increased muscle AMPK activation indirectly 
improves insulin resistance via ACC inhibition, leading to a decreased resting level of 
Malonyl Co-A and less production of inflammatory lipid intermediates (Muoio & 
Newgard, 2006). Our findings suggest possible disruptions in these or related pathways, 
similar in nature to those discussed involving NEFA and body fat metabolism. AICAR 
administration over a longer time frame may have lead to improvements in fatty acid 
metabolism that precede improvements in glucose clearing. 
Non-Esterified Fatty Acids 
 Week 10 hepatic metabolomic data reveals some significant differences in several 
metabolites related to fatty acid metabolism between the DIO AICAR and saline groups. 
Palmitic acid was significantly higher (P=0.0109) in the DIO AICAR group than in the 
DIO ad libitum saline group at week 10 (Figure 5-6). While the SD diet contained only 
0.7% palmitic acid, the HFD diet contained much higher levels of palmitic acid due to 
large amount of lard (31%) in the diet. As previously discussed, high levels of palmitic 
acid are associated with lipotoxicity and insulin resistance. This therefore reassures our 
findings of no significant improvements in fat composition or insulin resistance in the 
DIO AICAR group from week 8 to week 10. Upon further inspection, these results are 
actually peculiar given that body composition was not significantly different between the 
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two groups and the DIO AICAR group actually showed decreased food and energy 
intake.  
 Oleic acid was significantly lower (P=0.0029) in the DIO AICAR group 
compared to the DIO saline group (Figure 5-6). As discussed earlier, oleic acid is 
associated with improved insulin resistance and decreased lipotoxicity. This serves as 
further evidence of dysregulated fatty acid metabolism in the DIO AICAR group 
compared to the saline group. These findings again show that AICAR has failed to 
effectively improve the underlying metabolism stemming from DIO. The reason fatty 
acid metabolism actually appears to be worse in the AICAR group than the Saline group 
is not readily explained and requires further testing. 
 
Figure 5-6. Experiment 2: The liver metabolome at week 10 after saline, AICAR and feed 
restriction. Only those metabolites that were statistically different or tended (dotted) to be 
different between groups are shown. Values represent the level of significance when the specific 
planned comparisons were made. Metabolites shaded orange were higher in the DIO group, while 
those shaded blue were lower in the DIO group (n=4-6) 
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Experiment 1 Summary 
 The experiments reported in this thesis investigated the perturbations in body 
composition, blood glucose clearance, hepatic metabolism (metabolomics), and hepatic 
AMPK activation following DIO, weight loss, and weight regain in a mouse model. In 
Experiment 1, following 8 weeks of consuming a HFD ad libitum to establish DIO, we 
monitored changes in body composition and the above metabolic parameters after a 2 
week period of calorie restriction on the SD diet and then again after 3 weeks of ad 
libitum consumption of the SD diet. Due to effective methodology (discussed above), 
reduced food intake was observed throughout these 5 weeks, establishing a 5 week diet 
phase. 
 Throughout the first 8 weeks, DIO mice gained weight at a constant rate and 
weighed, on average, 18.4% more than Control mice fed the SD over the same period. 
This difference was primarily due to increased fat mass. By week 4 and continuing 
through to week 8 of feeding on HFD, body fat proportion was also significantly higher 
in the DIO mice. Feeding the HFD significantly elevated hepatic palmitic, linoleic, and 
linolenic acids, while reducing hepatic oleic acid levels in the DIO group compared to the 
Control group by week 8. Glucose clearance by the DIO mice was reduced relative to the 
Control mice by week 4, and this trend continued through to week 8.  
 We also examined a variety of correlations between various metabolic and 
physiological measurements throughout this 8 week period of feeding the HFD. For 
example, while the relationship between body weight and food intake was the same for 
both groups, the energy-dense HFD skewed energy intake of heavier mice toward 
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disproportionately higher values. HFD feeding thus had a greater negative impact on 
heavy mice. 
 After 2 weeks of calorie restriction, body fat proportion in the DIO mice 
decreased and, despite consuming the SD diet (lower energy-density and less fat) ad 
libitum for a further 3 weeks after the restriction period, body fat proportion of the DIO 
mice increased relative to the Control mice. Hepatic NEFA levels in the DIO mice also 
decreased throughout these two diet periods, approaching levels similar to the Control 
mice. However, principle component analysis of four NEFA levels (see above) showed 
spatially separated clustering of the DIO and Control groups at weeks 4, 8, and then again 
at week 13, indicating a persistent systematic deviation in hepatic NEFA between the 
DIO and Control groups.  
 Glucose clearance markedly improved throughout the diet phase in the DIO 
group. By the end of the 3 week period of consuming the SD diet ad libitum glucose 
clearance was higher in the DIO group compared to the Control group. This improvement 
in glucose clearance likely resulted from improved skeletal muscle insulin sensitivity as a 
result of the reduction in circulating NEFA concentrations. 
 Hepatic AMPK activation was higher in the Control group compared to the DIO 
group after 8 weeks of consuming the HFD diet ad libitum, as would be expected under 
conditions of excess energy intake. After 2 weeks of energy restricting the DIO group, 
hepatic AMPK activation increased, however, AMPK activation only increased to the 
same level as in the Control mice. Of particular note, after 3 weeks of consuming the SD 
diet ad libitum, hepatic AMPK activation in the DIO mice increased, rather than 
decreased. It would have been expected that, once the DIO mice were allowed to 
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consume ad libitum the SD diet, hepatic AMPK activation would be reduced since the 
mice were allowed to consume the SD diet to meet their energy requirements. That 
hepatic AMPK activation increased more than 2-fold suggests that the DIO mice were 
incapable of sensing energy intake but rather sensed the SD diet as being inadequate in 
meeting energy needs. Indeed, hepatic AMPK activation was considerably lower in the 
Control compared to the DIO mice even though the Control mice had also consumed the 
SD diet ad libitum. Clearly, there was a defect in the ability of DIO mice to properly 
“sense” energy intake relative to whole body energy needs. 
 Improved glucose clearance by the DIO mice throughout the energy restriction 
and SD diet ad libitum periods, along with a trend towards improvements in body 
composition and fatty acid metabolism, suggests a pronounced and abrupt shift away 
from adiposity and metabolic syndrome in the DIO mice. These trends first became 
apparent following the 2 week energy restriction period by the DIO mice. A detailed 
explanation of these findings is difficult to formulate given only basic metabolic 
measurements, but hepatic AMPK activation and glucose clearance after the 3 week SD 
diet ad libitum period by the DIO mice suggests that the mice may have some form of 
"metabolic overcompensation" and may indicate that DIO mice were in a state of weight 
flux throughout these two dietary periods which possibly resulted in rapid oxidation of 
blood NEFA. 
Experiment 2 Summary 
 Experiment 2 investigated the role of diet and AMPK in modulating the DIO 
perturbations observed in Experiment 1. Following 8 weeks of consuming the HFD ad 
libitum, mice in the DIO group were allocated to three diet and treatment regimes for 2 
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weeks: 1) HFD ad libitum plus injection of the AMPK activator AICAR, 2) HFD ad 
libitum plus injection of saline and 3) SD diet fed to 80% of energy requirements plus 
injection of saline. The Control mice were allocated to two treatments: 1) SD diet ad 
libitum plus injection of AICAR and 2) SD diet ad libitum plus injection of saline. 
 Comparisons in body composition, glucose clearance, and hepatic NEFA 
suggested that administration of AICAR to DIO mice had limited effects on the 
metabolic indicators associated with DIO. No significant differences in body fat 
proportion or glucose clearance were found between the DIO mice given AICAR and 
saline. Hepatic metabolomics analysis revealed that palmitic and linoleic acid levels were 
significantly elevated, while the oleic acid level was significantly lower in the DIO mice 
administered AICAR compared to the DIO mice administered saline. 
 There was a tendency for energy consumption by DIO mice administered AICAR 
to be reduced compared to the DIO mice administered saline. Consistent with this 
finding, body weight was significantly lower after the two week treatment period 
compared to the DIO mice administered saline injections. The latter suggests that 
elevated AMPK activation in peripheral tissues may play a role in modifying food intake 
behavior and therefore energy-sensing status in DIO mice. It is important to note that 
AICAR is unable to pass the blood-brain barrier appreciably, thus the effects on food 
intake did not result from a direct action on the brain. Literature regarding AMPK and 
food intake has focused solely on its role in the hypothalamus, thus future studies must be 
conducted to investigate the potential role of AMPK in other tissues that ultimately 
modify food intake. 
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 No significant changes in body weight, energy consumption, body fat proportion, 
or glucose clearance were found between the Control mice administered AICAR or 
saline. The effects of AICAR on energy consumption and body weight observed in the 
DIO groups, yet absent in the Control groups, suggest additional metabolic factors 
influencing and relaying the effects on AMPK activation to metabolic and physiological 
mechanisms. Certainly the type of diet, (i.e. low versus high fat), and thus the state of 
obesity, appears to have been responsible for altering the response to enhanced AMPK 
activation. Another possibility involves different activity of up-stream regulators of 
AMPK between the DIO and Control mice, reflective of differences in baseline 
metabolism. 
Experiment 1 and 2: Possible Roles of AMPK in DIO Metabolic Dysregulation 
 Elevating AMPK activation by administration of AICAR in Experiment 2 was 
clearly ineffective in inducing the trends of metabolic improvement following DIO. In 
Experiment 1, differences in glucose clearance and body composition improvement after 
8 weeks of feeding on HFD and after 2 weeks of food restriction on SD are most notable. 
The key differences between the two experiments are the diet and energy consumption 
changes that occur in DIO mice. The DIO mice in Experiment 1 were calorie restricted 
on SD, while the DIO mice, administered AICAR in Experiment 2, continued consuming 
the HFD diet ad libitum. 
 Our results show that the HFD elevated hepatic NEFA and increased body fat 
percentage. Calorie restriction on the SD diet tended to reverse these effects in 
Experiment 1. These effects persisted in Experiment 2 as HFD ad libitum feeding was 
continued despite a modest decrease in energy consumption and elevation of AMPK 
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(which functions to increase fatty acid oxidation to generate ATP). These findings 
suggest continual dietary fat intake may be the primary feature that allowed for the 
perpetuation of the metabolic dysregulation by preventing potential benefits from 
elevated AMPK activation. Such a perturbation likely involved up-stream regulators or 
cofactors necessary for proper long-term functioning of AMPK related pathways. Some 
compounds that are potentially involved will be speculatively discussed; however, future 
studies are required to confirm the involvement of such compounds in our observed 
results. 
 One possibility worthy of discussion here is the involvement of gene transcription 
processes related to AMPK signaling and fatty acid metabolism, as effects at these levels 
endure over longer periods of time. It has been shown that long-term promotion of fatty 
acid oxidation by activation of AMPK requires peroxisome profilerator-activated 
receptors (PPAR) and the transcriptional factor PPAR-γ co-activator-1  (PGC-1) (Lee  
et al., 2006). These factors, which are stimulated by exercise and calorie restriction, 
regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, 
gluconeogenesis, and other energy requiring pathways (Canto & Auwerx, 2009). Their 
expression is promoted by AICAR administration, and PGC-1 is phosphorylated 
directly by AMPK when activated. When inhibited via siRNAs, the effect of AICAR on 
fatty acid oxidation in vitro diminishes (Lee et al., 2006).  
 Studies involving PGC-1 suggest a possible mechanism of resistance to AMPK 
activation due to HFD. Diets high in palmitic acid have been shown to down-regulate the 
expression of PGC-1 (Kien, 2009). We have established that palmitic acid is elevated in 
DIO mice throughout the 8 weeks of consuming the HFD ad libitum. Hepatic NEFA 
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analysis in Experiment 2 also revealed elevated palmitic acid in the DIO mice 
administered AICAR. Persistently high palmitic acid may, therefore, reduce PGC-1 
expression. As noted earlier, PGC-1 is required for long term AMPK-mediated fatty 
acid oxidation, the process needed to reduce these palmitic acid levels still being ingested 
with the HFD. This scenario creates a persistent condition of high NEFA levels, leading 
to continued lipotoxicity and insulin resistance by peripheral tissues such as skeletal 
muscle. Further investigation utilizing PGC-1assays in our methodology is required to 
elucidate the possible role of this scenario following DIO. 
 Leptin resistance, discussed earlier, may also play a primary role in the metabolic 
trends observed through DIO and subsequent periods of calorie restriction and AICAR 
administration. Yu et al. (2004) found that both muscle and liver AMPK activation are 
reduced in leptin-receptor deficient Zucker rats fed a SD diet ad libitum. Such findings 
further suggest that calorie restriction may have played a key role in metabolic 
improvements observed solely in Experiment 1 because, as previously mentioned, it has 
been shown that calorie restriction greatly increases leptin sensitivity. Therefore, it is also 
possible that leptin resistance may have played a role in the persistent metabolic 
perturbations observed in Experiment 2 when AICAR was administered to the DIO mice 
fed the HFD. However, Yu et al. (2004) suggests that there is no direct role of leptin 
sensitivity in determining the effectiveness of AICAR in improving metabolic syndrome: 
Zucker rats fed a SD diet ad libitum and administered AICAR had improved glucose 
clearance and reduced triglyceride content in muscle and liver compared to 
corresponding Controls. 
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 Another regulatory component worthy of investigation is Ghrelin. Briggs et al. 
(2013) demonstrated that the propensity for weight rebound following calorie restriction 
in previously DIO mice may involve changes in ghrelin sensitivity. They suggested that a 
"high body weight" set point is maintained following calorie restriction by restoration of 
ghrelin sensitivity, which is composed of an increase in both ghrelin production and 
ghrelin-responsive neuronal populations in the hypothalamus. They found that ghrelin-
knockout mice that were calorie restricted following DIO exhibited less of a rebound in 
weight gain compared to Control DIO mice. 
Limitations of the Study 
 In Experiment 1, the poor correlation between several pairs of variables may 
reflect poor data rather than a lack of relationship. For example, the correlation between 
AMPK and integrated glucose values showed little covariance. We would expect some 
increase in AMPK activation to correlate with the observed increase in glucose clearance 
(Figure 4-27). Because group average glucose levels rise and fall as expected with fair 
precision, we can assume high variability with some error in AMPK values from ELISA. 
Future studies should conduct more extensive ELISA analysis, a logistical impossibility 
for our current study, to increase accuracy and precision. 
 The plot relating integral glucose values to NEFA indices is also disconcerting, 
showing a vaguely negative trend when a positive one is expected (Figure 4-15). We can 
stipulate that there is a limitation in the ability of the "total NEFA index" (equal to the 
sum of the logs of all NEFA indices for an individual mouse) to act as an overall gauge of 
circulating NEFA concentrations. This is due to variation in the metabolomic mass 
spectrometry readings where some metabolites are registered as being disproportionately 
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higher, skewing the average sum values for a given set of metabolites. Furthermore, 
metabolomic data for both Experiment 1 and 2 was overall relatively sparse, with many 
key DIO related metabolites absent from the data (such as Citrate, Taurine, Choline, 
Leucine) or disproportionately present in samples between groups and between weeks. 
This lack of data limits our ability to correlate an underlying metabolic state with DIO 
induced symptoms of metabolic syndrome and perceived energy status. The 
incompleteness of our metabolomic data was most likely due to incomplete derivatization 
and lack of separation in the GC-MS column, an issue that can be addressed in future 
related metabolomic studies. 
 Given our methodology, the differing effects of calorie restriction and diet on the 
efficacy of AICAR in Experiment 2 cannot be distinguished. To do so, our study should 
have included an additional DIO group in Experiment 2 that was calorie restricted but 
remained on HFD. 
Conclusions 
 Our study aimed to better model the metabolic changes through DIO and 
subsequent dieting in order to establish a better understanding of this progression and 
what contributes to a propensity for weight rebound once dieting has ended. We also 
aimed to investigate the potential role of AMPK in these processes. We attempted to 
address these goals in a novel approach, correlating various metabolic and physiological 
measurements to track metabolic trends through DIO and subsequent dieting. We also 
used liver and blood metabolomic analysis to correlate both specific metabolite changes 
and generalized shifts in overall metabolite composition to the aforementioned 
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relationships. Finally, we tracked changes in hepatic AMPK throughout this period and 
further evaluated its role by activating AMPK with AICAR following DIO. 
 While our results and correlations were generally incomplete given the 
imperfections of our AMPK and metabolomics data, we clearly observed distinct 
metabolic changes throughout the period of DIO and subsequent dieting, implicating 
important roles for calorie restriction and elevated hepatic AMPK in these trends. 
Furthermore, we clearly demonstrated the inability of AICAR to effectively combat DIO-
related metabolic dysregulation. These findings suggest AICAR is not likely to be an 
effective quick-fix solution to obesity and metabolic syndrome as recently popularized in 
the media (Zarembo, 2008). 
 Together our findings, and more importantly, our methods for studying DIO and 
subsequent dieting provide a promising approach to establish a more detailed model that 
can be further built upon in future studies. Further studies can also establish the response 
of AMPK throughout this period, specifically how its effect is mediated by diet and 
energy consumption and any associated up or downstream mediators of AMPK that 
become dysregulated throughout this period. Hopefully such work will contribute to 
developing future treatments that are more effective in combating obesity and changes in 
metabolic set point that may lead to weight rebound. 
Appendix A - Methodologies 114 
Appendix A- Methodologies 
 
Appendix A.1: Soxhlet Fat Extraction 
 
Note: Soxhlet Fat Extraction is run in triplicate, with an 18 sample per day maximum. 
 
1. Label and weigh ceramic thimbles, three per mouse. Record Weights. 
2. Using a metal scoopula, place about 1g of dried, milled powder mouse into each 
thimble. 
3. Record weight of thimble and sample. 
4. Stuff small piece of gauze into top of thimble, sealing in powder. 
5. Record weight of thimble, sample, and gauze. 
6. Bundle thimbles together in large piece of gauze, no more than three thimbles tall. 
Secure with rubber bands. 
7. Place into Soxhlet extraction system for at least 12 hours, preferably overnight. 
8. Record weight of thimble, sample, and gauze after extraction. 
9. Dispose of contents of thimble, and clean with air duster and soap water to be 
used for next sample. Let dry fully. 
Appendix A.2: Blood and Liver Metabolomic Extraction 
 
Make internal standards. Internal standard selection should represent the compounds that 
are not in the samples. 
1. Thaw blood or liver tissue on ice. Try to avoid getting sample warmed to room 
temp. 
2. Use 1.8-2 mL snap cap Eppendorf tube 
3. Weigh and record weight of sample (0.1 g for blood and 0.05 g for liver) into 
tube, weigh and record Sample Internal standard solution (0.1 g, Norleucine @ 
1.275 mM for blood and 3.8 mM for liver). For blood, add 1 mL ice-cold 
methanol, place on vortex-shaker for 15 min and centrifuge at 15,000 rpm for 15 
min at room temperature. For liver, add 1 mL ice-cold distilled 
H2O:methanol:chloroform (2:5:2), homogenize on ice for 1 min, then place on 
vortex-shaker for 15 min and centrifuge at 15,000 rpm for 15 min at room 
temperature. 
4. For both types of samples, pipette extract into a 2 mL V-vial, and blow down 
under N2 gas without heat. This may take 15-30 min. Vortex sample midway 
through blow down step to prevent water being trapped under lipids and dry upper 
layer. Once completely dry, proceed to step #5. 
5. Add 60 uL O-methoxylamine in pyridine (30 mg/mL) and then add 60 uL BSTFA 
+ 1% TCMS, cap and vortex thoroughly (30 secs). Micro-wave for 2 minutes at 
power level 2 (200 W) 
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6. Transfer from V-Vial to 0.5 mL eppendorf tube and centrifuge at 15,000 rpm for 
15 min at room temperature to remove debris if debris is observed at bottom of V-
Vial. 
7. Transfer the derivatized sample (avoid sucking up debris at bottom of tube) into 
GC vial insert and inject onto GC-MS using MethOxime method. 
 
Preparation of O-methoxylamine in pyridine solution: 
According to the volume for all the samples, weigh a certain amount of O-
methoxylamine and dissolve it in pyridine for final concentration of 30 mg/ml. 
Vortex vigorously until dissolved. Slight heat can also be applied to aide in 
dissolving. This concentration can also be adjusted in terms of the sample amount. 
 
Preparation of standard solution and retention index solution: 
1. For liver, make a stock internal standard solution containing 10 mg Norleucine/20 
mL double distilled H20 (3.825 mM) 
2. For blood samples, dilute stock 1:2 (ie. 3 fold dilution) with double distilled H20 
(ie. 1.275 mM) 
 
Appendix A.3: ELISA Procedure for AMPK Measurement (Life Technologies, 2013)  
 
1. Determine the number of 8-well strips needed for the assay. Insert these in the 
frame(s) for current use. (Re-bag and seal extra strips and frame. Store these in 
the refrigerator for future use.) 
2. Pipette 100 µl of the Standard Diluent Buffer to the well(s) reserved for the 
standard blanks. Well(s) reserved for chromogen blank(s) should be left empty. 
3. Pipette 100 µl of standards, controls, and diluted samples (typically >1:10 dilution 
for cell extract) to the appropriate microtiter wells. Tap gently on side of plate to 
thoroughly mix. 
4. Cover wells with plate cover and incubate for 2 hours at room temperature. 
5. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash 
wells 4 times. 
6. Pipette 100 µl Streptavidin-conjugated HRP (ELISA kits) or Biotin-conjugated 
Detection Antibody (phosphoELISA™) solution into each well except the 
chromogen blank(s). Tap gently on the side of the plate to mix. 
7. Cover wells with plate cover and incubate for 1 hour at room temperature. 
8. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash 
wells 4 times. 
9. Pipette 100 µl streptavidin-HRP (ELISA kits) or anti-rabbit IgG-HRP 
(phosphoELISA™ kits) solution to each well except the chromogen blank(s). 
10. Cover wells with the plate cover and incubate for 30 minutes at room temperature. 
11. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash 
wells 4 times. 
12. Pipette 100 µl of Stabilized Chromogen to each well. The liquid in the wells will 
begin to turn blue. 
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13. Incubate for 30 minutes at room temperature and in the dark.  Note: Do not cover 
the plate with aluminum foil or metalized mylar.  The incubation time for 
chromogen substrate is often determined by the microtiter plate reader used. 
Many plate readers have the capacity to record a maximum optical density (OD) 
of 3.0. The OD values should be monitored and the substrate reaction stopped 
before the OD of the positive wells exceed the limits of the instrument. The OD 
values at 450 nm can only be read after the Stop Solution has been added to each 
well. If using a reader that records only to 3.0 OD, stopping the assay after 20 to 
25 minutes is suggested. 
14. Pipette 100 µl of Stop Solution to each well. Tap gently on the side of the plate to 
mix. The solution in the wells should change from blue to yellow. 
15. Read the absorbance of each well at 450 nm having blanked the plate reader 
against a chromogen blank composed of 100 µl each of Stabilized Chromogen 
and Stop Solution. Read the plate within 2 hours after adding the Stop Solution. 
16. Plot the absorbance of the standards against the standard concentration. 
(Optimally, the background absorbance may be subtracted from all data points, 
including standards, unknowns and controls, prior to plotting.) Draw the best 
smooth curve through these points to construct the standard curve. If using curve 
fitting software, the four parameter algorithm provides the best curve fit. 
17. Read the protein concentrations for unknown samples and controls from the 
standard curve plotted in step 16. Multiply value(s) obtained for sample(s) by the 
appropriate dilution factor to correct for the dilution with Standard Diluent Buffer. 
(Samples producing signals higher than the highest standard should be further 
diluted in Standard Diluent Buffer and reanalyzed, multiplying the concentration 
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Table B-1: Experiment 1: Mouse Key 
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Appendix B.1: Experiment 1 Body Weight Tables 
 
Table B-2: Experiment 1: Weekly Body Weight (g) 
 
  
Exp. 1 Weekly Body Weight (g)
Sept 9-16 Sept 16-23 Sept 23-30 Sept 30-Oct 7 Oct 7-14 Oct 7-15 Oct 7-16 Oct 7-17 Oct 7-18 Oct 7-19 Oct 7-20 Oct 7-21 Oct 7-22
Initial Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13
C1 22.38 21.9 23.3 23.5 24
C2 21.3 22.7 24.25 25.5 26.5
C3 21.5 18.5 25.3 28.6 28.7
C4 25.3 26.7 27.25 28.7 29.7
C5 24 19.3 27.35 29.6 29.9
C6 26.5 27.5 30.55 33.1 34.9
C7 20.4 21.5 21.65 22.5 23.4 23.5 23.15 23.15 23.6
C8 21.4
C9 23.8 24.5 24.74 25.4 27.6 27.8 28 28.2 27
C10 22.7 20.4 25.67 28 28 29.1 31.9 32.4 24.7
C11 24.1 24.6 26.71 31.1 29 29.5 32.1 34.9 34
C12 22.5 24.5 27.25 29.4 30.5 30.5 32.7 33.8 32.5
C13 27.7 27.3 30.15 31 33.5 33.2 33.7 35.1 35.8 35.1 32.7
C14 23.5 23.3 27.69 28.3 29.5 29 30 32 32.3 31.5 30.4
C15 23.4 24.7 27.24 29.3 31.8 32.1 32.8 34.6 35.7 34.7 33.4
C16 23.4 24.6 26.96 29.8 31.5 30.6 30.9 32.5 32.3 32.7 31.6
C17 20.9 18.3 25.23 26 27.8 28.1 28.9 30.1 29.85 29.3 28.2
C18 21.4 24 19.96 24.9 27.2 21.7 25.6 28.1 29.2 29.2 28.4
C19 19.7 18 23.14 24.4 25.1 26.9 27.7 28.2 28.3 27.9 30.1 29.48 29.6 30
C20 23.8 24.4 26.14 27.1 28 27.7 28.3 28.9 30.1 30.1 31.6 31.08 31.7 31.9
C21 24.3 26 29.29 29.8 31.7 31.5 33.1 33.9 34.8 34.8 34.8 34.69 35.4 36.7
C22 24.7 26 30.54 32 32 32.8 34.4 35 36 34.9 36.1 35.5 38.6 36.4
C23 20.8 21.4 23.63 23.6 18.7 23.8 26.6 26.6 26.4 27.2 27.4 28.9 29.4 21.5
C24 22.1 23.5 27.1 26.9 28.4 28.3 29 29 29.8 30.3 30.3 32.11 32.3 31.9
T25 21.7 23.8 28.91 31.1 34.2
T26 20.2 21.4 23.15 24.5 26.3
T27 23.8 24.5 27.13 28.7 31.9
T28 21 22.1 22.33 24.1 24.4
T29 23.5 23.2 24.69 26 28.5
T30 25 25.9 27.32 28.9 32.1
T31 25 20.6 29.66 33.6 33.1 35.6 39 40.8 32.5
T32 24.7 28.4 31.18 32.1 34.2 34.9 37.7 39.8 41
T33 22.7 24 25.73 27.7 29.1 29.3 31.9 34.1 35
T34 23.5 23.4 27.1 28.1 30.9 31.2 33.4 35.8 37.7
T35 21.7 22.1 23.63 24.1 26.2 27.1 29.6 31.2 29.8
T36 22.4 23.4 23.72 24.6 26.4 28.1 28 29.2 30.2
T37 19.9 16.7 22.02 24.8 25.6 26.6 28.8 30.5 31 28.4 27
T38 22.6 23.9 26.33 29.5 31.7 33.8 35.8 38.6 39.8 37.8 37.5
T39 24.7 27.6 28.59 32 34.5 37 39.4 43.2 45.6 43.5 42.3
T40 23.6 26.3 26.98 30.1 31.9 34.9 36.9 38.2 39.8 38.5 37.8
T41 22 22.9 23.98 26.1 27.5 30 32.5 34.8 35.3 35 33.8
T42 21.4 22.3 23.18 25.1 25.2 27.8 29.6 32.6 33.5 33.4 32.1
T43 25.8 26.4 28.08 30.5 32.9 34.5 35.6 38.6 39.2 36.7 36.9 35.5 36.32 34.9
T44 19.8 15.5 22.46 24.7 27.1 28 30.5 31.8 33.2 31.2 30.2 30.3 30.6 30.1
T45 23.7 24.5 26.33 28.9 30.5 34.5 32.7 34.5 36 35.6 34.7 34.3 25.6 30.3
T46 24.9 26.6 27.93 30 32.7 34.5 36.2 38.5 40.3 39.4 39.3 36.3 37.1 39.3
T47 26.9 29.3 30.88 33 33.9 35.4 36.9 39.5 41.6 40.1 40.7 39.1 41.8 39.7
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Table B-3: Experiment 1: Body Weight (g) Welch’s 2-Tailed T-test 
 (Comparisons of 0.05 significance marked in green) 
 
  
Exp. 1 Body Weight (g) T Test
Significance of 0.05 Highlighted in Green
22.4 21.7 24.0 34.2
21.3 20.2 26.5 26.3
21.5 23.8 28.7 31.9
25.3 21 29.7 24.4
24.0 23.5 29.9 28.5
26.5 25 34.9 32.1
20.4 24.7 23.4 34.2
23.8 22.7 27.6 29.1
22.7 23.5 28.0 30.9
24.1 21.7 29.0 26.2
22.5 22.4 30.5 26.4
23.5 22.6 29.5 31.7
23.4 24.7 31.8 34.5
23.4 23.6 31.5 31.9
20.9 22 27.8 27.5
19.7 21.4 25.1 25.2
 23.8 25.8 28.0 32.9
24.3 19.8 31.7 27.1
24.7 24.9 32.0 32.7
22.1 26.9 28.4 33.9
23.6 27.8
Sample Size 20.00 21.00 Sample Size 20.00 21.00
Mean 23.01 23.12 Mean 28.90 29.97
StDev 1.70 1.84 StDev 2.83 3.32
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value






32.3 39.8 30.4 37.5
35.7 45.6 33.4 42.3
32.3 39.8 31.6 37.8
29.9 35.3 28.2 33.8
28.3 33.5 30.1 32.1
30.1 39.2 31.6 36.9 30 34.9
34.8 33.2 34.8 30.2 31.9 30.1
36.0 40.3 36.1 39.3 36.7 39.3
29.8 41.6 30.3 40.7 36.4 39.7
33.7 32.3 31.9 33.6
Sample Size 14.00 15.00 Sample Size 9.00 10.00 Sample Size 5.00 5.00
Mean 30.78 37.05 Mean 31.83 36.29 Mean 33.38 35.52
StDev 3.89 4.52 StDev 2.50 4.02 StDev 3.00 4.04
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value
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Appendix B.2: Experiment 1 Food and Energy Tables 
 
Table B-4: Experiment 1: Standard Diet Given and Leftover (g) 
 
  
Sept 9-16 Sept 16-23 Sept 23-30Sept 30-Oct 7Oct 7-14 Oct 7-15 Oct 7-16 Oct 7-17 Oct 7-18 Oct 7-19 Oct 7-20 Oct 7-21 Oct 7-22
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13
Added 34.4 38.2 31.2 30.1
Left 13.3 17.5 8.6 8.2
Added 32.1 36.8 30.8 30.6
Left 10.6 13.3 5.1 7.1
Added 33.4 34.7 53.8 30.9
Left 15.1 5.1 4.6 3.4
Added 38.3 36.6 30.0 30.9
Left 9.7 12.6 2.9 6.6
Added 37.3 35.7 30.7 30.3
Left 18.0 3.7 2.6 4.3
Added 40.3 34.8 29.8 30.5
Left 15.9 6.4 0.0 2.5
Added 30.7 37.3 32.4 30.9 37.2 35.8 34.8 35.3
Left 7.1 18.7 10.9 9.4 13.6 13.7 13.4 6.6
Added 36.9 36.9 30.7 31.5 34.8 36.4 35.5 35.7
Left 13.1 13.1 6.1 6.4 9.1 14.8 13.1 9.2
Added 35.0 34.1 31.1 31.8 34.0 34.8 36.1 34.6
Left 16.7 7.6 3.4 6.8 7.3 6.7 12.0 16.5
Added 38.1 36.0 68.0 32.5 35.0 35.3 36.2 35.4
Left 13.0 10.3 11.8 7.1 7.9 6.7 8.5 6.3
Added 34.1 34.6 32.3 32.6 37.0 35.9 36.6 35.7
Left 9.6 7.3 3.6 6.6 10.6 9.3 11.5 7.3
Added 35.8 34.3 29.4 30.8 34.8 34.5 36.0 35.0 35.7 35.2
Left 14.4 6.2 3.7 7.0 12.2 11.6 11.8 7.5 12.9 0.0
Added 35.1 34.7 31.0 30.0 36.9 34.3 36.1 47.2 35.2 35.3
Left 9.5 8.1 2.3 1.9 10.7 8.4 11.6 14.8 11.3 0.0
Added 38.0 35.0 31.4 30.8 36.8 36.3 36.5 34.3 36.3 35.1
Left 12.3 10.3 1.8 2.9 12.2 10.6 10.5 4.4 10.1 0.0
Added 31.9 35.1 29.8 30.5 37.6 35.1 36.4 35.4 37.8 35.0
Left 13.1 7.3 5.7 4.6 10.7 11.8 13.5 6.4 15.3 0.0
Added 32.7 36.7 30.5 32.1 35.4 34.5 36.8 35.3 34.6 34.6 36.7 37.2 37.6
Left 14.2 11.4 1.5 8.7 10.6 11.4 15.0 8.0 11.3 9.6 12.9 19.3 14.2
Added 36.5 34.7 32.6 31.4 36.5 34.3 36.1 34.5 34.5 35.2 34.9 35.7 37.5
Left 13.7 10.6 6.2 7.9 12.5 11.2 12.7 5.9 9.7 8.8 10.9 10.5 12.3
Added 37.3 35.3 29.6 31.9 36.4 35.7 36.0 35.8 34.7 34.8 34.4 36.8 36.5
Left 13.6 8.5 2.7 5.9 12.1 9.7 11.2 5.9 10.0 8.6 8.6 11.4 11.6
Added 37.8 35.1 30.6 31.8 35.8 36.3 36.5 35.4 34.7 35.3 35.5 36.2 36.5
Left 11.6 3.8 1.5 5.5 9.1 8.4 10.9 4.5 11.0 8.4 9.5 7.2 13.9
Added 35.7 35.9 31.2 30.0 32.7 35.3 35.0 35.1 35.3 35.0 36.5 36.5 36.0

































Appendix B – Experiment 1 Data Tables 121 
Table B-5: Experiment 1: DIO Given and Leftover (g) 
 
  
Sept 9-16 Sept 16-23 Sept 23-30Sept 30-Oct 7Oct 7-14 Oct 7-15 Oct 7-16 Oct 7-17 Oct 7-18 Oct 7-19 Oct 7-20 Oct 7-21 Oct 7-22
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13
Added 34.8 36.2 26.2 29.7
Left 18.8 13.8 3.5 7.6
Added 31.3 36.8 25.3 28.4
Left 15.5 19.5 7.1 8.8
Added 38.1 35.6 26.4 28.1
Left 21.4 17.4 6.7 6.5
Added 32.1 36.9 26.7 27.3
Left 15.5 21.3 10.3 11.8
Added 37.5 35.4 27.0 30.8
Left 21.0 18.3 8.9 12.0
Added 39.0 35.2 27.0 29.4
Left 20.7 16.2 7.5 9.1
Added 37.8 34.5 25.3 30.2 32.3 31.4 30.0 29.5
Left 14.8 12.6 5.4 9.8 11.0 10.7 9.4 5.0
Added 35.7 35.7 26.8 28.3 30.8 31.5 31.8 30.1
Left 17.6 18.2 5.0 7.8 11.4 12.4 11.8 6.0
Added 36.8 35.9 25.6 29.1 31.2 32.4 31.0 29.8
Left 23.1 14.6 7.1 8.4 13.2 14.0 11.4 5.4
Added 32.5 35.7 26.7 29.0 32.1 31.2 31.3 29.9
Left 17.6 20.4 10.4 10.7 14.1 12.0 13.5 9.9
Added 36.0 36.9 25.6 30.3 32.2 30.0 31.6 30.5
Left 20.5 20.6 8.4 12.2 14.3 15.0 15.8 6.7
Added 35.5 35.9 25.8 30.2 32.1 30.4 30.1 30.2 23.5 32.9
Left 18.9 16.3 5.5 10.0 12.2 11.4 11.1 5.4 0.0 0.0
Added 39.6 34.8 26.2 29.6 32.1 31.7 29.5 41.0 26.5 37.1
Left 18.7 14.4 3.2 6.8 10.3 10.2 6.6 13.6 0.0 0.0
Added 37.4 35.1 26.5 30.1 30.9 31.7 31.1 29.6 23.0 32.2
Left 19.5 13.4 4.1 6.7 7.7 9.0 10.3 3.7 0.0 0.0
Added 33.9 36.4 26.5 30.7 30.9 30.4 30.9 29.7 21.0 29.4
Left 18.7 19.8 8.8 11.9 12.4 11.2 12.4 6.2 0.0 0.0
Added 33.3 36.5 25.6 28.5 31.8 32.2 30.9 30.7 20.0 28.0
Left 16.8 19.1 8.2 10.3 11.5 13.1 10.9 5.6 0.0 0.0
Added 41.2 36.4 26.9 31.0 31.5 31.8 30.0 30.2 23.5 28.2 40.9 39.9 40.8
Left 21.6 14.2 6.0 9.2 10.8 11.5 9.5 7.3 0.0 0.0 18.1 13.4 16.5
Added 32.5 35.5 25.2 29.3 30.9 32.1 31.4 28.9 19.5 23.4 40.7 40.7 40.6
Left 18.4 14.7 7.3 8.5 13.2 12.7 13.5 4.7 0.0 0.0 17.9 17.1 17.0
Added 39.8 34.8 26.4 30.8 31.9 31.1 32.0 30.1 23.5 28.2 40.8 41.0 42.6
Left 20.6 14.0 6.9 9.7 11.4 11.9 12.2 5.7 0.0 0.0 20.2 13.6 16.3
Added 41.4 36.5 25.2 29.7 30.4 31.0 30.5 42.3 24.0 28.8 41.4 40.0 41.9
Left 21.5 16.4 5.6 9.0 10.5 11.2 10.8 16.7 0.0 0.0 16.1 9.3 17.2
Added 37.2 34.7 26.2 29.8 29.6 30.7 30.1 30.5 19.5 23.4 40.2 41.2 41.4
Left 20.2 18.5 10.4 10.8 12.0 12.7 12.9 7.3 0.0 0.0 15.8 15.4 15.9
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Table B-6: Experiment 1: Weekly Food Consumption (g) 
 
  
Exp. 1 Weekly Food Consumption (g)
Sept 9-16Sept 16-23Sept 23-30Sept 30-Oct 7Oct 7-14 Oct 7-15 Oct 7-16 Oct 7-17 Oct 7-18 Oct 7-19 Oct 7-20 Oct 7-21 Oct 7-22
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13
C1 21.1 20.7 22.6 21.9
C2 21.5 23.5 25.7 23.5
C3 18.3 29.6 49.2 27.5
C4 28.6 24.0 27.1 24.3
C5 19.3 32.0 28.1 26.0
C6 24.4 28.4 29.8 28.0
C7 23.6 18.6 21.5 21.5 23.6 22.1 21.4 28.7
C9 23.8 23.8 24.6 25.1 25.7 21.6 22.4 26.5
C10 18.3 26.5 27.7 25.0 26.7 28.1 24.1 18.1
C11 25.1 25.7 56.2 25.4 27.1 28.6 27.7 29.1
C12 24.5 27.3 28.7 26.0 26.4 26.6 25.1 28.4
C14 21.4 28.1 25.7 23.8 22.6 22.9 24.2 27.5 22.8 35.2
C15 25.6 26.6 28.7 28.1 26.2 25.9 24.5 32.4 23.9 35.3
C16 25.7 24.7 29.6 27.9 24.6 25.7 26.0 29.9 26.2 35.1
C17 18.8 27.8 24.1 25.9 26.9 23.3 22.9 29.0 22.5 35.0
C19 18.5 25.3 29.0 23.4 24.8 23.1 21.8 27.3 23.3 25.0 23.8 17.8 23.4
C20 22.8 24.1 26.4 23.5 24.0 23.1 23.4 28.6 24.8 26.4 24.0 25.3 25.2
C21 23.7 26.8 26.9 26.0 24.3 26.0 24.8 29.9 24.7 26.2 25.8 25.4 24.9
C22 26.2 31.3 29.1 26.3 26.7 27.9 25.6 30.9 23.7 26.9 26.0 29.0 22.6
C24 21.8 27.1 27.1 25.6 24.9 24.6 22.4 30.2 24.2 25.6 26.0 24.1 23.3
T25 16.0 22.4 22.7 22.1
T26 15.8 17.3 18.2 19.6
T27 16.7 18.2 19.7 21.6
T28 16.6 15.6 16.4 15.5
T29 16.5 17.1 18.1 18.8
T30 18.3 19.1 19.5 20.3
T32 23.0 21.9 19.9 20.4 21.3 20.7 20.6 24.5
T33 18.1 17.6 21.8 20.5 19.4 19.1 20.0 24.1
T34 13.7 21.3 18.5 20.7 18.0 18.4 19.6 24.4
T35 14.9 15.3 16.3 18.3 18.0 19.2 17.8 20.0
T36 15.5 16.3 17.2 18.1 17.9 15.0 15.8 23.8
T38 16.6 19.6 20.3 20.2 19.9 19.0 19.0 24.8 23.5 32.9
T39 20.9 20.4 23.0 22.8 21.8 21.5 22.9 27.4 26.5 37.1
T40 17.9 21.7 22.4 23.4 23.2 22.7 20.8 25.9 23.0 32.2
T41 15.2 16.6 17.7 18.8 18.5 19.2 18.5 23.5 21.0 29.4
T42 16.5 17.4 17.4 18.2 20.3 19.1 20.0 25.1 20.0 28.0
T43 19.6 22.2 20.9 21.8 20.7 20.3 20.5 22.9 23.5 28.2 22.8 26.5 24.3
T44 14.1 20.8 17.9 20.8 17.7 19.4 17.9 24.2 19.5 23.4 22.8 23.6 23.6
T46 19.2 20.8 19.5 21.1 20.5 19.2 19.8 24.4 23.5 28.2 20.6 27.5 26.3
T47 19.9 20.1 19.6 20.7 19.9 19.8 19.7 25.6 24.0 28.8 25.3 30.7 24.7
T48 17.0 16.2 15.8 19.0 17.6 18.0 17.2 23.2 19.5 23.4 24.4 25.8 25.5




Week 4 DIO Dissected
Week 8 DIO Dissected
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Table B-7: Experiment 1: Weekly Energy Consumption (kcal) 
 
  
Exp. 1 Weekly Energy Consumption (kcal)
Sept 9-16Sept 16-23Sept 23-30Sept 30-Oct 7Oct 7-14 Oct 7-15 Oct 7-16 Oct 7-17 Oct 7-18 Oct 7-19 Oct 7-20 Oct 7-21 Oct 7-22
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13
C1 65.5 64.1 70.2 68.0
C2 66.7 72.8 79.7 72.9
C3 56.7 91.7 152.5 85.2
C4 88.7 74.5 84.1 75.4
C5 59.8 99.2 87.1 80.7
C6 75.6 88.2 92.2 86.7
C7 73.2 57.7 66.5 66.8 73.2 68.4 66.3 89.0
C9 73.8 73.7 76.4 77.8 79.7 67.0 69.4 82.2
C10 56.7 82.1 85.8 77.4 82.8 87.1 74.7 56.1
C11 77.8 79.8 174.3 78.8 84.0 88.7 85.9 90.2
C12 76.0 84.5 89.1 80.7 81.8 82.5 77.8 88.0
C14 66.3 87.1 79.8 73.7 70.1 71.0 75.0 85.3 70.7 109.1
C15 79.4 82.4 89.0 87.0 81.2 80.3 76.0 100.4 74.1 109.4
C16 79.7 76.4 91.8 86.3 76.3 79.7 80.6 92.7 81.2 108.8
C17 58.3 86.1 74.7 80.3 83.4 72.2 71.0 89.9 69.8 108.5
C19 57.4 78.5 89.8 72.6 76.9 71.6 67.6 84.6 72.2 77.5 73.7 55.3 72.6
C20 70.7 74.6 81.8 72.8 74.4 71.6 72.5 88.7 76.9 81.8 74.3 78.3 78.1
C21 73.5 83.0 83.5 80.5 75.3 80.6 76.9 92.7 76.6 81.2 80.1 78.7 77.2
C22 81.2 96.9 90.1 81.7 82.8 86.5 79.4 95.8 73.5 83.4 80.7 89.9 70.1
C24 67.6 84.1 84.0 79.4 77.2 76.3 69.4 93.6 75.0 79.4 80.7 74.8 72.2
T25 81.6 114.4 115.5 112.9
T26 80.6 88.3 92.6 100.1
T27 85.2 92.9 100.4 110.0
T28 84.7 79.7 83.4 78.8
T29 84.2 87.2 92.2 96.1
T30 93.3 97.2 99.3 103.4
T32 117.3 111.8 101.4 104.2 108.6 105.6 105.1 125.0
T33 92.3 89.5 111.3 104.6 98.9 97.4 102.0 122.9
T34 69.9 108.5 94.2 105.5 91.8 93.8 100.0 124.4
T35 76.0 77.9 83.2 93.3 91.8 97.9 90.8 102.0
T36 79.1 83.0 87.5 92.5 91.3 76.5 80.6 121.4
T38 84.7 99.8 103.7 103.1 101.5 96.9 96.9 126.5 72.9 102.0
T39 106.6 103.9 117.2 116.2 111.2 109.7 116.8 139.7 82.2 115.0
T40 91.3 110.6 114.1 119.1 118.3 115.8 106.1 132.1 71.3 99.8
T41 77.5 84.8 90.5 96.0 94.4 97.9 94.4 119.9 65.1 91.1
T42 84.2 88.7 88.7 92.6 103.5 97.4 102.0 128.0 62.0 86.8
T43 100.0 113.2 106.3 111.2 105.6 103.5 104.6 116.8 72.9 87.4 70.7 82.2 75.3
T44 71.9 106.0 91.2 105.9 90.3 98.9 91.3 123.4 60.5 72.5 70.7 73.1 73.2
T46 97.9 105.9 99.4 107.5 104.6 97.9 101.0 124.4 72.9 87.4 63.9 85.1 81.5
T47 101.5 102.6 100.0 105.8 101.5 101.0 100.5 130.6 74.4 89.3 78.4 95.1 76.6


















Week 13 DIO 
Food Restrict
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Table B-8: Experiment 1: Weekly Food Consumption (g) Welch’s 2-Tailed T-test 




Exp. 1 Food Consumed (g) T Test
Significance of 0.05 Highlighted in Green
21.1 16 21.9 22.1
21.5 15.8 23.5 19.6
18.3 16.7 27.5 21.6
28.6 16.6 24.3 15.5
19.3 16.5 26.0 18.8
24.4 18.3 28.0 20.3
23.6 23 21.5 20.4
23.8 18.1 25.1 20.5
18.3 13.7 25.0 20.7
25.1 14.9 25.4 18.3
24.5 15.5 26.0 18.1
21.4 16.6 23.8 20.2
25.6 20.9 28.1 22.8
25.7 17.9 27.9 23.4
18.8 15.2 25.9 18.8
18.5 16.5 23.4 18.2
 22.8 19.6 23.5 21.8
23.7 14.1 26.0 20.8
26.2 19.2 26.3 21.1
21.8 19.9 25.6 20.7
17 19.0
Sample Size 20.00 21.00 Sample Size 20.00 21.00
Mean 22.65 17.24 Mean 25.24 20.12
StDev 2.98 2.31 StDev 1.89 1.83
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value






27.5 24.8 35.2 32.9
32.4 27.4 35.3 37.1
29.9 25.9 35.1 32.2
29.0 23.5 35 29.4
27.3 25.1 25 28
28.6 22.9 26.4 28.2 23.43 24.3
29.9 24.2 26.2 23.4 25.2 23.6
30.9 24.4 26.9 28.2 24.9 26.3
30.2 25.6 25.6 28.8 22.6 24.7
23.2 23.4 23.3 25.5
Sample Size 14.00 15.00 Sample Size 9.00 10.00 Sample Size 5.00 5.00
Mean 28.32 24.25 Mean 30.08 29.16 Mean 23.89 24.88
StDev 3.31 1.63 StDev 4.84 4.16 StDev 1.11 1.05
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value
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Table B-9: Experiment 1: Weekly Energy Consumption (kcal) Welch’s 2-Tailed T-test 
(Comparisons of 0.05 significance marked in green) 
 
  
Exp. 1 Energy Consumed (g) T Test
Significance of 0.05 Highlighted in Green
65.5 81.6 68.0 112.9
66.7 80.58 72.9 100.1
56.7 85.17 85.2 110.0
88.7 84.66 75.4 78.8
59.8 84.15 80.7 96.1
75.6 93.33 86.7 103.4
73.2 117.3 66.8 104.2
73.8 92.31 77.8 104.6
56.7 69.87 77.4 105.5
77.8 75.99 78.8 93.3
76.0 79.05 80.7 92.5
66.3 84.66 73.7 103.1
79.4 106.59 87.0 116.2
79.7 91.29 86.3 119.1
58.3 77.52 80.3 96.0
57.4 84.15 72.6 92.6
 70.7 99.96 72.8 111.2
73.5 71.91 80.5 105.9
81.2 97.92 81.7 107.5
67.6 101.49 79.4 105.8
86.7 96.7
Sample Size 20.00 21.00 Sample Size 20.00 21.00
Mean 70.22 87.91 Mean 78.23 102.63
StDev 9.24 11.76 StDev 5.87 9.31
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value






85.3 126.5 109.12 101.99
100.4 139.7 109.43 115.01
92.7 132.1 108.81 99.82
89.9 119.9 108.5 91.14
84.6 128.0 77.5 86.8
88.7 116.8 81.84 87.42 72.633 75.33
92.7 123.4 81.22 72.54 78.12 73.16
95.8 124.4 83.39 87.42 77.19 81.53
93.6 130.6 79.36 89.28 70.06 76.57
118.3 72.54 72.23 79.05
Sample Size 14.00 15.00 Sample Size 9.00 10.00 Sample Size 5.00 5.00
Mean 87.80 123.69 Mean 93.24 90.40 Mean 74.05 77.13
StDev 10.27 8.33 StDev 15.01 12.91 StDev 3.45 3.25
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value
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Appendix B.3: Experiment 1 Body Composition Tables 
Table B-10: Experiment 1: Dissected Tissue Weights (g) 
 
  
Exp. 1 Dissected Tissue Weights (g)
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Table B-11: Experiment 1: Soxhlet Fat Extraction (g) 
 
  
















1 18.55 19.46 20.62 20.23 1 20.27 21.82 22.56 21.48
2 20.30 21.21 22.43 22.04 2 18.94 19.84 21.14 20.50
3 14.48 15.38 16.05 15.67 3 21.61 22.62 23.83 23.11
1 15.48 16.59 17.44 16.96 1 12.71 13.67 14.88 14.35
2 15.42 16.45 17.22 16.76 2 15.87 16.87 17.57 17.03
3 18.65 19.52 20.08 19.70 3 13.27 14.28 15.28 14.73
1 25.46 26.54 27.59 27.22 1 15.62 17.02 18.06 17.15
2 21.52 22.46 23.07 22.57 2 16.91 18.30 19.51 18.62
3 17.02 18.00 19.14 18.81 3 16.45 17.51 18.75 18.04
1 20.82 21.85 22.87 22.55 1 16.56 17.53 18.59 18.22
2 12.95 13.95 15.19 14.90 2 21.84 22.82 23.57 23.20
3 14.82 15.74 16.96 16.69 3 17.53 18.98 20.08 19.53
1 13.02 14.27 15.59 15.16 1 14.80 15.94 16.92 16.28
2 15.74 16.81 17.50 17.13 2 16.45 17.70 18.36 17.66
3 16.82 17.45 18.41 18.09 3 17.61 18.74 20.20 19.56
1 16.99 17.93 19.09 18.73 1 14.10 15.23 15.93 15.24
2 21.95 22.78 23.48 23.16 2 16.15 17.38 18.69 17.92
3 18.86 19.79 20.86 20.51 3 20.54 21.92 23.05 22.18
1 16.11 16.93 18.14 17.87 1 18.27 15.91 16.58 15.76
2 17.09 18.02 19.17 18.87 2 25.96 22.87 23.63 22.84
3 16.78 17.89 18.78 18.43 3 18.96 17.35 18.35 17.44
1 21.83 22.80 24.16 23.67 1 16.26 14.30 15.11 14.40
2 16.48 17.43 18.20 17.75 2 18.62 17.62 18.70 17.86
3 16.31 17.36 18.34 17.87 3 20.20 18.51 19.60 18.92
1 15.44 16.52 17.53 16.98 1 17.35 15.15 16.30 15.51
2 17.53 18.57 20.81 20.24 2 18.84 17.68 19.16 18.25
3 17.85 18.86 20.43 19.89 3 20.62 19.16 20.49 19.67
1 16.96 17.90 18.98 18.47 1 19.85 18.07 19.06 18.29
2 24.30 25.33 26.03 25.47 2 23.98 21.12 22.67 22.13
3 21.21 22.22 22.83 22.28 3 23.51 21.57 22.79 22.12
1 25.36 26.82 27.68 26.82 1 18.08 17.57 18.71 18.11
2 20.04 21.18 22.58 21.88 2 19.74 17.22 18.30 17.60
3 18.46 19.35 20.43 19.87 3 25.44 22.79 23.86 23.43
1 21.44 22.40 23.20 22.74 1 13.25 14.11 15.25 14.62
2 14.78 15.70 16.89 16.43 2 18.80 19.75 20.42 19.75
3 21.27 22.23 23.32 22.85 3 13.00 14.07 14.82 14.05
1 16.80 17.95 18.72 17.99 1 20.89 21.77 22.82 22.16
2 18.86 19.82 20.98 20.35 2 18.80 19.91 20.67 19.84
3 14.77 15.98 16.65 15.89 3 18.82 20.01 21.00 20.15
1 16.10 17.14 18.35 18.00 1 16.43 17.40 18.61 18.01
2 17.31 18.30 19.77 19.43 2 17.51 18.46 19.53 18.93
3 15.47 16.51 17.21 16.85 3 16.76 17.68 18.36 17.79
1 20.96 21.84 22.91 22.54 1 18.93 20.13 20.79 19.99
2 16.82 17.66 18.77 18.41 2 16.68 17.77 19.16 18.42
3 15.41 16.51 17.73 17.27 3 14.78 15.88 16.57 15.84
1 21.94 22.99 24.13 23.68 1 17.62 19.01 20.36 19.50
2 18.83 19.65 20.89 20.54 2 16.77 17.95 19.11 18.39
3 14.47 15.70 16.45 15.93 3 21.52 22.55 23.87 23.22
1 17.08 18.27 19.09 18.44 1 16.57 17.78 18.84 18.08
2 21.52 22.37 23.03 22.56 2 16.13 17.46 18.49 17.65
3 17.46 18.42 19.44 18.91 3 15.62 16.66 18.04 17.37
1 18.84 19.68 21.00 20.51 1 20.54 21.74 22.33 21.61
2 16.78 17.56 18.60 18.16 2 16.41 17.37 18.15 17.57
3 13.02 14.17 14.86 14.21 3 21.80 22.98 23.65 22.95
1 17.30 18.28 18.95 18.34 1 21.81 23.38 24.04 22.74
2 17.08 18.34 18.94 18.17 2 14.65 15.61 16.76 16.07
3 16.80 17.90 19.07 18.42 3 21.38 22.40 23.54 22.80
1 13.25 14.21 15.27 14.69 1 14.12 15.17 16.15 15.45
2 17.02 18.09 19.49 18.84 2 13.27 14.16 14.91 14.60
3 16.31 17.44 18.27 17.59 3 18.93 19.94 20.70 20.03
1 14.47 15.75 16.74 15.96 1 17.54 18.49 19.83 19.19
2 13.01 14.09 15.45 14.79 2 21.92 23.07 23.9 23.14
3 16.09 17.07 18.23 17.62 3 17.01 18.27 19.15 18.31
1 17.46 18.44 19.33 18.80
2 21.94 22.89 24.27 23.70
3 20.93 21.65 22.34 21.94
1 20.04 20.99 21.88 21.32
2 20.32 21.35 22.03 21.44
3 16.42 17.63 18.46 17.76
1 14.79 15.62 16.79 16.28
2 18.59 19.58 20.36 19.76
3 24.22 25.30 25.99 25.33
1 16.85 17.94 19.09 18.40
2 21.45 22.36 23.42 22.85
3 21.78 22.75 24.11 23.48
1 14.79 15.98 16.97 16.21
2 17.81 18.75 19.97 19.16
3 25.39 26.45 27.84 27.15
1 14.81 15.75 16.42 15.87
2 20.29 21.31 22.07 21.43
3 15.90 16.86 17.61 16.98
T41
Week 10 DIO 
Food Restrict




















Week 4 Standard 
Diet
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Table B-12: Experiment 1: Body Composition Mass (g) 
 
  







Dry Fat Body 
mass (g)       




Body Mass (g)     







Body Mass (g)     










C1 47.44% 52.56% 6.74 3.20 3.54 15.4 8.09
C2 53.00% 47.00% 7.47 3.96 3.51 16.5 7.75
C3 54.36% 45.64% 8.51 4.63 3.88 18.4 8.40
C4 61.08% 38.92% 9.67 5.91 3.76 19.06 7.42
C5 48.78% 51.22% 8.21 4.01 4.20 19.04 9.75
C6 63.95% 36.05% 11.61 7.42 4.19 22.36 8.06
C7 34.34% 65.66% 6.31 2.17 4.14 23.84 15.65
C9 42.55% 57.45% 8.04 3.42 4.62 17.65 10.14
C10 55.04% 44.96% 8.11 4.46 3.65 21.44 9.64
C11 55.04% 44.96% 11.73 6.46 5.27 16.02 7.20
C12 57.39% 42.61% 11.85 6.80 5.05 19.44 8.28
C14 60.55% 39.45% 11.65 7.05 4.60 15.4 6.07
C15 60.43% 39.57% 12.86 7.77 5.09 17.98 7.11
C16 61.32% 38.68% 12.49 7.66 4.83 17.84 6.90
C17 54.96% 45.04% 10.03 5.51 4.52 23.02 10.37
C19 57.99% 42.01% 10.54 6.11 4.43 23.02 9.67
C20 61.11% 38.89% 11.61 7.09 4.52 30.76 11.96
C21 63.67% 36.33% 13.16 8.38 4.78 26.09 9.48
C22 64.50% 35.50% 14.08 9.08 5.00 27.77 9.86
C24 61.95% 38.05% 11.2 6.94 4.26 20.55 7.82
T25 70.84% 29.16% 14.24 10.09 4.15 23.2 6.77
T26 54.79% 45.21% 8.48 4.65 3.83 21.86 9.88
T27 65.34% 34.66% 11.79 7.70 4.09 24.61 8.53
T28 37.94% 62.06% 6.42 2.44 3.98 23.47 14.56
T29 56.23% 43.77% 9.48 5.33 4.15 20.81 9.11
T30 62.25% 37.75% 11.4 7.10 4.30 19.34 7.30
T32 75.52% 24.48% 19.54 14.76 4.78 27.24 6.67
T33 70.04% 29.96% 15.66 10.97 4.69 31.13 9.33
T34 74.61% 25.39% 17.53 13.08 4.45 25.08 6.37
T35 65.09% 34.91% 12.21 7.95 4.26 24.1 8.41
T36 55.78% 44.22% 10.9 6.08 4.82 22.27 9.85
T38 71.33% 28.67% 15.89 11.33 4.56 22.7 6.51
T39 73.81% 26.19% 18.62 13.74 4.88 24.89 6.52
T40 62.34% 37.66% 12.95 8.07 4.88 25.54 9.62
T41 67.29% 32.71% 13.27 8.93 4.34 15.08 4.93
T42 62.25% 37.75% 11.38 7.08 4.30 21.75 8.21
T43 63.46% 36.54% 12.69 8.05 4.64 24.38 8.91
T44 59.91% 40.09% 10.69 6.40 4.29 21.2 8.50
T46 75.74% 24.26% 15.48 11.72 3.76 26.99 6.55
T47 66.50% 33.50% 14.66 9.75 4.91 27.35 9.16
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Table B-14: Experiment 1: Dry Fat Percentages Welch’s 2-Tailed T-test 
(Comparisons of 0.05 significance marked in green) 
 
  
Exp. 1 Dry Fat Percentages T Test
Significance of 0.05 Highlighted in Green
20.76% 43.48%
24.00% 21.26% 9.09% 54.17%
25.14% 31.30% 19.38% 35.23%
30.99% 10.38% 20.82% 52.15%
21.04% 25.62% 40.30% 32.97%
33.21% 36.70% 34.98% 27.30%
Sample Size 6.00 6.00 Sample Size 5.00 5.00
Mean 26.87% 25.05% Mean 24.92% 40.37%
StDev 5.06% 10.06% StDev 12.61% 12.05%
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
45.81% 49.93% 26.55% 33.03%
43.22% 55.21% 23.06% 30.21%
42.93% 31.61% 32.12% 43.44%
23.95% 59.21% 32.70% 35.65%
32.57% 33.76% 35.92%
Sample Size 4.00 5.00 Sample Size 5.00 5.00
Mean 38.98% 45.71% Mean 29.64% 35.65%
StDev 10.10% 12.86% StDev 4.62% 4.93%
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
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Appendix B.4: Experiment 1 Glucose Clearance Tables 
Table B-15: Experiment 1: Week 0 Baseline Glucose Levels 
 
  
Exp. 1 Glucose Concentration





Week 0 226.5 0.213 8.86
Baseline Concentration [mg/1 gram 
solution]
Amount Given
166.67 0.255 Total Area
Before: 2.65 Decimal Time: -0.1 0.5 1.0 1.5 2.0
After: 2.39 Glucose: 212.0 347.0 302.0 258.0 201.0
Injected: 0.26 Area Under Curve 144.4 158.2 140.0 113.8 556.4
Standardized to Glucose Injected 111.5 122.2 108.1 87.9 429.6
Standardized to G Concentration 151.5 166.0 146.9 119.4 583.9
Standardized to Amount Given 126.6 138.6 122.7 99.7 487.6
Lean Body Mass 7.78 Standardized to Lean Body Mass 144.2 158.0 139.8 113.6 555.7
Before: 2.63 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.38 Glucose: 197.0 356.0 358.0 286.0 203.0
Injected: 0.25 Area Under Curve 139.8 176.0 164.1 121.6 601.5
Standardized to Glucose Injected 112.3 141.4 131.8 97.6 483.1
Standardized to G Concentration 152.6 192.1 179.2 132.7 656.6
Standardized to Amount Given 127.4 160.5 149.6 110.8 548.3
Lean Body Mass 8.33 Standardized to Body Weight 135.6 170.8 159.2 117.9 583.5
Before: 2.62 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.37 Glucose: 171.0 310.0 300.0 294.0 232.0
Injected: 0.25 Area Under Curve 121.6 150.0 148.1 133.3 552.9
Standardized to Glucose Injected 95.7 118.1 116.6 104.9 435.3
Standardized to G Concentration 130.1 160.5 158.5 142.6 591.6
Standardized to Amount Given 108.7 134.0 132.3 119.1 494.1
Lean Body Mass 9.18 Standardized to Body Weight 104.8 129.3 127.7 114.9 476.7
Before: 2.60 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.35 Glucose: 201.0 216.0 235.0 295.0 250.0
Injected: 0.25 Area Under Curve 105.4 110.9 132.1 136.3 484.7
Standardized to Glucose Injected 83.3 87.6 104.5 107.7 383.1
Standardized to G Concentration 113.2 119.1 141.9 146.4 520.7
Standardized to Amount Given 94.6 99.5 118.5 122.2 434.8
Body Weight 11.40 Standardized to Body Weight 73.5 77.3 92.1 95.0 338.0
Before: 2.65 Decimal Time: 0.1 0.6 1.1 1.6 2.1




102.6 105.6 98.7 87.9
394.8
Standardized to Glucose Injected 77.7 80.0 74.8 66.6 299.1
Standardized to G Concentration 105.7 108.7 101.6 90.5 406.5
Standardized to Amount Given 88.2 90.8 84.9 75.6 339.5
Lean Body Mass 8.88 Standardized to Body Weight 88.0 90.6 84.7 75.4 338.8
Before: 2.59 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.34 Glucose: 175.0 293.0 255.0 259.0 199.0
Injected: 0.26 Area Under Curve 118.8 136.2 127.0 115.5 497.5
Standardized to Glucose Injected 93.2 106.9 99.6 90.6 390.2
Standardized to G Concentration 126.6 145.2 135.4 123.1 530.3
Standardized to Amount Given 105.8 121.3 113.0 102.8 442.8
Lean Body Mass 8.72 Standardized to Body Weight 107.5 123.2 114.9 104.4 450.0
Before: 2.60 Decimal Time: 0.2 0.7 1.2 1.6 2.2
After: 2.35 Glucose: 195.0 348.0 274.0 255.0 174.0
Injected: 0.25 Area Under Curve 135.7 155.1 131.4 118.1 540.2
Standardized to Glucose Injected 108.5 124.1 105.1 94.5 432.2
Standardized to G Concentration 147.5 168.6 142.8 128.4 587.3
Standardized to Amount Given 123.2 140.8 119.3 107.2 490.5
Lean Body Mass 10.62 Standardized to Body Weight 102.7 117.4 99.5 89.4 409.0
Before: 2.62 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.37 Glucose: 199.0 340.4 287.0 249.0 193.1
Injected: 0.25 Area Under Curve 136.7 154.8 133.8 112.4 537.6
Standardized to Glucose Injected 109.3 123.8 107.0 89.9 430.1
Standardized to G Concentration 148.6 168.3 145.4 122.2 584.4
Standardized to Amount Given 124.1 140.5 121.5 102.0 488.1
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Exp. 1 Glucose Tolerance
Week 4






226.5 0.213 8.86 Total Area
Before: 2.284 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.501 Glucose: 198.0 359.0 297.0 205.0 161.0
Injected: 0.217 Area Under Curve 139.7 164.7 126.6 90.7 521.8
Standardized to Glucose Injected 128.8 151.8 116.7 83.6 480.9
Lean Body Mass 8.09 Standardized to Body Weight 141.0 166.2 127.8 91.6 526.5
Before: 2.280 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.496 Glucose: 174.0 258.0 237.0 229.0 191.0
Injected: 0.216 Area Under Curve 108.7 123.8 116.2 106.1 454.7
Standardized to Glucose Injected 100.6 114.6 107.6 98.2 421.0
Body Weight 7.75 Standardized to Body Weight 115.0 130.9 122.9 112.3 481.1
Before: 2.265 Decimal Time: 0.1 0.6 1.1 1.6 2.0
After: 2.479 Glucose: 171.0 310.0 300.0 294.0 232.0
Injected: 0.214 Area Under Curve 120.7 152.9 149.6 128.7 551.9
Standardized to Glucose Injected 112.8 142.9 139.8 120.2 515.8
Body Weight 8.40 Standardized to Body Weight 119.0 150.8 147.5 126.9 544.2
Before: 2.258 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.470 Glucose: 201.0 216.0 235.0 295.0 250.0
Injected: 0.212 Area Under Curve 105.6 111.7 132.4 135.9 485.6
Standardized to Glucose Injected 99.6 105.4 124.9 128.2 458.1
Body Weight 7.42 Standardized to Body Weight 119.0 125.8 149.2 153.1 547.1
Before: 2.261 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.477 Glucose: 186.0 220.0 207.0 191.0 158.0
Injected: 0.216 Area Under Curve 102.7 105.6 100.3 86.8 395.5
Standardized to Glucose Injected 95.1 97.8 92.9 80.3 366.2
Body Weight 9.75 Standardized to Body Weight 86.4 88.9 84.4 73.0 332.7
Before: 2.271 Decimal Time: 0.1 0.6 1.1 1.6 2.0
After: 2.467 Glucose: 175.0 293.0 255.0 259.0 199.0
Injected: 0.196 Area Under Curve 117.8 135.4 128.3 84.5 466.1
Standardized to Glucose Injected 120.3 138.2 130.9 86.3 475.6
Body Weight 8.06 Standardized to Body Weight 132.2 151.9 143.9 94.8 522.8
Before: 2.27 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.482 Glucose: 184.2 276.0 255.2 245.5 198.5
Injected: 0.212 Area Under Curve 115.9 132.3 125.6 110.6 484.3
Standardized to Glucose Injected 109.3 124.8 118.5 104.3 456.9
Body Weight 8.246 Standardized to Body Weight 117.5 134.1 127.3 112.1 490.9
Standard
C6
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Table B-17: Experiment 1: Week 4 DIO Glucose Levels 
 
  
Exp. 1 Glucose Tolerance
Week 4






226.5 0.213 8.86 Total Area
Before: 2.264 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.480 Glucose: 217.0 401.0 339.0 307.0 241.0
Injected: 0.216 Area Under Curve 154.6 188.4 159.4 135.8 638.2
Standardized to Glucose Injected 143.1 174.4 147.6 125.7 590.9
Body Weight 6.765 Standardized to Body Weight 187.5 228.5 193.4 164.7 773.9
Before: 2.273 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.483 Glucose: 190.0 352.0 347.0 269.0 205.0
Injected: 0.210 Area Under Curve 135.3 175.1 153.5 119.0 582.9
Standardized to Glucose Injected 128.8 166.8 146.2 113.4 555.2
Body Weight 9.882 Standardized to Body Weight 115.5 149.6 131.1 101.6 497.8
Before: 2.296 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.511 Glucose: 215.0 365.0 354.0 317.0 276.0
Injected: 0.215 Area Under Curve 146.5 179.3 166.4 148.7 641.0
Standardized to Glucose Injected 136.3 166.7 154.8 138.4 596.3
Body Weight 8.531 Standardized to Body Weight 141.6 173.2 160.8 143.7 619.3
Before: 2.249 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.464 Glucose: 174.0 317.0 241.0 202.0 176.0
Injected: 0.215 Area Under Curve 123.2 139.3 110.1 94.4 466.9
Standardized to Glucose Injected 114.6 129.6 102.4 87.8 434.3
Body Weight 14.565 Standardized to Body Weight 69.7 78.8 62.3 53.4 264.2
Before: 2.260 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.478 Glucose: 171.0 328.0 298.0 230.0 186.0
Injected: 0.218 Area Under Curve 124.6 157.3 131.3 103.4 516.6
Standardized to Glucose Injected 114.3 144.3 120.5 94.8 473.9
Body Weight 9.108 Standardized to Body Weight 111.2 140.4 117.2 92.3 461.1
Before: 2.296 Decimal Time: 0.3 0.8 1.3 1.8 2.3
After: 2.506 Glucose: 203.0 322.0 298.0 229.0 209.0
Injected: 0.210 Area Under Curve 131.2 153.8 136.7 104.9 526.6
Standardized to Glucose Injected 124.9 146.5 130.1 99.9 501.5
Body Weight 7.300 Standardized to Body Weight 151.6 177.8 158.0 121.3 608.7
Before: 2.273 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.487 Glucose: 195.0 347.5 312.8 259.0 215.5
Injected: 0.214 Area Under Curve 135.2 166.2 143.0 117.6 562.1
Standardized to Glucose Injected 126.4 155.3 133.7 109.9 525.3
Body Weight 9.358 Standardized to Body Weight 119.7 147.0 126.6 104.1 497.4
Standard
T30
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Table B-18: Experiment 1: Week 8 Standard Diet Glucose Levels 
 
  
Exp. 1 Glucose Concentration






Week 8 226.5 0.213 8.86




222.78 0.215 Total Area
Before: 2.49 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.27 Glucose: 200.0 456.0 320.0 207.0 164.0
Injected: 0.22 Area Under Curve 165.4 193.5 131.0 93.5 583.4
Standardized to Glucose Injected 150.3 175.9 119.1 85.0 530.3
Standardized to G Concentration 152.8 178.8 121.1 86.4 539.2
Standardized to Amount Given 151.6 177.3 120.1 85.7 534.8
Lean Body Mass 15.65 Standardized to Body Weight 85.8 100.4 68.0 48.5 302.7
Before: 2.48 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.27 Glucose: 174.0 314.0 309.0 219.0 191.0
Injected: 0.21 Area Under Curve 122.7 156.7 131.1 102.8 513.4
Standardized to Glucose Injected 118.0 150.7 126.1 98.9 493.7
Standardized to G Concentration 120.0 153.2 128.2 100.5 501.9
Standardized to Amount Given 119.0 151.9 127.1 99.7 497.8
Lean Body Mass 10.14 Standardized to Body Weight 104.0 132.8 111.1 87.1 435.0
Before: 2.47 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.26 Glucose: 121.0 357.0 279.0 186.0 123.0
Injected: 0.21 Area Under Curve 119.7 158.6 116.7 76.3 471.3
Standardized to Glucose Injected 114.5 151.7 111.7 73.1 451.0
Standardized to G Concentration 116.5 154.3 113.5 74.3 458.5
Standardized to Amount Given 115.5 153.0 112.6 73.7 454.8
Lean Body Mass 12.31 Standardized to Body Weight 83.2 110.2 81.1 53.0 327.5
Before: 2.47 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.25 Glucose: 180.0 266.0 309.0 266.0 174.0
Injected: 0.21 Area Under Curve 114.2 140.3 143.7 109.3 507.5
Standardized to Glucose Injected 107.3 131.8 134.9 102.6 476.5
Standardized to G Concentration 109.0 134.0 137.2 104.3 484.5
Standardized to Amount Given 108.1 132.8 136.0 103.5 480.5
Lean Body Mass 7.20 Standardized to Body Weight 133.0 163.4 167.3 127.3 591.1
Before: 2.47 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.25 Glucose: 173.0 244.0 223.0 209.0 194.0
Injected: 0.21 Area Under Curve 105.2 116.4 108.8 100.1 430.5
Standardized to Glucose Injected 98.4 108.7 101.7 93.5 402.3
Standardized to G Concentration 100.0 110.6 103.4 95.1 409.0
Standardized to Amount Given 99.2 109.7 102.5 94.3 405.6
Lean Body Mass 8.28 Standardized to Body Weight 106.1 117.3 109.7 100.9 433.9
Before: 2.47 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.26 Glucose: 169.6 327.4 288.0 217.4 169.2
Injected: 0.21 Area Under Curve 125.5 153.0 126.4 96.4 501.2
Standardized to Glucose Injected 117.9 143.8 118.8 90.6 471.1
Standardized to G Concentration 119.9 146.2 120.7 92.1 478.9
Standardized to Amount Given 118.9 145.0 119.7 91.3 475.0
Lean Body Mass 10.72 Standardized to Body Weight 98.3 119.9 99.0 75.5 392.7
Standard
C12
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Table B-19: Experiment 1: Week 8 DIO Glucose Levels 
 
  
Exp. 1 Glucose Concentration






Week 8 226.5 0.213 8.86




222.78 0.215 Total Area
Before: 2.48 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.27 Glucose: 184.0 329.0 356.0 312.0 231.0
Injected: 0.22 Area Under Curve 129.5 171.5 163.8 136.5 601.4
Standardized to Glucose Injected 119.9 158.8 151.7 126.4 556.9
Standardized to G Concentration 121.9 161.5 154.2 128.5 566.2
Standardized to Amount Given 120.9 160.2 153.0 127.4 561.5
Lean Body Mass 6.668 Standardized to Body Weight 160.7 212.8 203.3 169.3 746.1
Before: 2.45 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.25 Glucose: 193.0 368.0 321.0 272.0 212.0
Injected: 0.20 Area Under Curve 140.5 172.7 147.8 120.9 581.9
Standardized to Glucose Injected 140.5 172.7 147.8 120.9 581.9
Standardized to G Concentration 142.8 175.6 150.2 123.0 591.6
Standardized to Amount Given 141.7 174.2 149.0 121.9 586.7
Lean Body Mass 9.327 Standardized to Body Weight 134.6 165.5 141.5 115.8 557.4
Before: 2.46 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.25 Glucose: 175.0 391.0 353.0 287.0 193.0
Injected: 0.21 Area Under Curve 140.2 186.5 162.6 119.3 608.7
Standardized to Glucose Injected 135.5 180.2 157.1 115.3 588.1
Standardized to G Concentration 137.8 183.2 159.7 117.2 597.9
Standardized to Amount Given 136.6 181.7 158.4 116.3 593.0
Lean Body Mass 8.182 Standardized to Body Weight 148.0 196.8 171.5 125.9 642.1
Before: 2.46 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.21 Glucose: 155.0 374.0 379.0 259.0 166.0
Injected: 0.25 Area Under Curve 132.5 189.9 157.4 106.6 586.4
Standardized to Glucose Injected 106.8 153.2 126.9 86.0 472.9
Standardized to G Concentration 108.6 155.7 129.0 87.4 480.8
Standardized to Amount Given 107.7 154.4 128.0 86.7 476.8
Lean Body Mass 8.414 Standardized to Body Weight 113.4 162.6 134.8 91.3 502.1
Before: 2.47 Decimal Time: 0.3 0.8 1.3 1.8 2.3
After: 2.26 Glucose: 163.0 441.0 386.0 216.0 157.0
Injected: 0.21 Area Under Curve 151.3 209.4 148.8 93.0 602.5
Standardized to Glucose Injected 143.4 198.5 141.1 88.1 571.1
Standardized to G Concentration 145.8 201.8 143.4 89.6 580.6
Standardized to Amount Given 144.6 200.1 142.2 88.9 575.8
Lean Body Mass 11.290 Standardized to Body Weight 113.4 157.1 111.6 69.8 451.9
Before: 2.47 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.25 Glucose: 174.0 380.6 359.0 269.2 191.8
Injected: 0.22 Area Under Curve 138.8 185.9 156.1 115.3 596.1
Standardized to Glucose Injected 128.3 171.8 144.3 106.5 550.9
Standardized to G Concentration 130.4 174.7 146.7 108.3 560.1
Standardized to Amount Given 129.4 173.3 145.5 107.4 555.5
Lean Body Mass 8.78 Standardized to Body Weight 130.6 174.9 146.9 108.4 560.8
Standard
T36
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Table B-20: Experiment 1: Week 10 Standard Diet Glucose Levels 
 
  
Exp. 1 Glucose Concentration





Week 10 226.5 0.213 8.86
Standard Diet Concentration [mg/1 gram 
solution]
Amount Given
222.78 0.215 Total Area
Before: 2.48 Decimal Time: 0.2 0.7 1.2 1.8 2.2
After: 2.27 Glucose: 182.0 226.0 174.0 247.0 241.0
Injected: 0.21 Area Under Curve 101.8 100.8 109.1 117.9 429.5
Standardized to Glucose Injected 95.2 94.2 101.9 110.2 401.4
Standardized to G Concentration 93.5 92.5 100.1 108.2 394.3
Standardized to Amount Given 92.2 91.2 98.7 106.7 388.8
Lean Body Mass 6.07 Standardized to Body Weight 134.4 133.1 144.0 155.6 567.1
Before: 2.51 Decimal Time: 0.3 0.7 1.3 1.8 2.3
After: 2.30 Glucose: 170.0 302.0 298.0 269.0 200.0
Injected: 0.22 Area Under Curve 115.1 158.3 148.4 108.1 529.9
Standardized to Glucose Injected 107.0 147.2 138.1 100.6 492.9
Standardized to G Concentration 105.1 144.6 135.6 98.8 484.1
Standardized to Amount Given 103.7 142.6 133.7 97.4 477.4
Lean Body Mass 7.11 Standardized to Body Weight 129.1 177.6 166.6 121.3 594.5
Before: 2.46 Decimal Time: 0.3 0.8 1.3 1.8 2.3
After: 2.24 Glucose: 162.0 330.0 257.0 212.0 183.0
Injected: 0.22 Area Under Curve 122.8 156.9 117.7 92.2 489.5
Standardized to Glucose Injected 113.2 144.6 108.5 84.9 451.2
Standardized to G Concentration 111.2 142.0 106.6 83.4 443.1
Standardized to Amount Given 109.6 140.0 105.1 82.3 437.0
Lean Body Mass 7.11 Standardized to Body Weight 136.5 174.4 130.9 102.5 544.2
Before: 2.47 Decimal Time: 0.3 0.8 1.3 1.8 2.3
After: 2.25 Glucose: 159.0 245.0 251.0 224.0 176.0
Injected: 0.21 Area Under Curve 100.5 129.5 118.9 96.3 445.2
Standardized to Glucose Injected 95.3 122.8 112.7 91.3 422.0
Standardized to G Concentration 93.6 120.6 110.7 89.6 414.4
Standardized to Amount Given 92.3 118.9 109.1 88.4 408.7
Lean Body Mass 6.90 Standardized to Body Weight 118.5 152.7 140.2 113.5 524.8
Before: 2.48 Decimal Time: 0.3 0.8 1.3 1.8 2.3
After: 2.27 Glucose: 168.3 275.8 245.0 238.0 200.0
Injected: 0.21 Area Under Curve 110.1 136.0 123.4 103.6 473.0
Standardized to Glucose Injected 102.8 126.9 115.2 96.7 441.6
Standardized to G Concentration 100.9 124.7 113.1 95.0 433.7
Standardized to Amount Given 99.5 122.9 111.5 93.7 427.7
Lean Body Mass 6.80 Standardized to Body Weight 129.7 160.2 145.3 122.0 557.2
Standard
C17
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Table B-21: Experiment 1: Week 10 DIO Glucose Levels 
 
  
Exp. 1 Glucose Concentration





Week 10 226.5 0.213 8.86
DIO Concentration [mg/1 gram 
solution]
Amount Given
222.78 0.215 Total Area
Before: 2.48 Decimal Time: 0.3 0.9 1.3 1.9 2.3
After: 2.27 Glucose: 120.0 286.0 262.0 196.0 178.0
Injected: 0.22 Area Under Curve 105.2 132.1 116.2 90.0 443.4
Standardized to Glucose Injected 97.8 122.8 108.1 83.7 412.5
Standardized to G Concentration 96.1 120.7 106.1 82.2 405.1
Standardized to Amount Given 94.8 119.0 104.7 81.1 399.5
Lean Body Mass 6.508 Standardized to Body Weight 129.0 162.0 142.5 110.4 543.9
Before: 2.47 Decimal Time: 0.4 0.9 1.4 1.9 2.4
After: 2.26 Glucose: 169.0 275.0 246.0 247.0 195.0
Injected: 0.22 Area Under Curve 115.4 125.0 124.6 109.2 474.1
Standardized to Glucose Injected 107.3 116.2 115.9 101.6 441.0
Standardized to G Concentration 105.4 114.2 113.8 99.8 433.2
Standardized to Amount Given 104.0 112.6 112.2 98.4 427.2
Lean Body Mass 6.519 Standardized to Body Weight 141.3 153.0 152.5 133.7 580.5
Before: 2.48 Decimal Time: 0.4 0.9 1.4 1.9 2.4
After: 2.26 Glucose: 281.0 316.0 240.0 169.0 166.0
Injected: 0.22 Area Under Curve 151.2 136.5 103.8 83.4 475.0
Standardized to Glucose Injected 139.4 125.8 95.7 76.9 437.8
Standardized to G Concentration 136.9 123.6 94.0 75.5 430.0
Standardized to Amount Given 135.0 121.9 92.7 74.5 424.1
Lean Body Mass 9.618 Standardized to Body Weight 124.4 112.3 85.4 68.6 390.6
Before: 2.48 Decimal Time: 0.4 0.9 1.4 1.9 2.4
After: 2.25 Glucose: 176.0 444.0 353.0 278.0 204.0
Injected: 0.22 Area Under Curve 156.3 197.8 157.3 120.8 632.2
Standardized to Glucose Injected 141.4 179.0 142.4 109.4 572.2
Standardized to G Concentration 138.9 175.8 139.8 107.4 562.0
Standardized to Amount Given 137.0 173.4 137.9 105.9 554.2
Lean Body Mass 4.933 Standardized to Body Weight 246.1 311.5 247.7 190.3 995.5
Before: 2.53 Decimal Time: 0.4 0.9 1.4 2.1 2.4
After: 2.31 Glucose: 168.0 212.0 197.0 195.0 154.0
Injected: 0.22 Area Under Curve 96.4 100.5 131.3 57.4 385.6
Standardized to Glucose Injected 88.0 91.8 119.9 52.5 352.2
Standardized to G Concentration 86.4 90.1 117.8 51.5 345.9
Standardized to Amount Given 85.2 88.9 116.2 50.8 341.1
Lean Body Mass 8.210 Standardized to Body Weight 92.0 95.9 125.4 54.8 368.1
Before: 2.49 Decimal Time: 0.4 0.9 1.4 1.9 2.4
After: 2.27 Glucose: 182.8 306.6 259.6 217.0 179.4
Injected: 0.22 Area Under Curve 125.1 138.2 128.2 91.3 482.7
Standardized to Glucose Injected 115.1 127.1 117.9 84.0 444.1
Standardized to G Concentration 113.0 124.8 115.8 82.5 436.2
Standardized to Amount Given 111.4 123.1 114.2 81.4 430.1
Lean Body Mass 7.16 Standardized to Body Weight 138.0 152.4 141.4 100.7 532.5
T41
T42
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Table B-22: Experiment 1: Week 13 Standard Diet Glucose Levels 
 
  
Exp. 1 Glucose Concentration






Week 13 226.5 0.213 8.86




230.61 0.217 Total Area
Before: 2.49 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.27 Glucose: 168.0 269.0 227.0 213.0 195.0
Injected: 0.23 Area Under Curve 109.1 124.7 109.3 104.2 447.2
Standardized to Glucose Injected 96.6 110.3 96.7 92.2 395.8
Standardized to G Concentration 94.9 108.4 95.0 90.5 388.7
Standardized to Amount Given 93.0 106.3 93.1 88.8 381.3
Lean Body Mass 9.67 Standardized to Body Weight 85.2 97.4 85.4 81.4 349.3
Before: 2.48 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.26 Glucose: 185.0 342.0 398.0 282.0 207.0
Injected: 0.23 Area Under Curve 131.7 186.3 168.7 122.4 609.1
Standardized to Glucose Injected 116.0 164.2 148.6 107.8 536.6
Standardized to G Concentration 113.9 161.2 146.0 105.9 527.1
Standardized to Amount Given 111.8 158.2 143.2 103.9 516.9
Lean Body Mass 11.96 Standardized to Body Weight 82.8 117.1 106.0 76.9 382.9
Before: 2.52 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.29 Glucose: 163.0 254.0 203.0 192.0 181.0
Injected: 0.23 Area Under Curve 104.3 114.3 98.7 93.2 410.4
Standardized to Glucose Injected 91.0 99.8 86.2 81.4 358.4
Standardized to G Concentration 89.4 98.0 84.7 79.9 352.0
Standardized to Amount Given 87.7 96.1 83.0 78.4 345.3
Lean Body Mass 9.48 Standardized to Body Weight 82.0 89.9 77.6 73.3 322.8
Before: 2.52 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.30 Glucose: 184.0 244.0 237.0 215.0 175.0
Injected: 0.22 Area Under Curve 107.0 120.7 112.6 97.4 437.7
Standardized to Glucose Injected 95.5 107.8 100.5 87.0 390.8
Standardized to G Concentration 93.8 105.9 98.7 85.5 383.9
Standardized to Amount Given 92.0 103.8 96.8 83.8 376.5
Lean Body Mass 7.90 Standardized to Body Weight 103.2 116.4 108.6 94.0 422.2
Before: 2.49 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.27 Glucose: 178.0 280.0 268.0 243.0 241.0
Injected: 0.22 Area Under Curve 115.3 137.1 126.8 123.1 502.2
Standardized to Glucose Injected 102.9 122.4 113.2 109.9 448.4
Standardized to G Concentration 101.1 120.2 111.2 107.9 440.4
Standardized to Amount Given 99.1 117.9 109.0 105.9 431.9
Lean Body Mass 7.82 Standardized to Body Weight 112.3 133.6 123.5 120.0 489.4
Before: 2.47 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.27 Glucose: 175.6 277.8 266.6 229.0 199.8
Injected: 0.21 Area Under Curve 113.4 136.6 123.2 108.0 481.3
Standardized to Glucose Injected 110.1 132.6 119.6 104.9 467.3
Standardized to G Concentration 108.1 130.3 117.5 103.0 458.9
Standardized to Amount Given 106.1 127.8 115.2 101.0 450.1
Lean Body Mass 9.37 Standardized to Body Weight 100.3 120.9 109.0 95.6 425.8
Standard
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Table B-23: Experiment 1: Week 13 DIO Glucose Levels 
 
  
Exp. 1 Glucose Concentration






Week 13 226.5 0.213 8.86




230.61 0.217 Total Area
Before: 2.48 Decimal Time: 0.1 0.6 1.1 1.6 2.1
After: 2.27 Glucose: 161.0 231.0 210.0 213.0 173.0
Injected: 0.21 Area Under Curve 97.6 110.4 106.1 97.0 411.1
Standardized to Glucose Injected 94.3 106.7 102.5 93.7 397.2
Standardized to G Concentration 92.6 104.8 100.7 92.0 390.1
Standardized to Amount Given 90.8 102.8 98.8 90.3 382.6
Lean Body Mass 8.908 Standardized to Body Weight 90.3 102.2 98.2 89.8 380.6
Before: 2.46 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.25 Glucose: 181.0 371.0 302.0 231.0 186.0
Injected: 0.21 Area Under Curve 137.8 167.7 134.8 105.3 545.6
Standardized to Glucose Injected 130.7 158.9 127.8 99.8 517.2
Standardized to G Concentration 128.3 156.1 125.5 98.0 508.0
Standardized to Amount Given 125.9 153.1 123.1 96.1 498.2
Lean Body Mass 8.498 Standardized to Body Weight 131.2 159.6 128.3 100.2 519.4
Before: 2.47 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.26 Glucose: 132.0 184.0 164.0 161.0 137.0
Injected: 0.21 Area Under Curve 79.1 87.1 81.3 74.6 322.1
Standardized to Glucose Injected 75.7 83.3 77.8 71.4 308.2
Standardized to G Concentration 74.3 81.9 76.4 70.1 302.7
Standardized to Amount Given 72.9 80.3 74.9 68.8 296.9
Lean Body Mass 6.547 Standardized to Body Weight 98.7 108.7 101.4 93.0 401.8
Before: 2.50 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.29 Glucose: 215.0 285.0 214.0 203.0 172.0
Injected: 0.21 Area Under Curve 124.9 126.4 102.7 97.4 451.5
Standardized to Glucose Injected 119.0 120.4 97.9 92.8 430.0
Standardized to G Concentration 116.9 118.2 96.1 91.2 422.4
Standardized to Amount Given 114.6 116.0 94.3 89.4 414.3
Lean Body Mass 12.049 Standardized to Body Weight 84.3 85.3 69.3 65.7 304.6
Before: 2.47 Decimal Time: 0.2 0.7 1.2 1.7 2.3
After: 2.27 Glucose: 162.0 274.0 219.0 189.0 154.0
Injected: 0.20 Area Under Curve 110.4 124.1 100.0 88.6 423.1
Standardized to Glucose Injected 108.8 122.3 98.5 87.3 416.8
Standardized to G Concentration 106.8 120.1 96.7 85.7 409.4
Standardized to Amount Given 104.8 117.8 94.9 84.1 401.6
Lean Body Mass 7.624 Standardized to Body Weight 121.8 136.9 110.3 97.7 466.7
Before: 2.48 Decimal Time: 0.2 0.7 1.2 1.7 2.2
After: 2.27 Glucose: 170.2 269.0 221.8 199.4 164.4
Injected: 0.21 Area Under Curve 110.0 123.2 104.9 92.6 430.6
Standardized to Glucose Injected 105.8 118.4 100.9 89.0 414.1
Standardized to G Concentration 103.9 116.3 99.1 87.4 406.7
Standardized to Amount Given 101.9 114.1 97.2 85.7 398.9
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Table B-24: Experiment 1: Glucose Levels Welch’s 2-Tailed T-test 
(Comparisons of 0.05 significance marked in green) 
 
Exp. 1 Glucose Tolerance T Test
Significance of 0.05 Highlighted in Green
521.80 638.20
454.69 582.93 583.37 601.42
551.86 640.97 513.41 581.90
485.57 466.89 471.31 608.67
395.46 516.60 507.48 586.37
466.07 526.56 430.45 602.46
Sample Size 6.00 6.00 Sample Size 5.00 5.00
Mean 470.73 546.79 Mean 501.20 596.16
StDev 56.45 66.86 StDev 56.65 11.43
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
429.52 443.39 447.24 411.08
529.87 474.11 609.08 545.63
489.53 475.03 410.39 322.06
445.17 632.25 437.72 451.54
385.62 502.18 423.10
Sample Size 4.00 5.00 Sample Size 5.00 5.00
Mean 473.52 482.08 Mean 481.32 430.68
StDev 45.36 91.47 StDev 78.82 80.45
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
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Appendix C - Experiment 2 Data Tables 
Table C-1: Experiment 2: Mouse Key 
 
  










C1 x x x
C2 x x x
C3 x x x
C4 x x x
C5 x x x
C7 x x x x
C8 x x x x
C9 x x x x
C10 x x x x
C11 x x x x
C12 x x x x
C13 x
C14 x x x x
C15 x x x x
C16 x x x x
C17 x
C18 x
T19 x x x
T20 x x x
T21 x x x
T22 x x x
T23 x x x
T24 x x x x
T25 x x x x
T26 x x x x
T27 x x x x
T28 x x x x
T29 x x x x
T30 x x x x
T31 x x x x
T32 x x x x x
T33 x x x x
T34 x x x x
T35 x x x x
T36 x x x x x
T37 x x x x
T38 x x x x
T39 x x x x
T40 x x x x
T41 x x x x
Week DissectedFood Intake Injected (Week 10)Diet
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Appendix C.1: Experiment 2 Body Weight Tables 
Table C-2: Experiment 2: Weekly Body Weight (g) 
 
  
3/2/12 3/9/12 3/16/12 3/23/12 3/30/12 4/6/12 4/13/12 4/20/12 4/27/12 5/4/12 5/11/12






C1 19.6 21.2 22.5 23.5 24.4 24.7 24.9 25.6 26.1
C2 23.2 24.8 26.1 26.9 27.9 29.7 31.9 32.1 32.2
C3 22.5 24.1 25.3 26.6 26.2 26.8 28.0 28.3 31.3
C4 23.5 24.6 24.5 25.0 25.1 26.5 26.9 27.2 27.4
C5 21.7 22.6 23.5 24.8 24.6 25.3 25.6 26.2 26.8
C7 22.3 23.7 26.1 26.0 26.3 26.2 27.6 27.0 28.8 28.9 28.5
C8 24.0 25.0 26.1 26.3 26.6 28.2 27.2 27.5 28.7 29.2 28.7
C9 22.7 23.5 24.4 25.6 25.5 25.9 26.3 27.9 27.1 20.7 27.7
C10 19.6 20.8 20.7 21.4 22.8 22.7 23.4 24.9 25.5 25.3 23.9
C11 22.7 23.2 24.9 27.6 27.9 30.7 31.0 32.0 32.9 32.9 33.9
C12 20.6 21.8 21.3 22.6 22.9 23.6 24.2 25.5 26.0 24.9 27.6
C13 21.5 23.8 24.6
C14 22.1 23.9 23.7 24.7 25.0 25.8 25.9 27.1 27.3 20.5 24.7
C15 22.3 22.4 23.3 24.0 25.1 26.4 26.8 27.1 28.3 28.4 27.5
C16 20.9 22.3 22.1 23.6 24.0 24.7 24.8 26.8 26.8 27.4 27.6
C17 21.6 21.4 14.9
C18 20.6 21.4 21.8 23.0 23.1 22.9 23.8 25.5 26.2
T19 21.6 18.8 22.8 25.4 24.4 29.1 31.2 33.5 36.2
T20 21.0 24.6 26.9 27.4 32.1 35.6 39.0 41.5 43.4
T21 21.7 26.4 28.6 32.1 36.9 41.2 43.9 45.8 47.5
T22 22.9 25.5 27.8 29.9 34.2 36.7 39.2 40.7 32.1
T23 20.7 23.4 25.1 25.8 28.6 29.5 31.8 33.6 35.2
T24 19.7 23.3 25.1 26.0 30.4 33.0 34.9 37.8 40.0 41.5 40.8
T25 22.2 24.6 27.4 28.1 33.8 37.6 40.0 42.6 44.7 45.8 43.6
T26 21.2 24.5 27.9 30.2 34.3 36.9 40.4 42.8 46.2 38.8 42.8
T27 21.2 23.7 18.5 24.2 28.8 31.4 33.8 35.3 38.4 38.9 38.9
T28 16.6 23.2 25.8 26.3 30.1 32.8 34.8 37.2 40.0 31.0 36.7
T29 20.2 15.5 23.7 26.3 30.9 34.8 38.0 40.6 42.6 42.9 42.9
T30 22.1 23.2 25.4 26.4 29.7 32.4 34.3 35.0 36.5 34.5 34.8
T31 21.5 25.8 26.5 30.3 34.0 36.6 38.2 40.8 43.3 41.2 35.0
T32 22.0 24.9 26.8 28.7 32.5 35.8 37.4 40.6 38.0
T33 19.8 23.9 26.1 28.7 33.3 25.1 34.2 37.4 29.0 35.8 38.4
T34 18.9 22.2 24.6 25.8 19.5 30.3 34.1 36.9 39.6 37.3 37.0
T35 20.8 25.7 28.3 30.4 35.1 38.1 40.0 42.2 44.9 42.3 40.5
T36 21.7 20.6 21.6 22.2 24.8 26.5 18.8 25.7
T37 15.5 22.5 25.0 27.0 29.4 32.3 34.6 36.9 39.2 37.6 37.9
T38 21.8 24.4 26.4 28.9 32.5 34.8 37.4 40.1 41.9 39.5 39.5
T39 21.5 23.6 27.2 29.3 32.8 36.8 38.6 41.7 44.6 43.5 43.2
T40 21.0 23.4 24.5 26.3 29.4 32.3 34.9 37.7 40.2 38.9 39.3
T41 21.0 24.2 25.4 27.5 30.9 32.8 36.1 38.0 41.3 35.4 35.0










Week 8 DIO Ad 
Lib
Week 10 DIO 
Ad Lib Saline
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Table C-3: Experiment 2: Body Weight (g) Welch’s 2-Tailed T-test 




Exp 2. Body Weight (g) T Test
Significance of 0.05 Highlighted in Green
40.76 34.79
 28.45 27.60  43.59 35.00
28.66 24.70 42.77 38.35
27.74 27.54 38.92 36.95
23.90 27.64 36.74 40.54
33.85 42.92
Sample Size 5.00 4.00 Sample Size 6.00 5.00
Mean 28.52 26.87 Mean 40.95 37.13
StDev 3.55 1.45 StDev 2.68 2.41
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
28.45 40.76
 28.66 43.59  27.60 34.79
27.74 42.77 24.70 35.00
26.09 36.18 23.90 38.92 27.54 38.35
 32.20 43.41 33.85 36.74 27.64 36.95
31.33 47.54 42.92 40.54
27.40 32.10 Sample Size 5.00 6.00 Sample Size 4.00 5.00
26.82 35.20 Mean 28.52 40.95 Mean 26.87 37.13
28.75 40.00 StDev 3.55 2.68 StDev 1.45 2.41
28.73 44.67 Sx Sx
27.07 46.15 Deg. Of Freedom Deg. Of Freedom
25.53 38.40 t value t value







39.20  43.59 39.50  34.79 37.85
41.87 42.77 43.19 35.00 39.50
44.62 38.92 39.33 38.35 43.19
40.22 36.74 35.00 36.95 39.33
41.28 42.92 40.54 35.00
Sample Size 14.00 21.00 Sample Size 6.00 5.00 Sample Size 5.00 5.00
Mean 28.23 40.32 Mean 40.95 38.97 Mean 37.13 38.97
StDev 2.35 4.64 StDev 2.68 2.97 StDev 2.41 2.97
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value
P(Means are equal) P(Means are equal) P(Means are equal)






Week 10 DIO 
Ad Lib Saline
















Week 10 DIO 
Ad Lib Saline
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Appendix C.2: Experiment 2 Food and Energy Tables 
Table C-4: Experiment 2: Standard Diet Food Given and Leftover (g) 
 
  
3/9/12 3/16/12 3/23/12 3/30/12 4/6/12 4/13/12 4/20/12 4/27/12 5/4/12 5/11/12
week 1 week 2 week 3 week 4 week 5 week 6 week 7 week 8 week 9 week 10
given 30.0 30.9 29.6 36.0 32.3 34.4 32.6 30.1
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 5.2 6.1 6.1 11.9 10.0 11.7 9.4 7.9
given 30.1 30.8 30.4 34.8 33.5 35.3 32.3 32.5
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 4.7 4.7 6.0 9.3 6.9 7.4 6.7 7.9
given 30.0 30.2 29.9 34.6 33.9 35.2 30.2 32.6
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 4.9 6.5 7.0 12.4 10.9 11.9 6.9 7.3
given 29.9 29.8 30.4 34.9 34.8 35.1 31.1 29.8
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 6.8 6.8 10.0 12.9 11.7 11.5 9.0 7.2
given 30.2 31.2 30.5 35.3 32.5 34.1 31.7 31.8
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 8.5 8.2 7.8 12.8 10.5 11.9 8.8 8.5
given 29.9 30.1 31.5 35.6 33.9 34.6 30.2 29.6 30.2 30.7
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 8.2 5.1 8.9 12.1 11.0 10.7 5.7 2.5 6.6 8.7
given 30.1 31.8 31.4 35.4 35.4 35.8 29.4 32.7 30.1 31.6
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 5.8 6.6 7.9 12.8 11.5 14.9 5.6 7.9 7.7 8.6
given 30.2 30.5 29.2 35.4 35.6 35.3 31.1 29.6 29.7 29.3
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.5
left 5.8 5.7 5.8 13.1 13.3 11.7 5.9 7.3 15.0 11.7
given 30.0 30.5 30.7 35.2 35.1 35.1 32.0 32.1 30.6 31.8
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 9.5 13.0 12.1 13.7 15.3 15.7 9.6 9.8 10.3 14.1
given 29.7 30.7 30.7 35.4 34.4 35.9 30.7 30.4 29.7 31.3
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 7.1 6.0 6.5 10.0 7.2 12.1 3.6 5.4 3.9 5.8
given 29.7 30.6 30.2 35.6 36.0 35.5 30.9 29.1 31.5 30.7
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 12.2 8.8 9.6 15.1 14.7 13.8 9.4 7.7 12.4 10.3
given 29.6 30.0 31.0
added 0.0 0.0 0.0
left 4.9 5.7
given 30.9 31.3 31.7 35.5 35.0 35.9 29.8 32.2 29.8 29.9
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.6
left 7.2 8.8 9.8 13.0 13.4 13.5 6.2 8.4 17.2 12.2
given 29.5 30.8 31.2 35.1 35.4 34.5 31.4 32.3 30.6 30.4
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 4.5 3.2 6.0 8.4 9.4 8.6 6.0 5.6 7.2 6.7
given 30.1 30.6 31.6 34.7 34.8 34.5 32.0 31.1 30.8 30.2
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 7.7 10.0 10.6 13.0 13.0 13.2 9.6 9.3 10.0 8.4
given 30.1 31.3 30.0
added 0.0 0.0 0.0
left 9.6 18.4
given 30.1 29.8 31.6 35.3 33.1 35.7 31.7 31.0 30.9
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
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Table C-5: Experiment 2: DIO Food Given and Leftover (g) 
 
  
3/9/12 3/16/12 3/23/12 3/30/12 4/6/12 4/13/12 4/20/12 4/27/12 5/4/12 5/11/12
week 1 week 2 week 3 week 4 week 5 week 6 week 7 week 8 week 9 week 10
given 24.1 30.4 24.4 34.9 33.4 35.3 35.9 36.2
added 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 12.0 8.7 5.4 14.8 13.7 15.6 13.8 15.2
given 23.8 31.4 25.2 35.6 34.7 34.6 35.3 35.0
added 6.2 0.0 0.0 0.0 42.2 0.0 0.0 0.0
left 8.5 10.9 5.1 1.9 28.8 10.0 11.4 12.2
given 22.8 30.3 25.3 35.9 34.4 34.8 35.5 36.7
added 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 8.1 11.2 4.6 13.5 12.4 14.0 15.5 17.8
given 23.8 30.9 25.8 34.9 35.1 35.2 33.7 36.7
added 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 10.3 10.5 5.3 12.2 14.7 14.7 14.2 29.0
given 23.3 30.8 25.8 35.9 34.9 35.5 35.0 34.9
added 6.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 11.4 12.7 8.0 15.3 16.5 16.7 15.9 16.4
given 24.4 29.5 25.4 35.9 36.9 35.5 36.1 35.7 35.6 34.9
added 6.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 11.1 11.0 7.0 11.9 14.0 12.9 12.3 11.3 10.2 15.3
given 23.0 29.8 25.3 35.3 35.2 35.6 35.4 37.0 35.1 36.3
added 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.6 0.0
left 8.8 9.1 8.6 6.8 3.9 4.8 3.7 5.6 10.2 19.7
given 23.0 29.9 25.1 35.5 33.7 35.0 34.8 36.0 35.2 34.6
added 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 10.1 8.9 5.7 12.7 13.5 14.5 14.3 14.9 22.2 12.8
given 23.6 31.8 25.9 36.0 36.3 35.3 34.7 35.5 35.0 35.0
added 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 9.9 16.8 5.4 13.1 14.1 14.0 14.0 13.1 14.5 16.6
given 22.9 29.9 25.8 35.1 35.2 35.3 34.8 36.7 34.8 34.7
added 5.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 7.9 11.0 7.5 13.1 14.6 14.9 14.2 15.2 25.3 12.1
given 23.4 30.6 25.4 34.9 34.3 36.2 34.7 36.8 35.6 36.2
added 0.0 0.0 0.0 0.0 14.8 0.0 0.0 0.0 0.0 0.0
left 11.1 9.5 6.4 6.5 12.6 8.2 10.1 13.1 14.3 19.0
given 23.1 29.8 26.0 35.4 34.2 35.7 35.7 35.4 35.7 34.8
added 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 12.6 11.7 8.7 15.2 13.8 16.2 18.6 18.1 23.0 20.2
given 23.3 30.7 25.7 35.0 35.1 34.7 35.1 34.5 35.9 34.8
added 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 8.4 12.7 4.2 13.4 14.4 15.5 15.0 14.9 22.2 28.1
given 22.6 30.8 24.9 35.5 36.0 35.1 35.7 36.0 34.3
added 5.9 0.0 0.0 23.4 44.2 9.9 0.0 0.0 0.0
left 10.2 12.4 6.8 5.7 6.8 14.8 14.3 17.8
given 23.5 30.4 25.5 35.7 34.6 34.5 35.0 34.8 34.8 36.0
added 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 12.1 11.8 5.9 12.1 25.1 8.9 11.8 25.4 12.2 14.4
given 23.9 29.7 25.0 35.5 35.6 35.5 35.6 34.8 35.5 36.1
added 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 11.0 10.5 6.6 22.0 8.3 11.7 12.6 13.4 20.2 19.6
given 23.6 29.3 25.6 35.6 35.0 35.8 35.3 35.6 35.0 35.8
added 7.0 0.0 0.0 23.5 15.4 0.0 0.0 0.0 0.0 0.0
left 9.1 8.5 5.1 4.2 9.3 12.2 11.5 16.9 20.8 20.6
given 23.7 29.5 25.8 35.0 36.0 35.7 35.2 35.3
added 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 14.0 13.9 11.6 17.2 18.3 28.8 14.0
given 24.5 31.8 25.0 36.1 36.7 34.7 35.1 36.4 29.8 29.9
added 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 11.0 12.1 5.3 14.9 14.2 11.1 12.1 14.0 5.8 1.0
given 23.5 29.4 25.1 35.5 35.9 35.9 36.6 37.0 28.8 28.9
added 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 10.2 10.2 4.2 11.9 14.5 14.1 14.2 15.4 9.0 2.2
given 22.9 29.7 25.6 35.8 36.9 34.1 35.6 35.9 31.0 30.8
added 7.1 0.0 0.0 22.1 20.8 9.0 0.0 0.0 0.0 0.0
left 9.2 9.0 5.4 5.9 7.1 10.1 7.2 12.2 5.3 1.9
given 24.2 29.7 25.1 35.5 34.9 34.6 35.7 35.8 28.4 28.1
added 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 11.2 11.8 6.4 14.0 14.0 14.0 14.4 14.7 5.4 2.8
given 24.1 29.9 26.0 34.9 35.5 35.5 35.8 36.0 29.2 28.9
added 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
left 10.7 12.4 7.2 14.5 15.2 14.4 14.7 14.1 12.2 3.6
Week 10 DIO 
Ad Lib AICAR
Week 10 DIO 
Food Restrict 
Saline
Exp. 2 High Fat Diet (DIO) Given and Leftover (grams)
T41
Week 8 DIO Ad 
Lib
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3/9/12 3/16/12 3/23/12 3/30/12 4/6/12 4/13/12 4/20/12 4/27/12 5/4/12 5/11/12
1 2 3 4 5 6 7 8 9 10
C1 24.80 24.80 23.44 24.15 22.30 22.66 23.26 22.20
C2 25.40 26.10 24.36 25.53 26.51 27.88 25.58 24.64
C3 25.10 23.70 22.83 22.29 22.99 23.31 23.37 25.33
C4 23.10 23.00 20.42 22.03 23.12 23.61 22.10 22.62
C5 21.70 23.00 22.75 22.44 22.02 22.29 22.91 23.33
C7 21.70 25.00 22.59 23.51 22.86 23.93 24.46 27.13 23.57 21.99
C8 24.30 25.20 23.53 22.65 23.85 20.86 23.77 24.73 22.44 23.03
C9 24.40 24.80 23.45 22.25 22.27 23.62 25.14 22.31 14.75 29.08
C10 20.50 17.50 18.56 21.56 19.83 19.40 22.44 22.27 20.35 17.63
C11 22.60 24.70 24.25 25.38 27.20 23.74 27.10 25.01 25.84 25.48
C12 17.50 21.80 20.54 20.46 21.29 21.70 21.48 21.43 19.15 20.41
C14 23.70 22.50 21.89 22.52 21.61 22.35 23.59 23.80 12.63 29.27
C15 25.00 27.60 25.29 26.68 25.93 25.92 25.40 26.76 23.38 23.70
C16 22.40 20.60 20.96 21.74 21.78 21.26 22.37 21.84 20.85 21.80
T19 12.10 21.70 19.02 20.08 19.68 19.70 22.06 21.04
T20 21.50 20.50 20.10 33.73 48.09 24.63 23.84 22.81
T21 21.20 19.10 20.66 22.41 22.01 20.81 19.94 18.98
T22 20.30 20.40 20.47 22.68 20.35 20.42 19.59 7.71
T23 18.60 18.10 17.76 20.51 18.34 18.84 19.13 18.54
T24 20.00 18.50 18.45 24.01 22.97 22.59 23.80 24.34 25.33 19.64
T25 20.00 20.70 16.71 28.44 31.26 30.75 31.75 31.44 40.55 16.56
T26 19.00 21.00 19.38 22.74 20.22 20.52 20.45 21.07 12.96 21.78
T27 19.90 15.00 20.48 22.83 22.19 21.32 20.69 22.40 20.48 18.44
T28 20.70 18.90 18.28 21.98 20.63 20.43 20.59 21.49 9.45 22.64
T29 12.30 21.11 19.06 28.47 36.54 27.96 24.60 23.73 21.28 17.15
T30 16.70 18.11 17.28 20.18 20.43 19.48 17.09 17.33 12.77 14.67
T31 21.20 18.01 21.49 21.62 20.74 19.15 20.14 19.63 13.64 6.77
T33 18.20 18.60 19.62 23.60 9.54 25.62 23.21 9.38 22.60 21.53
T34 19.80 19.20 18.47 13.42 27.29 23.83 23.00 21.38 15.34 16.49
T35 21.50 20.80 20.54 54.96 41.03 23.57 23.80 18.67 14.19 15.22
T37 20.60 19.70 19.77 21.19 22.53 23.63 23.06 22.34 24.01 28.95
T38 19.70 19.20 20.96 23.57 21.37 21.79 22.31 21.54 19.82 26.75
T39 20.80 20.70 20.18 51.95 50.68 33.06 28.41 23.69 25.72 28.94
T40 18.90 17.90 18.70 21.55 20.89 20.54 21.34 21.12 22.99 25.30












Week 8 DIO Ad 
Lib
Week 10 DIO 
Ad Lib Saline
Week 10 DIO 
Ad Lib AICAR
Week 10 DIO 
Food Restrict 
Saline
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3/9/12 3/16/12 3/23/12 3/30/12 4/6/12 4/13/12 4/20/12 4/27/12 5/4/12 5/11/12
week 1 week 2 week 3 week 4 week 5 week 6 week 7 week 8 week 9 week 10
C1 76.88 76.88 72.66 74.87 69.13 70.25 72.11 68.82
C2 78.74 80.91 75.52 79.14 82.18 86.43 79.30 76.38
C3 77.81 73.47 70.77 69.10 71.27 72.26 72.45 78.52
C4 71.61 71.30 63.30 68.29 71.67 73.19 68.51 70.12
C5 67.27 71.30 70.53 69.56 68.26 69.10 71.02 72.32
C7 67.27 77.50 70.03 72.88 70.87 74.18 75.83 84.10 73.07 68.17
C8 75.33 78.12 72.94 70.22 73.94 64.67 73.69 76.66 69.56 71.39
C9 75.64 76.88 72.70 68.98 69.04 73.22 77.93 69.16 45.73 90.15
C10 63.55 54.25 57.54 66.84 61.47 60.14 69.56 69.04 63.09 54.65
C11 70.06 76.57 75.18 78.68 84.32 73.59 84.01 77.53 80.10 78.99
C12 54.25 67.58 63.67 63.43 66.00 67.27 66.59 66.43 59.37 63.27
C14 73.47 69.75 67.86 69.81 66.99 69.29 73.13 73.78 39.15 90.74
C15 77.50 85.56 78.40 82.71 80.38 80.35 78.74 82.96 72.48 73.47
C16 69.44 63.86 64.98 67.39 67.52 65.91 69.35 67.70 64.64 67.58
T19 61.71 110.67 97.00 102.41 100.37 100.47 112.51 107.30
T20 109.65 104.55 102.51 172.02 245.26 125.61 121.58 116.33
T21 108.12 97.41 105.37 114.29 112.25 106.13 101.69 96.80
T22 103.53 104.04 104.40 115.67 103.79 104.14 99.91 39.32
T23 94.86 92.31 90.58 104.60 93.53 96.08 97.56 94.55
T24 102.00 94.35 94.10 122.45 117.15 115.21 121.38 124.13 129.18 100.16
T25 102.00 105.57 85.22 145.04 159.43 156.83 161.93 160.34 206.81 84.46
T26 96.90 107.10 98.84 115.97 103.12 104.65 104.30 107.46 66.10 111.08
T27 101.49 76.50 104.45 116.43 113.17 108.73 105.52 114.24 104.45 94.04
T28 105.57 96.39 93.23 112.10 105.21 104.19 105.01 109.60 48.20 115.46
T29 62.73 107.66 97.21 145.20 186.35 142.60 125.46 121.02 108.53 87.47
T30 85.17 92.36 88.13 102.92 104.19 99.35 87.16 88.38 65.13 74.82
T31 108.12 91.85 109.60 110.26 105.77 97.67 102.71 100.11 69.56 34.53
T33 92.82 94.86 100.06 120.36 48.65 130.66 118.37 47.84 115.26 109.80
T34 100.98 97.92 94.20 68.44 139.18 121.53 117.30 109.04 78.23 84.10
T35 109.65 106.08 104.75 280.30 209.25 120.21 121.38 95.22 72.37 77.62
T37 105.06 100.47 100.83 108.07 114.90 120.51 117.61 113.93 74.44 89.75
T38 100.47 97.92 106.90 120.21 108.99 111.13 113.78 109.85 61.44 82.93
T39 106.08 105.57 102.92 264.95 258.47 168.61 144.89 120.82 79.73 89.71
T40 96.39 91.29 95.37 109.91 106.54 104.75 108.83 107.71 71.27 78.43












Week 8 DIO Ad 
Lib
Week 10 DIO 
Ad Lib Saline
Week 10 DIO 
Ad Lib AICAR
Week 10 DIO 
Food Restrict 
Saline
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Table C-9: Experiment 2: Food Consumed (g) Welch’s 2-Tailed T-test 




Exp 2. Food Consumed (g) T Test
Significance of 0.05 Highlighted in Green
19.64 14.67
 21.99 20.41  16.56 6.77
23.03 29.27 21.78 21.53
29.08 23.70 18.44 16.49
17.63 21.80 22.64 15.22
25.48 17.15
Sample Size 5.00 4.00 Sample Size 6.00 5.00
Mean 23.44 23.80 Mean 19.37 14.94
StDev 4.24 3.89 StDev 2.46 5.31
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
21.99 19.64
 23.03 16.56  20.41 14.67
29.08 21.78 29.27 6.77
22.20 21.04 17.63 18.44 23.70 21.53
 24.64 22.81 25.48 22.64 21.80 16.49
25.33 18.98 17.15 15.22
22.62 7.71 Sample Size 5.00 6.00 Sample Size 4.00 5.00
23.33 18.54 Mean 23.44 19.37 Mean 23.80 14.94
27.13 24.34 StDev 4.24 2.46 StDev 3.89 5.31
24.73 31.44 Sx Sx
22.31 21.07 Deg. Of Freedom Deg. Of Freedom
22.27 22.40 t value t value







22.34  16.56 26.75  14.67 28.95
21.54 21.78 28.94 6.77 26.75
23.69 18.44 25.30 21.53 28.94
21.12 22.64 25.31 16.49 25.30
21.88 17.15 15.22 25.31
Sample Size 14.00 21.00 Sample Size 6.00 5.00 Sample Size 5.00 5.00
Mean 23.81 20.50 Mean 19.37 27.05 Mean 14.94 27.05
StDev 1.83 4.90 StDev 2.46 1.83 StDev 5.31 1.83
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value








Week 10 DIO 
Ad Lib AICAR
Week 10 DIO 
Food Restrict






























Week 10 DIO 
Ad Lib Saline
Week 10 DIO 
Ad Lib AICAR
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Table C-10: Experiment 2: Energy Intake (kcal) Welch’s 2-Tailed T-test 
(Comparisons of 0.05 significance marked in green) 
 
  
Exp 2. Energy Consumed (kcal) T Test
Significance of 0.05 Highlighted in Green
100.16 74.82
 68.17 63.27  84.46 34.53
71.39 90.74 111.08 109.80
90.15 73.47 94.04 84.10
54.65 67.58 115.46 77.62
78.99 87.47
Sample Size 5.00 4.00 Sample Size 6.00 5.00
Mean 72.67 73.76 Mean 98.78 76.17
StDev 13.15 12.06 StDev 12.55 27.07
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
68.17 100.16
 71.39 84.46  63.27 74.82
90.15 111.08 90.74 34.53
68.82 107.30 54.65 94.04 73.47 109.80
 76.38 116.33 78.99 115.46 67.58 84.10
78.52 96.80 87.47 77.62
70.12 39.32 Sample Size 5.00 6.00 Sample Size 4.00 5.00
72.32 94.55 Mean 72.67 98.78 Mean 73.76 76.17
84.10 124.13 StDev 13.15 12.55 StDev 12.06 27.07
76.66 160.34 Sx Sx
69.16 107.46 Deg. Of Freedom Deg. Of Freedom
69.04 114.24 t value t value







113.93  84.46 82.93  74.82 89.75
109.85 111.08 89.71 34.53 82.93
120.82 94.04 78.43 109.80 89.71
107.71 115.46 78.46 84.10 78.43
111.59 87.47 77.62 78.46
Sample Size 14.00 21.00 Sample Size 6.00 5.00 Sample Size 5.00 5.00
Mean 73.82 104.55 Mean 98.78 83.86 Mean 76.17 83.86
StDev 5.67 25.00 StDev 12.55 5.67 StDev 27.07 5.67
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value





Week 10 DIO 
Ad Lib AICAR
Week 10 DIO 
Food Restrict
5.66 5.71 12.37









Week 10 DIO 
Ad Lib Saline
























Week 10 DIO 
Ad Lib Saline
Week 10 DIO 
Food Restrict
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Appendix C.3: Experiment 2 Body Composition Tables 
Table C-11: Experiment 2: Dissected Tissue Weights (g) 
 
  
Exp. 2 Dissected Tissue Weights
Fat (g) Liver (g) Carcass (g)
B1 0.57 1.50 13.96
B2 0.61 1.29 13.88
B3 0.68 1.05 12.97
B4 0.62 1.51 13.86
B5 0.59 1.34 13.54
C1 0.85 1.09 16.18
C2 1.56 1.22 21.13
C3 1.50 1.46 19.14
C4 1.05 1.11 17.25
C5 1.07 1.04 16.19
C7 1.29 1.19 17.90
C8 1.20 1.22 18.29
C9 1.00 1.30 16.89
C10 1.04 0.99 14.40
C11 1.87 1.58 20.90
C12 0.72 1.12 15.75
C14 0.87 1.32 17.11
C15 0.81 0.91 17.46
C16 1.29 1.26 17.30
T19 2.26 1.27 22.25
T20 4.29 1.19 27.98
T21 4.62 1.97 31.05
T22 2.44 1.00 22.03
T23 2.56 1.18 23.15
T24 3.22 1.03 25.16
T25 3.41 1.49 28.69
T26 3.93 1.43 27.55
T27 3.18 1.22 25.48
T28 2.49 1.36 23.15
T29 3.85 1.31 27.79
T30 2.53 1.28 21.17
T31 3.16 1.11 22.46
T33 2.81 1.49 24.05
T34 2.58 1.30 23.52
T35 3.16 1.51 26.48
T37 2.61 1.13 23.45
T38 2.51 1.49 26.16
T39 3.03 1.39 27.34
T40 3.33 1.30 25.14
T41 3.07 1.31 22.12















Week 8 DIO 
Ad Lib
Week 10 DIO 
Ad Lib Saline
Week 10 DIO 
Ad Lib 
AICAR
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Table C-12: Experiment 2: Soxhlet Fat Extraction (g) 
 
  






Tube, Sample, & 
Gauze (g)
Extracted (g) Tube Tube Weight (g)
Tube & Sample 
(g)
Tube, Sample, & 
Gauze (g)
Extracted (g)
1 17.00 17.94 19.14 18.88 1 16.56 17.45 18.33 17.76
2 18.82 19.72 20.52 20.28 2 17.58 18.74 19.86 19.11
3 17.61 18.43 19.44 19.22 3 16.86 17.98 19.11 18.39
1 18.93 19.84 20.79 20.54 1 15.58 16.64 17.46 16.73
2 21.51 22.57 23.43 23.15 2 22.39 23.54 24.36 23.56
3 15.38 16.40 17.41 17.14 3 20.53 21.67 22.55 21.77
1 21.78 22.72 23.57 23.31 1 19.13 20.03 20.86 20.18
2 16.40 17.65 18.53 18.18 2 14.42 15.40 16.28 15.53
3 17.29 18.32 19.61 19.30 3 15.82 17.17 18.26 17.22
1 16.02 17.08 18.23 17.99 1 14.44 15.46 16.26 15.63
2 16.70 17.55 18.40 18.19 2 20.26 21.20 22.24 21.64
3 16.29 17.15 18.03 17.85 3 16.55 17.39 18.23 17.68
1 13.24 14.36 15.10 14.81 1 21.77 22.55 23.68 23.15
2 16.43 17.57 18.44 18.14 2 18.38 19.43 20.62 20.06
3 16.75 17.83 18.70 18.43 3 18.13 19.37 20.33 19.37
1 14.63 15.85 16.68 16.30 1 24.23 25.26 26.17 25.48
2 20.88 21.96 22.82 22.50 2 17.27 18.13 19.11 18.54
3 18.79 19.74 20.66 20.38 3 21.91 22.83 23.70 23.09
1 17.05 17.90 18.77 18.28 1 16.41 17.35 18.18 17.49
2 17.50 18.83 19.64 18.91 2 17.08 18.16 19.03 18.24
3 13.22 14.20 15.54 14.97 3 16.98 18.10 18.92 18.08
1 14.79 15.64 16.90 16.46 1 17.09 17.93 19.37 18.75
2 16.76 17.66 18.48 18.03 2 16.98 18.34 19.15 18.14
3 15.98 17.27 18.10 17.45 3 16.52 17.49 18.50 17.79
1 12.83 13.79 14.54 14.18 1 18.93 20.31 21.10 20.19
2 15.47 16.59 17.38 16.95 2 22.14 22.36 24.44 23.58
3 14.28 15.67 16.51 16.18 3 23.54 24.70 25.50 24.73
1 14.77 15.77 16.58 16.33 1 22.61 23.85 24.88 24.09
2 16.24 17.15 18.04 17.80 2 13.86 14.68 15.72 15.20
3 17.53 18.48 19.30 19.06 3 16.12 17.30 18.54 17.80
1 18.77 19.68 20.55 20.15 1 21.44 22.47 23.40 22.75
2 16.97 18.14 19.11 18.63 2 15.45 16.50 17.40 16.65
3 17.84 18.67 19.82 19.46 3 15.94 16.90 17.75 16.97
1 16.67 17.50 18.37 18.01 1 13.23 14.44 15.40 14.71
2 20.04 20.90 21.76 21.39 2 14.81 15.77 16.62 16.05
3 25.39 26.33 27.13 26.72 3 18.60 19.80 20.66 19.93
1 16.85 17.52 18.32 18.05 1 21.80 22.74 23.48 22.81
2 16.92 17.68 18.76 18.48 2 17.30 18.23 19.20 18.59
3 20.32 21.30 22.49 22.12 3 18.82 19.71 20.57 19.95
1 21.03 22.37 23.20 22.58 1 16.04 16.86 17.67 17.14
2 22.66 23.70 25.00 24.49 2 16.71 17.77 18.76 18.08
3 22.88 23.58 24.75 24.41 3 16.76 17.54 18.64 18.12
1 21.40 22.60 23.70 22.98 1 19.12 19.96 20.83 20.27
2 19.91 20.88 21.80 21.26 2 14.81 15.99 17.05 16.27
3 20.43 21.89 22.65 21.86 3 14.43 15.36 16.09 15.50
1 21.03 22.07 23.17 22.78 1 16.75 17.91 19.18 18.35
2 16.51 17.64 18.52 18.12 2 16.43 17.37 18.35 17.69
3 15.93 16.93 17.92 17.56 3 17.50 18.44 19.76 19.09
1 16.12 16.98 18.24 17.89 1 20.53 21.42 22.24 21.74
2 17.07 17.89 18.62 18.34 2 18.93 19.98 20.77 20.17
3 22.11 23.28 24.15 23.75 3 15.81 16.68 17.51 17.21
1 16.82 17.83 18.68 18.38 1 16.23 17.28 18.55 17.85
2 21.89 22.94 23.89 23.57 2 14.40 15.37 16.19 15.55
3 19.87 20.99 21.82 21.48 3 14.78 15.70 16.83 16.21
1 16.98 17.83 18.97 18.55 1 15.37 16.42 17.17 16.48
2 16.66 17.46 18.26 17.87 2 16.40 17.62 18.41 17.60
3 17.06 18.03 19.07 18.60 3 17.50 18.57 19.44 18.81
1 17.57 18.61 19.72 19.00
2 22.36 23.33 24.12 23.47
3 17.54 18.60 19.72 19.00
1 17.05 18.09 18.95 18.26
2 21.51 22.42 23.25 22.64
3 13.21 14.20 15.06 14.41
Week 10 DIO 
Ad Lib AICAR
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Table C-13: Experiment 2: Body Composition Mass (g) 
 
  







Dry Fat Body 
mass (g)       
(%Fat x Dry 
Powder Weight)
Dry Lean Body 
Mass (g)     




Wet Lean Body 
Mass (g)     









B1 27.1% 72.9% 4.95 1.339 3.611 13.89 10.13
B2 26.8% 73.2% 4.03 1.079 2.951 11.07 8.10
B3 26.8% 73.2% 4.66 1.248 3.412 12.63 9.25
B4 22.8% 77.2% 3.53 0.803 2.727 10.78 8.33
B5 25.7% 74.3% 5.08 1.307 3.773 14.20 10.55
C1 30.1% 69.9% 6.23 1.874 4.356 15.33 10.72
C2 56.9% 43.1% 10.88 6.191 4.689 22.08 9.52
C3 50.7% 49.3% 9.28 4.707 4.573 20.28 9.99
C4 33.2% 66.8% 7.07 2.348 4.722 17.67 11.80
C5 25.5% 74.5% 5.97 1.525 4.445 17.00 12.66
C7 42.7% 57.3% 7.65 3.270 4.380 18.35 10.51
C8 43.3% 56.7% 8.28 3.583 4.697 19.72 11.19
C9 38.2% 61.8% 7.15 2.734 4.416 18.08 11.17
C10 47.7% 52.3% 6.55 3.124 3.426 14.88 7.78
C11 56.6% 43.4% 10.19 5.767 4.423 21.78 9.45
C12 36.3% 63.7% 6.24 2.265 3.975 15.57 9.92
C14 36.3% 63.7% 6.85 2.490 4.360 17.58 11.19
C15 30.2% 69.8% 6.42 1.937 4.483 17.76 12.40
C16 48.9% 51.1% 7.94 3.880 4.060 17.98 9.19
T19 64.3% 35.7% 12.98 8.350 4.630 23.65 8.44
T20 69.0% 31.0% 17.88 12.329 5.551 31.42 9.76
T21 76.4% 23.6% 22.55 17.222 5.328 34.66 8.19
T22 63.7% 36.3% 12.4 7.898 4.502 23.01 8.35
T23 66.2% 33.8% 13.43 8.895 4.535 23.70 8.00
T24 66.8% 33.2% 15.1 10.093 5.007 27.48 9.11
T25 73.9% 26.1% 18.97 14.020 4.950 30.57 7.98
T26 73.8% 26.2% 18.94 13.972 4.968 30.55 8.01
T27 66.5% 33.5% 15.8 10.514 5.286 27.53 9.21
T28 63.5% 36.5% 13.08 8.306 4.774 24.85 9.07
T29 71.9% 28.1% 19.27 13.847 5.423 30.88 8.69
T30 59.0% 41.0% 11.46 6.762 4.698 23.28 9.54
T31 69.1% 30.9% 15.08 10.415 4.665 24.77 7.66
T33 65.0% 35.0% 14.07 9.147 4.923 25.78 9.02
T34 65.6% 34.4% 13.4 8.791 4.609 25.18 8.66
T35 71.2% 28.8% 16.75 11.926 4.824 28.66 8.25
T37 56.8% 43.2% 12.28 6.979 5.301 25.46 10.99
T38 66.5% 33.5% 15.41 10.250 5.160 28.16 9.43
T39 66.2% 33.8% 16.34 10.812 5.528 29.50 9.98
T40 68.0% 32.0% 15.52 10.556 4.964 27.34 8.74




















Week 8 DIO Ad 
Lib
Week 10 DIO 
Ad Lib Saline
Week 10 DIO 
Ad Lib AICAR
Week 10 DIO 
Food Restrict 
Saline
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Table C-15: Experiment 2: Fat Percentages Welch’s 2-Tailed T-test 
(Comparisons of 0.05 significance marked in green) 
 
  
Exp 2. Fat Percentages T Test
Significance of 0.05 Highlighted in Green
0.37 0.29
 0.18 0.15  0.46 0.42
0.18 0.14 0.46 0.35
0.15 0.11 0.38 0.35
0.21 0.22 0.33 0.42
0.26 0.45
Sample Size 5.00 4.00 Sample Size 6.00 5.00
Mean 0.20 0.15 Mean 0.41 0.37
StDev 0.04 0.04 StDev 0.05 0.05
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
0.18 0.37
 0.18 0.46  0.15 0.29
0.15 0.46 0.14 0.42
0.21 0.38 0.11 0.35
0.26 0.33 0.22 0.35
0.45 0.42
Sample Size 5.00 6.00 Sample Size 4.00 5.00
Mean 0.20 0.41 Mean 0.15 0.37
StDev 0.04 0.05 StDev 0.04 0.05
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
0.37 0.27
0.12 0.35  0.46 0.36  0.29 0.27
 0.28 0.39 0.46 0.37 0.42 0.36
0.23 0.50 0.38 0.39 0.35 0.37
0.13 0.34 0.33 0.38 0.35 0.39
0.09 0.38 0.45 0.42 0.38
Sample Size 5.00 5.00 Sample Size 6.00 5.00 Sample Size 5.00 5.00
Mean 0.17 0.39 Mean 0.41 0.35 Mean 0.37 0.35
StDev 0.08 0.06 StDev 0.05 0.05 StDev 0.05 0.05
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value
P(Means are equal) P(Means are equal) P(Means are equal)
Week 10 DIO 
Ad Lib AICAR
0.03
Week 10 DIO 
Ad Lib Saline





















Week 10 DIO 
Ad Lib AICAR












Week 10 DIO 
Ad Lib Saline
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Appendix C.4: Experiment 2 Glucose Clearance Tables 
Table C-16: Experiment 2: Week 8 Standard Diet Glucose Levels 
 
  
Exp. 2 Glucose Concentration
Week 8
Standard Diet Ad Lib Lean Body 
Mass (g)
Concentration (mg/1 gram 
solution)
Amount Given
10.94 220.63 0.214 Total Area
Before: 2.30 Decimal Time: 0.000 0.501 0.999 1.499 1.994
After: 2.48 Glucose: 162 289 281 222 181
Injected: 0.18 Area Under Curve 112.9 142.1 125.8 99.6 480.4
Standardized to Glucose Injected 125.4 157.9 139.8 110.6 533.7
Standardized to G Concentration 125.4 157.9 139.8 110.6 533.7
Standardized to Amount Given 125.4 157.9 139.8 110.6 533.7
Lean Body Mass 10.72 Standardized to Lean Body Mass 128.0 161.1 142.7 112.9 544.7
Before: 2.29 Decimal Time: 0.018 0.518 1.026 1.523 2.467
After: 2.50 Glucose: 197 356 338 349 250
Injected: 0.21 Area Under Curve 138.3 176.2 170.7 282.6 767.8
Standardized to Glucose Injected 131.7 167.8 162.6 269.2 731.2
Standardized to G Concentration 131.7 167.8 162.6 269.2 731.2
Standardized to Amount Given 131.7 167.8 162.6 269.2 731.2
Lean Body Mass 9.52 Standardized to LBM 151.3 192.9 186.8 309.3 840.4
Before: 2.30 Decimal Time: 0.041 0.545 1.129 1.549 2.042
After: 2.50 Glucose: 151 244 319 283 282
Injected: 0.20 Area Under Curve 99.5 164.4 126.6 139.2 529.7
Standardized to Glucose Injected 99.5 164.4 126.6 139.2 529.7
Standardized to G Concentration 99.5 164.4 126.6 139.2 529.7
Standardized to Amount Given 99.5 164.4 126.6 139.2 529.7
Lean Body Mass 9.99 Standardized to LBM 108.8 180.0 138.5 152.3 579.7
Before: 2.27 Decimal Time: 0.064 0.566 1.080 1.572 2.100
After: 2.50 Glucose: 160 278 263 194 164
Injected: 0.23 Area Under Curve 110.0 139.0 112.3 94.5 455.9
Standardized to Glucose Injected 95.6 120.9 97.7 82.2 396.4
Standardized to G Concentration 95.6 120.9 97.7 82.2 396.4
Standardized to Amount Given 95.6 120.9 97.7 82.2 396.4
Lean Body Mass 11.80 Standardized to LBM 88.6 112.0 90.5 76.2 367.4
Before: 2.27 Decimal Time: 0.095 0.598 1.109 1.607 2.101
After: 2.50 Glucose: 204 282 286 210 188
Injected: 0.23 Area Under Curve 122.2 145.1 123.5 98.2 489.0
Standardized to Glucose Injected 106.3 126.2 107.4 85.4 425.2
Standardized to G Concentration 106.3 126.2 107.4 85.4 425.2
Standardized to Amount Given 106.3 126.2 107.4 85.4 425.2
Lean Body Mass 12.66 Standardized to LBM 91.9 109.0 92.8 73.8 367.5
Before: 2.29 Decimal Time: 0.0 0.5 1.0 1.5 2.097
After: 2.50 Glucose: 174.8 289.8 297.4 251.6 213
Injected: 0.21 Area Under Curve 116.6 153.6 132.2 137.1 539.5
Standardized to Glucose Injected 111.0 146.3 125.9 130.6 513.8
Standardized to G Concentration 111.0 146.3 125.9 130.6 513.8
Standardized to Amount Given 111.0 146.3 125.9 130.6 513.8







Wk 8 C 
Mean
Appendix C – Experiment 2 Data Tables 157 
Table C-17: Experiment 2: Week 8 DIO Glucose Levels 
 
  
Exp. 2 Glucose Concentration
Lean Body 
Mass (g)
Concentration (mg/1 gram 
solution)
Amount Given
Week 8 10.94 220.63 0.214
DIO Ad Lib Concentration (mg/1 gram 
solution)
Amount Given
293.37 0.214 Total Area
Before: 2.26 Decimal Time: 0.124 0.624 1.141 1.638 2.137
After: 2.49 Glucose: 199 415 420 373 362
Injected: 0.23 Area Under Curve 153.6 215.8 197.0 183.2 749.7
Standardized to Glucose Injected 133.6 187.7 171.3 159.3 651.9
Standardized to G Concentration 100.4 141.1 128.9 119.8 490.3
Standardized to Amount Given 100.4 141.1 128.9 119.8 490.3
Lean Body Mass 8.44 Standardized to LBM 130.2 183.0 167.1 155.4 635.6
Before: 2.25 Decimal Time: 0.146 0.648 1.161 1.659 2.153
After: 2.47 Glucose: 206 491 470 494 411
Injected: 0.22 Area Under Curve 174.9 246.1 240.5 223.4 884.9
Standardized to Glucose Injected 159.0 223.7 218.6 203.1 804.4
Standardized to G Concentration 119.6 168.3 164.4 152.7 605.0
Standardized to Amount Given 119.6 168.3 164.4 152.7 605.0
Lean Body Mass 9.76 Standardized to LBM 134.1 188.7 184.3 171.2 678.3
Before: 2.28 Decimal Time: 0.173 0.671 1.179 1.681 2.188
After: 2.49 Glucose: 255 572 540 492 428
Injected: 0.21 Area Under Curve 205.8 282.6 259.0 232.9 980.4
Standardized to Glucose Injected 196.0 269.2 246.7 221.8 933.7
Standardized to G Concentration 147.4 202.4 185.5 166.8 702.2
Standardized to Amount Given 147.4 202.4 185.5 166.8 702.2
Lean Body Mass 8.19 Standardized to LBM 196.9 270.4 247.8 222.9 937.9
Before: 2.26 Decimal Time: 0.193 0.691 1.199 1.701 2.204
After: 2.48 Glucose: 149 507 539 505 360
Injected: 0.22 Area Under Curve 163.3 265.4 262.5 217.5 908.6
Standardized to Glucose Injected 148.4 241.3 238.6 197.7 826.0
Standardized to G Concentration 111.6 181.5 179.4 148.7 621.2
Standardized to Amount Given 111.6 181.5 179.4 148.7 621.2
Lean Body Mass 8.35 Standardized to LBM 146.1 237.6 234.9 194.6 813.2
Before: 2.26 Decimal Time: 0.211 0.712 1.217 1.719 2.226
After: 2.47 Glucose: 209 519 374 444 322
Injected: 0.21 Area Under Curve 182.2 225.4 205.4 194.2 807.1
Standardized to Glucose Injected 173.5 214.6 195.6 184.9 768.7
Standardized to G Concentration 130.5 161.4 147.1 139.1 578.1
Standardized to Amount Given 130.5 161.4 147.1 139.1 578.1
Lean Body Mass 8.00 Standardized to LBM 178.4 220.6 201.1 190.1 790.1
Before: 2.26 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.48 Glucose: 203.6 500.8 468.6 461.6 376.6
Injected: 0.22 Area Under Curve 176.0 247.2 232.8 210.2 866.2
Standardized to Glucose Injected 161.5 226.8 213.6 192.9 794.7
Standardized to G Concentration 121.4 170.5 160.6 145.1 597.6
Standardized to Amount Given 121.4 170.5 160.6 145.1 597.6
Lean Body Mass 8.55 Standardized to LBM 155.4 218.2 205.5 185.6 764.8
Standard
T19
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Table C-18: Experiment 2: Week 10 Standard Diet Saline Glucose Levels 
 
  
Exp. 2 Glucose Concentration
Lean Body 
Mass (g)
Concentration (mg/1 gram 
solution)
Amount Given
Week 10 10.94 220.63 0.214
Standard Diet Ad Lib Saline Concentration (mg/1 gram 
solution)
Amount Given
221.94 0.244 Total Area
Before: 2.289 Decimal Time: 0.000 0.500 1.008 1.509 2.026
After: 2.562 Glucose: 152 342 252 181 178
Injected: 0.27 Area Under Curve 123.5 151.0 108.3 92.9 475.7
Standardized to Glucose Injected 90.5 110.6 79.3 68.1 348.5
Standardized to G Concentration 89.9 110.0 78.9 67.7 346.4
Standardized to Amount Given 78.8 96.3 69.1 59.2 303.4
Lean Body Mass 10.51 Standardized to LBM 82.0 100.2 71.9 61.7 315.8
Before: 2.292 Decimal Time: 0.031 0.531 1.032 1.532 2.048
After: 2.577 Glucose: 168 255 229 196 194
Injected: 0.29 Area Under Curve 105.8 121.3 106.4 100.6 434.0
Standardized to Glucose Injected 74.2 85.1 74.6 70.6 304.5
Standardized to G Concentration 73.8 84.6 74.2 70.2 302.7
Standardized to Amount Given 64.6 74.1 65.0 61.5 265.1
Lean Body Mass 11.19 Standardized to LBM 63.2 72.4 63.5 60.1 259.3
Before: 2.243 Decimal Time: 0.048 0.548 1.049 1.557 2.056
After: 2.519 Glucose: 223 436 348 345 203
Injected: 0.28 Area Under Curve 164.8 196.8 175.8 136.8 674.0
Standardized to Glucose Injected 119.4 142.6 127.4 99.1 488.4
Standardized to G Concentration 118.7 141.7 126.6 98.5 485.5
Standardized to Amount Given 103.9 124.1 110.9 86.3 425.2
Lean Body Mass 11.17 Standardized to LBM 101.8 121.6 108.6 84.5 416.5
Before: 2.277 Decimal Time: 0.063 0.563 1.075 1.578 2.083
After: 2.557 Glucose: 149 252 209 231 232
Injected: 0.28 Area Under Curve 100.3 118.1 110.7 116.8 445.9
Standardized to Glucose Injected 71.6 84.4 79.1 83.5 318.5
Standardized to G Concentration 71.2 83.9 78.6 83.0 316.6
Standardized to Amount Given 62.3 73.5 68.8 72.7 277.3
Lean Body Mass 7.78 Standardized to LBM 87.6 103.2 96.7 102.1 389.7
Before: 2.260 Decimal Time: 0.088 0.588 1.108 1.586 2.123
After: 2.542 Glucose: 181 222 196 221 201
Injected: 0.28 Area Under Curve 100.8 108.6 99.7 113.2 422.3
Standardized to Glucose Injected 71.5 77.0 70.7 80.3 299.5
Standardized to G Concentration 71.0 76.6 70.3 79.8 297.7
Standardized to Amount Given 62.2 67.1 61.6 69.9 260.7
Lean Body Mass 9.45 Standardized to LBM 72.0 77.6 71.2 80.8 301.6
Before: 2.27 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.55 Glucose: 174.6 301.4 246.8 234.8 201.6
Injected: 0.28 Area Under Curve 119.0 139.4 119.9 112.3 490.6
Standardized to Glucose Injected 85.2 99.9 85.9 80.5 351.5
Standardized to G Concentration 84.7 99.3 85.4 80.0 349.4
Standardized to Amount Given 74.2 87.0 74.8 70.0 306.0
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Table C-19: Experiment 2: Week 10 Standard Diet AICAR Glucose Levels 
 
  
Exp. 2 Glucose Concentration
Lean Body 
Mass (g)
Concentration (mg/1 gram 
solution)
Amount Given
Week 10 10.94 220.63 0.214
Standard Diet Ad Lib AICAR Concentration (mg/1 gram 
solution)
Amount Given
221.94 0.244 Total Area
Before: 2.245 Decimal Time: 0.104 0.606 1.125 1.607 2.134
After: 2.543 Glucose: 174 219 194 195 165
Injected: 0.30 Area Under Curve 98.6 107.3 93.8 94.8 394.4
Standardized to Glucose Injected 66.2 72.0 62.9 63.6 264.7
Standardized to G Concentration 65.8 71.6 62.6 63.2 263.2
Standardized to Amount Given 57.6 62.7 54.8 55.4 230.5
Lean Body Mass 9.92 Standardized to LBM 63.6 69.1 60.4 61.1 254.2
Before: 2.283 Decimal Time: 0.117 0.621 1.139 1.632 2.149
After: 2.563 Glucose: 184 399 324 323 204
Injected: 0.28 Area Under Curve 147.0 187.3 159.5 136.4 630.1
Standardized to Glucose Injected 105.0 133.8 113.9 97.4 450.1
Standardized to G Concentration 104.4 133.0 113.3 96.8 447.4
Standardized to Amount Given 91.4 116.5 99.2 84.8 391.8
Lean Body Mass 11.19 Standardized to LBM 89.3 113.8 96.9 82.9 383.0
Before: 2.281 Decimal Time: 0.132 0.634 1.149 1.648 2.166
After: 2.564 Glucose: 120 207 187 159 148
Injected: 0.28 Area Under Curve 82.1 101.6 86.2 79.5 349.4
Standardized to Glucose Injected 58.0 71.8 60.9 56.2 246.9
Standardized to G Concentration 57.7 71.4 60.6 55.9 245.5
Standardized to Amount Given 50.5 62.5 53.0 48.9 215.0
Lean Body Mass 12.40 Standardized to LBM 44.6 55.1 46.8 43.2 189.6
Before: 2.292 Decimal Time: 0.144 0.646 1.163 1.664 2.173
After: 2.568 Glucose: 155 185 163 202 197
Injected: 0.28 Area Under Curve 85.3 90.0 91.5 101.4 368.2
Standardized to Glucose Injected 61.8 65.2 66.3 73.5 266.8
Standardized to G Concentration 61.5 64.9 65.9 73.1 265.3
Standardized to Amount Given 53.8 56.8 57.7 64.0 232.3
Lean Body Mass 9.19 Standardized to LBM 64.0 67.6 68.6 76.1 276.4
Before: 2.28 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.56 Glucose: 158.3 252.5 217.0 219.8 178.5
Injected: 0.28 Area Under Curve 103.2 121.5 107.8 103.1 435.6
Standardized to Glucose Injected 72.6 85.5 75.9 72.5 306.5
Standardized to G Concentration 72.2 85.0 75.4 72.1 304.7
Standardized to Amount Given 63.2 74.4 66.0 63.1 266.8
Lean Body Mass 10.68 Standardized to LBM 64.8 76.3 67.7 64.7 273.4
Standard
C16
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Table C-20: Experiment 2: Week 10 DIO Ad libitum Saline Glucose Levels 
 
  
Exp. 2 Glucose Concentration
Lean Body Mass 
(g)
Concentration (mg/1 gram 
solution)
Amount Given
Week 10 10.94 220.63 0.214
DIO Ad Lib Saline Concentration (mg/1 gram 
solution)
Amount Given
285.90 0.244 Total Area
Before: 2.294 Decimal Time: 0.000 0.503 1.008 1.512 2.003
After: 2.510 Glucose: 174 508 449 427 300
Injected: 0.22 Area Under Curve 171.4 241.5 221.1 178.5 812.5
Standardized to Glucose Injected 158.7 223.6 204.7 165.3 752.4
Standardized to G Concentration 122.5 172.6 158.0 127.6 580.6
Standardized to Amount Given 107.3 151.1 138.3 111.7 508.5
Lean Body Mass 9.111 Standardized to LBM 128.8 181.4 166.1 134.1 610.4
Before: 2.253 Decimal Time: 0.031 0.530 1.028 1.531 2.028
After: 2.475 Glucose: 194 442 314 296 274
Injected: 0.22 Area Under Curve 158.6 188.2 153.3 141.7 641.8
Standardized to Glucose Injected 142.8 169.5 138.2 127.7 578.2
Standardized to G Concentration 110.2 130.8 106.6 98.5 446.2
Standardized to Amount Given 96.5 114.6 93.4 86.3 390.7
Lean Body Mass 7.977 Standardized to LBM 132.4 157.1 128.0 118.3 535.7
Before: 2.253 Decimal Time: 0.058 0.560 1.055 1.548 2.059
After: 2.475 Glucose: 204 388 504 405 351
Injected: 0.22 Area Under Curve 148.5 220.6 224.0 193.5 786.6
Standardized to Glucose Injected 133.8 198.8 201.8 174.3 708.7
Standardized to G Concentration 103.2 153.4 155.7 134.5 546.9
Standardized to Amount Given 90.4 134.3 136.4 117.8 478.9
Lean Body Mass 8.014 Standardized to LBM 123.4 183.3 186.1 160.8 653.7
Before: 2.281 Decimal Time: 0.088 0.592 1.094 1.578 2.086
After: 2.502 Glucose: 196 437 366 270 200
Injected: 0.22 Area Under Curve 159.6 201.9 153.8 119.4 634.6
Standardized to Glucose Injected 144.4 182.7 139.2 108.0 574.3
Standardized to G Concentration 111.4 141.0 107.4 83.4 443.2
Standardized to Amount Given 97.6 123.5 94.1 73.0 388.1
Lean Body Mass 9.210 Standardized to LBM 115.9 146.6 111.7 86.7 460.9
Before: 2.293 Decimal Time: 0.118 0.625 1.124 1.606 2.117
After: 2.515 Glucose: 231 526 396 342 270
Injected: 0.22 Area Under Curve 191.9 230.2 177.7 156.4 756.3
Standardized to Glucose Injected 172.9 207.4 160.1 140.9 681.3
Standardized to G Concentration 133.4 160.1 123.6 108.7 525.8
Standardized to Amount Given 116.8 140.2 108.2 95.2 460.4
Lean Body Mass 9.070 Standardized to LBM 140.9 169.0 130.5 114.8 555.2
Before: 2.255 Decimal Time: 0.140 0.646 1.152 1.633 2.137
After: 2.473 Glucose: 201 494 333 286 223
Injected: 0.22 Area Under Curve 175.7 209.4 148.8 128.4 662.3
Standardized to Glucose Injected 161.2 192.1 136.5 117.8 607.6
Standardized to G Concentration 124.4 148.2 105.4 90.9 468.9
Standardized to Amount Given 108.9 129.8 92.3 79.6 410.6
Lean Body Mass 8.690 Standardized to LBM 137.1 163.4 116.1 100.2 516.8
Before: 2.27 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.49 Glucose: 200.0 465.8 393.7 337.7 269.7
Injected: 0.22 Area Under Curve 167.6 215.3 179.6 153.0 715.5
Standardized to Glucose Injected 152.2 195.6 163.1 139.0 649.9
Standardized to G Concentration 117.5 150.9 125.9 107.3 501.5
Standardized to Amount Given 102.9 132.2 110.2 94.0 439.2
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Table C-21: Experiment 2: Week 10 DIO Ad libitum AICAR Glucose Levels 
 
  
Exp. 2 Glucose Concentration
Lean Body Mass 
(g)
Concentration (mg/1 gram 
solution)
Amount Given
Week 10 10.94 220.63 0.214
DIO Ad Lib AICAR Concentration (mg/1 gram 
solution)
Amount Given
285.90 0.244 Total Area
Before: 2.260 Decimal Time: 0.169 0.667 1.181 1.655 2.162
After: 2.480 Glucose: 204 570 520 548 565
Injected: 0.22 Area Under Curve 192.4 280.1 253.4 282.3 1008.1
Standardized to Glucose Injected 174.9 254.6 230.3 256.6 916.5
Standardized to G Concentration 135.0 196.5 177.7 198.0 707.2
Standardized to Amount Given 118.2 172.1 155.7 173.4 619.4
Lean Body Mass 9.54 Standardized to LBM 135.5 197.2 178.4 198.8 709.9
Before: 2.250 Decimal Time: 0.189 0.693 1.203 1.683 2.184
After: 2.468 Glucose: 133 250 200 200 203
Injected: 0.22 Area Under Curve 96.3 114.8 96.1 100.9 408.1
Standardized to Glucose Injected 88.4 105.3 88.2 92.5 374.4
Standardized to G Concentration 68.2 81.3 68.0 71.4 288.9
Standardized to Amount Given 59.7 71.2 59.6 62.5 253.0
Lean Body Mass 7.66 Standardized to LBM 85.3 101.6 85.1 89.3 361.2
Before: 2.262 Decimal Time: 0.219 0.729 1.226 1.721 2.216
After: 2.480 Glucose: 228 465 466 392 352
Injected: 0.22 Area Under Curve 176.8 231.2 212.6 184.0 804.6
Standardized to Glucose Injected 162.2 212.1 195.0 168.8 738.2
Standardized to G Concentration 125.2 163.7 150.5 130.3 569.7
Standardized to Amount Given 109.6 143.3 131.8 114.1 498.9
Lean Body Mass 9.02 Standardized to LBM 132.9 173.8 159.8 138.4 604.9
Before: 2.279 Decimal Time: 0.251 0.754 1.261 1.755 2.244
After: 2.496 Glucose: 218 438 351 335 314
Injected: 0.22 Area Under Curve 165.0 199.7 169.5 158.8 693.0
Standardized to Glucose Injected 152.1 184.0 156.2 146.4 638.7
Standardized to G Concentration 117.4 142.0 120.6 113.0 492.9
Standardized to Amount Given 102.8 124.4 105.6 98.9 431.6
Lean Body Mass 8.66 Standardized to LBM 129.8 157.1 133.3 124.9 545.1
Before: 2.262 Decimal Time: 0.275 0.773 1.283 1.776 2.272
After: 2.480 Glucose: 222 429 322 289 254
Injected: 0.22 Area Under Curve 162.0 191.7 150.5 134.6 638.9
Standardized to Glucose Injected 148.6 175.9 138.1 123.5 586.1
Standardized to G Concentration 114.7 135.7 106.6 95.3 452.3
Standardized to Amount Given 100.5 118.9 93.3 83.5 396.1
Lean Body Mass 8.25 Standardized to LBM 133.1 157.5 123.7 110.6 524.9
Before: 2.26 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.48 Glucose: 201.0 430.4 371.8 352.8 337.6
Injected: 0.22 Area Under Curve 158.6 203.6 176.6 171.8 710.5
Standardized to Glucose Injected 145.3 186.6 161.9 157.4 651.2
Standardized to G Concentration 112.2 144.0 124.9 121.5 502.6
Standardized to Amount Given 98.2 126.1 109.4 106.4 440.1
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Table C-22: Experiment 2: Week 10 DIO Food Restricted Glucose Level 
 
  
Exp. 2 Glucose Concentration
Lean Body Mass 
(g)
Concentration (mg/1 gram 
solution)
Amount Given
Week 10 10.94 220.63 0.214
DIO Food Restrict Saline Concentration (mg/1 gram 
solution)
Amount Given
285.90 0.244 Total Area
Before: 2.255 Decimal Time: 0.304 0.811 1.309 1.798 2.300
After: 2.479 Glucose: 191 432 371 268 186
Injected: 0.22 Area Under Curve 157.9 200.1 156.2 114.0 628.2
Standardized to Glucose Injected 141.0 178.6 139.5 101.8 560.9
Standardized to G Concentration 108.8 137.9 107.6 78.6 432.8
Standardized to Amount Given 95.3 120.7 94.3 68.8 379.1
Lean Body Mass 10.99 Standardized to LBM 94.8 120.1 93.8 68.5 377.2
Before: 2.262 Decimal Time: 0.325 0.833 1.332 1.819 2.329
After: 2.479 Glucose: 174 407 409 365 288
Injected: 0.22 Area Under Curve 147.7 203.5 188.4 166.4 706.1
Standardized to Glucose Injected 136.1 187.6 173.7 153.4 650.8
Standardized to G Concentration 105.0 144.8 134.0 118.4 502.2
Standardized to Amount Given 92.0 126.8 117.4 103.7 439.8
Lean Body Mass 9.43 Standardized to LBM 106.7 147.1 136.1 120.2 510.1
Before: 2.262 Decimal Time: 0.344 0.851 1.355 1.847 2.350
After: 2.481 Glucose: 191 402 321 306 218
Injected: 0.22 Area Under Curve 150.4 182.3 154.3 131.7 618.7
Standardized to Glucose Injected 136.7 165.7 140.3 119.8 562.4
Standardized to G Concentration 105.5 127.9 108.3 92.4 434.0
Standardized to Amount Given 92.4 112.0 94.8 80.9 380.1
Lean Body Mass 9.98 Standardized to LBM 101.3 122.7 103.9 88.7 416.6
Before: 2.266 Decimal Time: 0.366 0.869 1.377 1.866 2.371
After: 2.488 Glucose: 197 456 285 249 192
Injected: 0.22 Area Under Curve 164.2 188.2 130.7 111.4 594.5
Standardized to Glucose Injected 149.3 171.1 118.8 101.2 540.5
Standardized to G Concentration 115.2 132.1 91.7 78.1 417.1
Standardized to Amount Given 100.9 115.6 80.3 68.4 365.3
Lean Body Mass 8.74 Standardized to LBM 126.2 144.6 100.4 85.6 456.8
Before: 2.285 Decimal Time: 0.387 0.886 1.404 1.886 2.397
After: 2.504 Glucose: 196 329 336 284 262
Injected: 0.22 Area Under Curve 130.9 172.3 149.2 139.6 592.1
Standardized to Glucose Injected 119.0 156.7 135.7 126.9 538.2
Standardized to G Concentration 91.8 120.9 104.7 97.9 415.4
Standardized to Amount Given 80.4 105.9 91.7 85.8 363.8
Lean Body Mass 8.21 Standardized to LBM 107.1 141.0 122.1 114.2 484.4
Before: 2.27 Decimal Time: 0.0 0.5 1.0 1.5 2.0
After: 2.49 Glucose: 189.8 405.2 344.4 294.4 229.2
Injected: 0.22 Area Under Curve 150.2 189.5 155.8 132.5 628.0
Standardized to Glucose Injected 136.5 172.3 141.6 120.5 570.9
Standardized to G Concentration 105.4 132.9 109.3 93.0 440.6
Standardized to Amount Given 92.3 116.4 95.7 81.4 385.8
Lean Body Mass 9.47 Standardized to LBM 106.6 134.4 110.5 94.0 445.5











Appendix C – Experiment 2 Data Tables 163 
Table C-23: Experiment 2: Glucose Clearance Welch’s 2-Tailed T-test 




Exp 2. Glucose Tolerance (mg glucose / dl blood) T Test
Significance of 0.05 Highlighted in Green
812.54 1008.12
 475.68 394.44  641.77 408.12
433.97 630.11 786.62 804.64
674.04 349.41 634.62 692.99
445.90 368.24 756.26 638.90
422.28 662.27
Sample Size 5.00 4.00 Sample Size 6.00 5.00
Mean 490.37 435.55 Mean 715.68 710.55
StDev 104.57 131.01 StDev 78.67 220.40
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
475.68 812.54
 433.97 641.77  394.44 1008.12
674.04 786.62 630.11 408.12
445.90 634.62 349.41 804.64
422.28 756.26 368.24 692.99
662.27 638.90
Sample Size 5.00 6.00 Sample Size 4.00 5.00
Mean 490.37 715.68 Mean 435.55 710.55
StDev 104.57 78.67 StDev 131.01 220.40
Sx Sx
Deg. Of Freedom Deg. Of Freedom
t value t value
P(Means are equal) P(Means are equal)
812.54 628.20
480.37 749.69  641.77 706.09  1008.12 628.20
 767.76 884.87 786.62 618.69 408.12 706.09
529.70 980.41 634.62 594.52 804.64 618.69
455.86 908.60 756.26 592.07 692.99 594.52
489.01 807.13 662.27 638.90 592.07
Sample Size 5.00 5.00 Sample Size 6.00 5.00 Sample Size 5.00 5.00
Mean 544.54 866.14 Mean 715.68 627.91 Mean 710.55 627.91
StDev 127.59 89.80 StDev 78.67 46.36 StDev 220.40 46.36
Sx Sx Sx
Deg. Of Freedom Deg. Of Freedom Deg. Of Freedom
t value t value t value
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Adenosine monophosphate (AMP): The nucleotide adenosine bonded to one phosphate 
group.  Also, the result of removing two phosphate groups from adenosine triphosphate. 
 Functionally, AMP contains a significantly lower amount of energy than ATP, as it is 
produced when energy is released by removing phosphate groups from ATP. 
 
Adenosine triphosphate (ATP): The nucleotide adenosine bonded to a triphosphate 
group.  ATP is the unit of energy in most cell processes, as phosphate groups are 
removed from ATP, thus releasing energy. 
 
AICAR: AICAR, or 5-amino-1-β-Dffff-ribofuranosyl-imidazole-4-carboxamide, is a 
drug analog of AMP that stimulates AMPK activity. 
 
Allosteric: The change in shape and activity of an enzyme resulting from a molecular 
binding of a regulatory substance to a site outside of the enzyme’s active site.  
 
AMP-activated protein kinase (AMPK): An energy sensor on both the cellular and 
organismal levels. AMPK works by responding to changes in the ratio of AMP to ATP. 
 In this system, AMP represents ‘used energy,’ while ATP represents ‘available energy,’ 
so an increase in this ratio indicates an energy deficient state, while a decrease indicates 
an energy rich state.  AMPK responds by controlling catabolic and anabolic processes in 
the cell and body. 
 
Anabolism: A set of metabolic pathways that use energy to build large molecules from 
smaller subunits, such as monosaccharides, fatty acids, amino acids, and nucleotides. 
 
Catabolism: A set of metabolic pathways that break down large molecules, such as 
polysaccharides, proteins, lipids, and nucleic acids, and release energy. 
 
Citric Acid Cycle (= Krebs Cycle, = Tricarboxylic acid (TCA) Cycle): The Citric 
Acid Cycle is an aerobic cellular process in which acetyl CoA and oxygen is used to 
produce ATP and carbon dioxide. 
 
Derivatization: A technique used to transform a chemical compound into a product of 
similar chemical structure. 
 
Electron Transport Chain: An ETC couples electron transfer from an electron donor to 
an electron acceptor with the transfer of H+ (proton) across a membrane. This results in 
an electrochemical proton gradient, which produces energy in the form of ATP. 
 
FADH2: FADH2 is the reduced form of FAD (flavin adenine dinucleotide). It carries 
high-energy electrons used for oxidative phosphorylation, sending its two high-energy 
electrons through the electron transport chain. 
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Fatty acid: A fatty acid is a carboxylic acid with a long hydrocarbon chain.  The most 
common fatty acids have a chain of 12 – 18 carbon atoms.  They can occur in either the 
esterified form as a triglyceride or in the nonesterified form as nonesterified fatty acid 
(NEFA).  
 
Gluconeogenesis (GNG): Gluconeogenesis is a metabolic process in which glucose is 
generated from non-carbohydrate substrates, such as from fats or protein. GNG occurs in 
the liver when an animal’s blood glucose levels drop too low. 
 
Glycolysis: The metabolic pathway that converts glucose into pyruvate. The energy 
released in the process is used to form ATP and NADH. 
 
Heterotrimeric: A macromolecule composed of three subunits of which at least one 
differs from the others. 
 
High density lipoprotein (HDL):  High density lipoprotein is one of five classes of 
lipoproteins, which are protein molecules that transport water-insoluble molecules such 
as cholesterol in the bloodstream.  High density lipoprotein is considered  as  “healthy” 
because it can remove cholesterol from arteries which prevent plaque buildup.  
 
Homogenization: Reducing a substance to extremely small particles and distributing it 
uniformly throughout a liquid. 
 
Hyperinsulinemia: Hyperinsulinemia is a clinical condition in which insulin levels in 
the blood are elevated above the normal range.   While hyperinsulinemia often occurs in 
Type II diabetes, the two words are not interchangeable. 
 
Hyperphagia: Hyperphagia is abnormally increased appetite that results in overeating. 
 
Hypertension: Hypertension is a medical condition in which blood pressure is 
chronically elevated. 
 
Hysteresis:  Hysteresis is the lagging period of time between a cause and its effect. 
 
Insulin resistance: Insulin resistance is a symptom of metabolic syndrome in which the 
body’s tissues do not respond effectively to insulin.  Thus, cellular uptake of glucose is 
reduced and blood glucose and fat levels are elevated.   
 
Lipogenesis: Lipogenesis is a metabolic process in which fatty acids are produced from 
non-lipid substrates, such as glucose.  The term lipogenesis is used to encompass both 
fatty acid synthesis and triglyceride synthesis.   Lipogenesis occurs in the liver and is 
secreted into the bloodstream. 
 
Lipotoxicity: Lipotoxicity is the pathological damage when there is elevated fat level in 
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the blood or tissues, particularly the liver.  The accumulation of lipids in the tissues 
ultimately leads to cell dysfunction and death. 
 
Low density lipoprotein (LDL): Low density lipoprotein is one of five classes of 
lipoproteins, which are protein molecules that transport water-insoluble molecules such 
as cholesterol in the bloodstream.  Studies have shown that an elevated level of low 
density lipoproteins promotes cardiovascular problems.  
 
Metabolic syndrome (Insulin resistance syndrome): Metabolic syndrome is a 
combination of many risk factors that increase the risk for a heart attack, stroke, and Type 
II diabetes.  The two identified causes of metabolic syndrome is insulin resistance and 
central obesity. 
 
Metabolites: To fit the definition of a metabolite, a dietary ingredient must bear a 
semblance to a "living" molecule both in structure and function. The candidate 
molecule(s) must interact favorably with the host's metabolic machinery. Enhancing the 
level of the candidate molecule must not present a toxic challenge to the host or 
otherwise cause an untold situation that would differ from the elevation of the host's 
molecule. The candidate molecule must have a known metabolic fate that does not violate 
the principles of metabolic turnover. The candidate molecule must behave in accordance 
with the principles of metabolic turnover. It must show timely degradation and excretion. 
It must not leave a lasting imprint on the metabolic systems of the host or cause the host 
system to adapt to a new position of homeostasis or need. In essence, it must not be 
addictive. Molecules fitting these criteria, or supplement ingredients that give rise to said 
molecules, would be considered capable of meeting the host need for optimal health, 
growth and development. 
 
Metabolomics (Metabonomics): Quantitiative and qualitative analysis of the complete 
set of metabolites present in a biological system. 
 
Metabolome:  The complete set of all metabolites formed by the cell in association with 
its metabolism. The metabolome comprises the endometabolome (all the intracellular 
metabolites) and the exometabolome (all the metabolites that are excreted into the growth 
medium or extracellular fluid). 
 
NADH: NADH is the reduced form of NAD+ (nicotinamide adenine dinucleotide). It is 
used as a reducing agent by transferring and donating electrons. 
 
Pleiotropic: In terms of AMPK, affecting multiple tissues and systems within an 
organism. 
 
Set Point Theory: The body has an internal regulator that controls how much fat the 
body metabolizes. This regulator works as a thermostat within the body directing energy 
storage and consumption, it differs amongst people (20). 
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Triglyceride (TG) = Triacylglycerol (TAG): A triglyceride is an ester composed of a 
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